Protocol  22-[ADDRESS_177992]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 1 of 147  A Phase 2 Randomized, Open -Label, Multisite Trial to Inform Public 
Health Strategies Involving the Use of MVA -BN Vaccine for Mpox  
 
  
DMID Protocol Number: 22 -0020 
 
Sponsor: Division of Microbiology and Infectious Diseases (DMID) 
 
Version Number: 6.[ADDRESS_177993]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 2 of 147  STATEMENT  OF COMPLIANCE  
Each institution engaged in this research will hold a current Federalwide  Assurance (FWA) issued 
by [CONTACT_28820] (OHRP) for federally funded research. The IRB/IEC 
must be registered with OHRP as applicable to the research.  
 
The study will be carried out in accordance with the following as applicable: 
• [LOCATION_002] Code of Federal Regulations (CFR) 45 CFR Part 46: Protection of Human Subjects  
• Food and Drug Administration (FDA) Regulations: 21 CFR Part 50 (Protection of Human Subjects), 21 CFR Part 54 (Financial Disclosure by [CONTACT_6230]), 21 CFR Part 56 
(Institutional Review Boards), 21 CFR Part 11 (Electronic Records and Electronic Signatures), and 21 CFR Part 312 (Investigational New Drug Application), and/or 21 CFR 812 (Investigational Device Exemptions) 
• The International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) E6(R2) Good Clinical Practice (GCP), and the Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research, Report of the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research  
• The policies and procedures of National Institutes of Health (NIH) Office of Extramural 
Research and DMID  
• The National Institute of Allergy and Infectious Diseases (NI AID) Terms of Award  
• Any additional Federal, State, and Local Regulations and Guidance 
 
 The signature [CONTACT_42749], and according to local legal and regulatory requirements, US federal regulations, and ICH E6(R2) Good Clinical Practice (GCP) guidelines.  
 
Site Investigator  Signature : 
 
 
[INVESTIGATOR_14586]:   Date:   
 Print Name, Credentials  
Print Title    
  
Protocol  22-[ADDRESS_177994]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_177995] OF FIGURES  .............................................................................................................................. 11 
1. PROTOCOL SUMMARY ........................................................................................................... 12 
1.1 Synopsis .........................................................................................................................12  
1.2 Schedule of Activities (SOA)  ........................................................................................15  
2. Introduction  .................................................................................................................................. 15 
2.1 Study Rationale ..............................................................................................................15  
2.2 Background ....................................................................................................................15  
2.3 Risk/Benefit Assessment  ...............................................................................................[ADDRESS_177996](s) and Administration.............................................................................[ADDRESS_177997] Description .....................................................................................19  
6.1.2  Dosing and Administration ....................................................................................20  
6.1.3  Dose Escalation  ......................................................................................................20  
6.1.4  Dose Modifications ................................................................................................20  
6.1.5  Criteria for Redosing ..............................................................................................20  
6.2 Preparation/Handling/Storage/Accountability ...............................................................[ADDRESS_177998] Storage and Stability.................................................................................21  
6.2.4  Preparation  .............................................................................................................22  
6.3 Measures to Minimize Bias: Randomization and Blinding  ...........................................22  
6.3.1  Treatment Assignment Procedures  ........................................................................22  
6.3.2  Randomization .......................................................................................................22  
6.3.3  Blinding and Masking Procedures .........................................................................23  
6.4 Study Intervention Compliance .....................................................................................23  
6.5 Concomitant Therapy.....................................................................................................23  
7. STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  ............................................................................................ [ADDRESS_177999]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 4 of 147  8.6 Adverse Events and Serious Adverse Events ................................................................23  
8.6.1  Definition of Adverse Events (AE)........................................................................23  
[IP_ADDRESS]  Solicited Adverse Events ................................................................................... 24  
[IP_ADDRESS]  Unsolicited Events ............................................................................................. 24  
8.6.2  Definition of Serious Adverse Events....................................................................24  
8.6.3  Classification of an Adverse Event ........................................................................25  
[IP_ADDRESS]  Severity of Event................................................................................................ 25  
[IP_ADDRESS]  Relationship to Study Intervention .................................................................... 25  
8.6.5  Adverse Event Reporting .......................................................................................26  
[IP_ADDRESS]  Investigators Reporting of AEs .......................................................................... 26  
[IP_ADDRESS]  Special Reporting of Adverse Events ................................................................ 26  
8.6.6  Serious Adverse Event Reporting ..........................................................................26  
[IP_ADDRESS]  Investigators Reporting of SAEs ....................................................................... 26  
[IP_ADDRESS]  Regulatory Reporting of SAEs .......................................................................... 27  
8.6.7  Reporting Events to Participants ............................................................................28  
8.6.8  Reporting of Pregnancy .........................................................................................28  
8.7 Unanticipated Problems .................................................................................................28  
8.7.1  Definition of Unanticipated Problems (UP) ..........................................................28  
8.7.2  Unanticipated Problem Reporting..........................................................................28  
8.7.3  Reporting Unanticipated Problems to Participants ................................................29  
9. STATISTICAL CONSIDERATIONS  ......................................................................................... 29 
10. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  ................ 29 
10.1  Regulatory, Ethical, and Study Oversight Considerations.............................................29  
10.1.1  Informed Consent Process .....................................................................................30  
10.1.2  Study Termination and Clos ure .............................................................................30  
10.1.3  Confidentiality and Privacy ...................................................................................30  
10.1.4  Secondary Use of Stored Specimens and Data ......................................................32  
[IP_ADDRESS]  Samples for Secondary Research  ................................................................... 32  
[IP_ADDRESS]  Data Sharing for Secondary Research  ........................................................... [ADDRESS_178000] Keepi[INVESTIGATOR_007] ......................................................................33  
[IP_ADDRESS]  Data Collection and Management Responsibilities  ....................................... 33  
[IP_ADDRESS]  Data Coordinating Center / Biostatistician Responsibilities  .......................... 34  
[IP_ADDRESS]  Data Capture Methods  ................................................................................... 34  
[IP_ADDRESS]  Study Record Retention ................................................................................. 34  
[IP_ADDRESS]  Source Records  .............................................................................................. 34  
10.1.10  Protocol Deviations ................................................................................................35  
10.1.11  Publication and Data Sharing Policy .....................................................................35  
[IP_ADDRESS]  Human Data Sharing Plan .............................................................................. 35  
[IP_ADDRESS]  Genomic Data Sharing Plan  ........................................................................... 35  
[IP_ADDRESS]  Publication  ..................................................................................................... [ADDRESS_178001]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178002]  ...............................................................................................................36  
10.3  Abbreviations .................................................................................................................38  
10.4  Protocol Amendment History ........................................................................................40  
11. References  .................................................................................................................................... 42 
APPENDIX A – Stage 1: Dose Sparing Study in Adults  ..................................................................... [ADDRESS_178003]  OF FIGURES  .............................................................................................................................. 48 
1. PROTOCOL  SUMMARY  .......................................................................................................... 50 
1.1 Synopsis .........................................................................................................................50  
1.2 Schedule of Activities  (SOA)  .........................................................................................52  
1.3 Study Schema  .................................................................................................................53  
2. INTRODUCTION  ....................................................................................................................... 53 
2.1 Study Rationale  ..............................................................................................................53  
2.2 Background ....................................................................................................................53  
2.3 Risk/Benefit Assessment  ................................................................................................[ADDRESS_178004](s) and Administration  .............................................................................[ADDRESS_178005]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178006] Description  ......................................................................................65  
6.1.2  Dosing and Administration ....................................................................................65  
6.1.3  Dose Escalation  ......................................................................................................66  
6.1.4  Dose Modifications ................................................................................................66  
6.1.5  Criteria  for Redosing  ..............................................................................................66  
6.2 Preparation/Handling/Storage/Accountability ...............................................................[ADDRESS_178007]: JYNNEOS (MVA-
BN vaccine)  ...........................................................................................................................[ADDRESS_178008]: JYNNEOS  (MVA -BN vaccine)  ...............67  
6.2.4  Preparation  .............................................................................................................67  
6.3 Measures  to Minimize  Bias:  Randomization and Blinding  ............................................68  
6.3.1  Treatment  Assignment Procedures  .........................................................................68  
6.3.2  Randomization .......................................................................................................68  
6.3.3  Blinding and Masking Procedures  .........................................................................68  
6.4 Study Intervention Compliance  ......................................................................................68  
6.5 Concomitant Therapy  .....................................................................................................68  
6.5.1  Rescue Medicine  ....................................................................................................69  
7. STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  ............................................................................................... 69 
7.1 Halting  Criteria  and Discontinuation of Study Intervention  ...........................................69  
7.1.1  Study Halting  Criteria  ............................................................................................69  
[IP_ADDRESS]  Sentinel  Participant  Halting  Rules  ..................................................................... 69  
[IP_ADDRESS]  Cohort Halting  Rules  .......................................................................................... [ADDRESS_178009] 
Values or Abnormal Clinical Findings During Screening  .....................................................72  
8.1.2  Sick Visit ................................................................................................................72  
8.2 Immunogenicity Assessments  ........................................................................................73  
8.2.1  Immunogenicity/Efficacy  Evaluations  ...................................................................[ADDRESS_178010] of the Trial ....................................74  
8.4 Adverse Events and Serious Adverse Events  .................................................................74  
8.4.1  Definition  of Adverse Events  (AE)  ........................................................................74  
[IP_ADDRESS]  Solicited  Adverse Events  ................................................................................... 75  
[IP_ADDRESS]  Unsolicited  Events  ............................................................................................. 75  
8.4.2  Definition  of Serious Adverse Events  ....................................................................75  
[IP_ADDRESS]  Definition  of Medically  Attended  Adverse Events  (MAAE)  ............................. 76  
[IP_ADDRESS]  Definition  of Suspected  Unexpected  Serious Adverse  Reactions  (S[LOCATION_003]R)  ..... [ADDRESS_178011]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 7 of 147  8.4.3  Classification  of an Adverse Event  ........................................................................76  
[IP_ADDRESS]  Severity  of Event  ................................................................................................ 76  
[IP_ADDRESS]  Relationship  to Study Intervention  ..................................................................... 77  
8.4.4  Time  Period  and Frequency  for Event  Assessment  and Follow- Up ......................77  
8.4.5  Adverse Event Reporting  .......................................................................................78  
[IP_ADDRESS]  Investigators Reporting of AEs .......................................................................... 78  
[IP_ADDRESS]  Special  Reporting of Adverse Events  ................................................................. 78  
8.4.6  Serious Adverse Event Reporting  ..........................................................................78  
[IP_ADDRESS]  Investigators Reporting of SAEs  ........................................................................ 78  
[IP_ADDRESS]  Regulatory Reporting of SAEs  ........................................................................... [ADDRESS_178012]  (AESI)  ............................................................80  
8.4.9  Reporting of Pregnancy  ..........................................................................................80  
8.5 Unanticipated  Problems  .................................................................................................80  
8.5.1  Definition  of Unanticipated  Problems (UP) ...........................................................80  
8.5.2  Unanticipated  Problem Reporting  ..........................................................................80  
8.5.3  Reporting Unanticipated  Problems to Participants  .................................................81  
9. STATISTICAL  CONSIDERATIONS  ......................................................................................... 81 
9.1 Statistical Hypotheses .....................................................................................................81  
9.2 Sample  Size Determination  ............................................................................................82  
9.3 Statistical Analyses  ........................................................................................................83  
9.3.1  General Methodology ............................................................................................83  
9.3.2  Timing  of Analyses  ................................................................................................83  
[IP_ADDRESS]  Interim Safety  Analyses  ..................................................................................... 83  
[IP_ADDRESS]  Interim Immunogenicity Analyses  ..................................................................... 84  
[IP_ADDRESS]  Final  Analyses  .................................................................................................... 84  
9.3.3  Populations for Analyses  ........................................................................................84  
9.3.4  Baseline Characteristics  and Participant  Disposition .............................................84  
9.3.5  Immunogenicity Analyses  ......................................................................................84  
9.3.6  Safety  Analyses  ......................................................................................................85  
[IP_ADDRESS]  Reactogenicity .................................................................................................... 85  
[IP_ADDRESS]  Other  Adverse Events ......................................................................................... 85  
10. SUPPORTING DOCUMENTATION AND  OPERATIONAL CONSIDERATIONS  ................. 86 
10.1  Regulatory, Ethical,  and Study Oversight Considerations  ..............................................86  
10.1.1  Informed  Consent Process  ......................................................................................86  
[IP_ADDRESS]  Requirements  for Permission  by [CONTACT_122781]/Guardians  and Assent  by [CONTACT_63779] 
(in case of a minor)  ............................................................................................................ 87  
[IP_ADDRESS]  Other  Informed  Consent Procedures  .............................................................. 87  
10.1.2  Study Termination  and Closure  ..............................................................................88  
10.1.3  Confidentiality  and Privacy  ....................................................................................89  
10.1.4  Secondary  Use of Stored  Specimens  and Data  ......................................................90  
[IP_ADDRESS]  Samples  for Secondary Research  ................................................................... 90  
[IP_ADDRESS]  Data Sharing for Secondary  Research  ............................................................ [ADDRESS_178013]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178014]  Keepi[INVESTIGATOR_007]  .......................................................................93  
[IP_ADDRESS]  Data Collection  and Management  Responsibilities  ........................................ 93  
[IP_ADDRESS]  Data Coordinating Center  / Biostatistician  Responsibilities  .......................... 93  
[IP_ADDRESS]  Data Capture Methods  .................................................................................... 93  
[IP_ADDRESS]  Study Record  Retention  ................................................................................. 93  
[IP_ADDRESS]  Source Records  ............................................................................................... 94  
10.1.10  Protocol Deviations ................................................................................................94  
10.1.11  Publication  and Data Sharing Policy  ......................................................................94  
[IP_ADDRESS]  Human  Data Sharing Plan  .............................................................................. 94  
[IP_ADDRESS]  Genomic Data Sharing Plan ........................................................................... 95  
[IP_ADDRESS]  Publication  ..................................................................................................... [ADDRESS_178015] ...............................................................................................................95  
11. REFERENCES ............................................................................................................................ 97 
APPENDIX B – Stage 2: Adolescent and Adult Noninferiority Study  ................................................ 99 
TABLE OF CONTENTS  ................................................................................................................... 100 
1. Introduction  ................................................................................................................................ 103 
1.1 Study Rationale ............................................................................................................103  
1.2 Background ..................................................................................................................103  
1.3 Risk/Benefit Assessment  .............................................................................................[ADDRESS_178016]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178017](s) and Administration...........................................................................[ADDRESS_178018] Description ...................................................................................116  
5.1.2  Dosing and Administration ..................................................................................116  
5.1.3  Dose Escalation  ....................................................................................................117  
5.1.4  Dose Modifications ..............................................................................................117  
5.1.5  Criteria for Redosing ............................................................................................117  
5.2 Preparation/Handling/Storage/Accountability .............................................................[ADDRESS_178019] Storage and Stability...............................................................................117  
5.2.4  Preparation  ...........................................................................................................117  
5.3 Measures to Minimize Bias: Randomization and Blinding  .........................................118  
5.3.1  Treatment Assignment Procedures  ......................................................................118  
5.3.2  Randomization .....................................................................................................118  
5.3.3  Blinding and Masking Procedures .......................................................................118  
5.4 Study Intervention Compliance ...................................................................................118  
5.5 Concomitant Therapy...................................................................................................118  
6. STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  .......................................................................................... 119 
6.1 Halting Criteria and Discontinuation of Study Intervention ........................................119  
6.1.1  Study Halting Criteria  ..........................................................................................119  
[IP_ADDRESS]  Sentinel Participant Halting Rules  ................................................................... 119  
[IP_ADDRESS]  Cohort Halting Rules ....................................................................................... [ADDRESS_178020] 
Values or Abnormal Clinical Findings During Screening ...................................................122  
7.2 Sick Visit  ......................................................................................................................123  
7.3 Additional Study Procedures in Stage 2 ......................................................................123  
7.3.1  Phone Visits .........................................................................................................123  
7.3.2  Photography .........................................................................................................123  
7.4 Immunogenicity Assessments ......................................................................................123  
7.4.1  Immunogenicity/Efficacy Evaluations .................................................................[ADDRESS_178021]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178022] 
Values or Abnormal Clinical Findings During the Trial  .....................................................126  
7.6 Adverse Events and Serious Adverse Events ..............................................................126  
[IP_ADDRESS]  Definition of Medically Attended Adverse Events (MAAE) .......................... 126  
[IP_ADDRESS]  Definition of Suspected Unexpected Serious Adverse Reactions  (S[LOCATION_003]R)  ... 126  
[IP_ADDRESS]  Definition of Adverse Event of Special Interest (AESI) ................................. 126  
7.6.2  Classification of an Adverse Event ......................................................................127  
See main section of the protocol for a description of the classification of an AE in terms of 
severity and causality. ..........................................................................................................127  
7.6.3  Time Period and Frequency for Event Assessment and Follow- Up ....................127  
7.6.4  Adverse Event Reporting .....................................................................................127  
7.7 Unanticipated Problems ...............................................................................................127  
8. STATISTICAL CONSIDERATIONS  ....................................................................................... 127 
8.1 Statistical Hypotheses  ..................................................................................................127  
8.2 Sample Size Determination ..........................................................................................128  
8.3 Statistical Analyses  ......................................................................................................130  
8.3.1  General Methodology ..........................................................................................130  
8.3.2  Timing of Analyses ..............................................................................................130  
[IP_ADDRESS]  Interim Safety Analyses  ................................................................................... 130  
[IP_ADDRESS]  Interim Immunogenicity Analyses ................................................................... 130  
[IP_ADDRESS]  Final Analyses  .................................................................................................. 130  
8.3.3  Populations for Analyses .....................................................................................131  
8.3.4  Baseline Characteristics and Participant Disposition  ..........................................131  
8.3.5  Immunogenicity Analyses ...................................................................................131  
8.3.6  Safety Analyses  ....................................................................................................131  
[IP_ADDRESS]  Reactogenicity .................................................................................................. 132  
[IP_ADDRESS]  Other Adverse Events ...................................................................................... 132  
9. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  .............. 132 
9.1 Regulatory, Ethical, and Study Oversight Considerations...........................................132  
9.1.1  Informed Consent Process ...................................................................................133  
[IP_ADDRESS]  Requirements for Permission by [CONTACT_122781]/LARs and Assent by [CONTACT_63779] (in case 
of a minor)........................................................................................................................ 134  
[IP_ADDRESS]  Other Informed Consent Procedures  ................................................................ 135  
9.1.2  Study Termination and Closure ...........................................................................136  
9.1.3  Confidentiality and Privacy .................................................................................136  
9.1.4  Secondary Use of Stored Specimens and Data ....................................................137  
[IP_ADDRESS]  Samples for Secondary Research  ..................................................................... 137  
[IP_ADDRESS]  Data Sharing for Secondary Research  ............................................................. [ADDRESS_178023] Keepi[INVESTIGATOR_007] ....................................................................140  
[IP_ADDRESS]  Data Collection and Management Responsibilities  ......................................... 140  
[IP_ADDRESS]  Data Coordinating Center / Biostatistician Responsibilities  ............................ [ADDRESS_178024]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 11 of 147  [IP_ADDRESS]  Data Capture Methods  ..................................................................................... 140  
[IP_ADDRESS]  Study Record Retention ................................................................................... 141  
[IP_ADDRESS]  Source Records  ................................................................................................ 141  
9.1.10  Protocol Deviations ..............................................................................................141  
9.1.11  Publication and Data Sharing Policy ...................................................................141  
[IP_ADDRESS]  Human Data Sharing Plan ............................................................................ 142  
[IP_ADDRESS]  Genomic Data Sharing Plan  ......................................................................... 142  
[IP_ADDRESS]  Publication  ................................................................................................... [ADDRESS_178025]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178026] case was identified in May of 2022 in the [LOCATION_008], mpox (previously known 
as monkeypox) has rapi[INVESTIGATOR_154333] [ADDRESS_178027]- exposure prophylaxis with JYNNEOS (Modified Vaccinia Ankara -Bavarian 
Nordic [ MVA- BN] vacci ne) is also recommended for other moderate or high- risk exposures, 
including in young infants, even though safety and immunogenicity data are sparse in pediatric populations. While the incidence of mpox is declining in the U.S., there is still uncertainty about when this outbreak will end and whether it will establish endemicity in high- risk groups. In 
addition, there is a global vaccine shortage and increasing vaccine supply will take time.   This Phase 2, open- label multi- site platform trial will evaluate strategies to inform public health 
decisions regarding the use of JYNNEOS for mpox prevention and mitigation of outbreaks. As JYNNEOS is also used for smallpox prophylaxis, this trial will also inform public health decisions on the use of the vaccine for smallpox. The trial is divided into stages according to public health 
needs and scientific priorities. Public health strategies will be evaluated in separate stages of the trial and include intradermal dose sparing strategies in adults (Stage 1) and extension of the target population for JYNNEOS to include adolescents (Stage 2). This protocol may add additional arms as needed based on public health needs and priorities. The study arms will be conducted in different stages that could overlap.  Each stage of the study will have a separate protocol in an appendix (e.g., Stage 1 is described in Appendix A, Stage 2 in Appendix B, etc.).  Commonalities between the stages will be included and highlighted in this main section of this protocol.  Stage 1 Approximately 230 healthy, vaccinia -naïve adults ages 18 to 50 years, inclusive, will be enrolled 
to retain 210 participants assuming a 10% drop- out rate. Participants will be randomized 1:1:1 to 
one of three study arms ( Table 1). Participants in Arms 1 and 2 will receive a 2 -dose intradermal 
regimen of 2x10
7 and 1x107 MVA- BN, respectively and Arm 3 will receive the licensed 2 -dose SC 
regimen of 1x108 MVA -BN.  All va ccines will be administered on Day 1 and 29. There will be  
eight study visits (plus an optional screening visit) with the last visit at approximately one year after the first study vaccination. Participants reporting mpox- like illness and who have a positi ve 
MPXV diagnostic test (laboratory- confirmed mpox case) will be seen at a sick visit. Enrollment of 
this Stage ended on October 13, 2022.  Stage 2 Approximately 315 healthy, vaccinia -naïve adolescents ages 12 to 17 years, inclusive, will be 
enrolled in Ar m 5 to retain 300 participants assuming a 5% drop- out rate ( Table 1). Approximately 
Protocol  22-[ADDRESS_178028]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 13 of 147  135 healthy, vaccinia -naïve adults ages 18 to 50 years, inclusive, will be enrolled in Arm 4.  These 
adults (Arm 4) will be combined with participants from Arm 3 (adults given subcutaneous standard 
dose in Stage 1)  and together will be the  comparator group for the primary endpoint, non- inferiority 
testing . Participants in Arms 4 and 5 wi ll receive the 2 -dose SC regimen of 1x108 MVA- BN. All 
vaccines will be administered on Day 1 and 29. There will be nine study visits (plus an optional screening visit) with the last visit at approximately one year after the second study vaccination. Partic ipants reporting a laboratory- confirmed case of mpox will be seen at a sick visit.  
 
Table 1 Study Schema  
  Arm  N Age in 
years  Dose of JYNNEOS  
(MVA -BN) Route of 
Administration*  
Stage 1 
Adult  1 76 18-50 2 x 107 TCID 50, (0.1 mL)  Intradermal  
2 77 1 x 107 TCID 50, (0.05 mL)  Intradermal  
3 76 1 x 108 TCID 50, (0.5 mL)  Subcutaneous  
Stage 2  
Adult and 
Adolescent  4 135 18-50 1 x 108 TCID 50, (0.5 mL)  Subcutaneous  
5 315 12-17 1 x 108 TCID 50, (0.5 mL)  Subcutaneous  
*Subcutaneous is administered in the upper arm  on Day [ADDRESS_178029] 
(inner side) of the forearm on Day 1 and Day 29.  
 
Primary Objectives:  
Stage 1 (Adult) 
• To determine if peak (Day 43) humoral immune responses in adults ages 18-50 years following an ID regimen of 2 x 10
7 TCID 50 MVA- BN are non -inferior to the licensed 
regimen of 1 x 108 TCID 50 MVA- BN administered SC.  
• To determine if peak (Day 43) humoral immune responses in adults ages 18-50 years follo wing an ID regimen of 1 x 10
7 TCID 50 MVA- BN are non -inferior to the licensed 
regimen of 1 x 108 TCID 50 MVA- BN administered SC  
 Stage 2 (Adult and Adolescent)  
• To determine if peak (Day 43) humoral immune responses in adolescents ages 12 to 17 years following administration of a 2-dose 1 x 10
8 TCID 50 MVA- BN regimen 
administered SC are non -inferior to the response in adults ages 18 to 50 years who 
received the licensed 2 -dose SC regimen of 1 x 108 TCID 50 MVA- BN. 
• To describe safety of a [ADDRESS_178030] of Objectives/Endpoints, see corresponding section of the protocol.    Inclusion Criteria  
Inclusion criteria will remain relatively consistent between stages with differences only in the 
ability to give informed consent in pediatric populations. See inclusion criteria  for each stage in 
corresponding section of the protocol.    
Protocol  22-[ADDRESS_178031]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 14 of 147  Exclusion Criteria  
Exclusion criteria will remain relatively consistent between stages with differences due to limited 
data on the safety profile in pediatric population. See exclusion criteria for each stage in corresponding section of the protocol.  Study Phase  
Phase 2   Study Population This platform trial will enroll a study population that is healthy, vaccinia -naïve, non- pregnant, and 
non-breastfeeding. Participants with stable chronic medical conditions including those with 
controlled HIV can participate.  In Stage 1 and Stage 2, adults ages 18 to 50 years, inclusive, will be enrolled, and in Stage 2, adolescents ages 12 to 17 years, inclusive will also be enrolled.  The 
study will attempt to enroll a representative study population that is demographically diverse, and for the adult study (Stage 1), that is proportional to those affected by [CONTACT_154375]. In Stage 2, the  study will aim to enroll a population that is 
representative of the U.S. population to ensure broad applicability of the study findings given that 
the findings will be used to inform a label change in the U.S. for use of JYNNEOS in adolescents. 
While adolescents are not the main population impacted by [CONTACT_154376], there is a risk that sexually active adolescents could be impacted if mpox were introduced into this population.  Sites  
Up to [ADDRESS_178032]
udy intervention  
JYNNEOS is live vaccine produced from the strain MVA -BN, an attenuated orthopoxvirus, that 
does not replicate in human cells. A 2- dose SC regimen of 1 x 108 TCID 50 MVA -BN g iven 4 weeks 
apart is FDA -approved and licensed as a smallpox and mpox vaccine for adults, and FDA -
authorized under an emergency use authorization (EUA) for children and adolescents  in the United 
States.  In addition, the FDA authorized an EUA for use of a  2-dose ID regimen of [ADDRESS_178033] 9, 2022.  In Stage 1 of this study, a 2- dose ID 
regimen of 1 x 107 TCID 50 MVA- BN, given 4 weeks apart, was evaluated as an investigational 
dose sparing regimen. 
 Stage 1 (A dult)  
There will be three study arms in which JYNNEOS will be administered by [CONTACT_154377] 1 and 29.  Stage 2 (Adult and Adolescent) There will be two study arms in which JYNNEOS will be administered by [CONTACT_154378] [ADDRESS_178034]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178035] (DSMB) for objective study oversight and review of 
any study pause. 
 
1.2 Schedule of Activities (SOA)  
For the Schedule of Activities (SOA) for each study stage refer to the corresponding appendix. Refer to Manual of Procedures (MOP) for detailed description of study activities.  
 
2. INTRODUCTION  
 
2.1 Study Rationale  
On July 23, 2022, WHO declared the 2022 mpox outbreak a public health emergency of international concern (PHEIC).
[ADDRESS_178036], the number of confirmed mpox cases in the U.S. surpassed that of any other country
2,3. To mitigate the consequences of this 
outbreak, JYNNEOS vaccine is being offered to individuals considered to be at high risk. However, there is a global vaccine shortage and increasing the supply will take time. This study will evaluate vaccine d ose sparing strategies to extend the limited supply during this global public health crisis 
in Stage 1, and in Stage 2, the study will evaluate vaccine safety and immunogenicity among adolescents ages 12 to 17 years to extend eligibility to adolescent population.  
 
2.2 Background  
Mpox is a reemerging infectious disease caused by [CONTACT_154379] (MPXV), a large double -
stranded DNA virus belonging to the genus  Orthopoxvirus .[ADDRESS_178037]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178038] been 83,424 confirmed mpox cas es 
in 110 locations and countries; most cases have been from 103 non- endemic areas including 29,740 
confirmed cases and 20 deaths in the [LOCATION_002].2  
 Vaccination is being used as a mitigation strategy in the current mpox outbreak for those exposed to and those deemed to be at higher risk of being exposed to mpox. There is one FDA -approved 
vaccine for mpox: JYNNEOS Modified Vaccinia Ankara- Bavarian Nordic (MVA -BN). A second 
vaccine, ACAM2000, is likely effective but is not FDA -approved for mpox and associated with 
moderate risk of myocarditis and pericarditis (5.7 cases per 1,000 vaccinated) as well as encephalomyelitis, progressive vaccinia, generalized vaccinia, and ocular complications. 
ACAM2000 should not be given to people with a weakened immune system, eczema, cardiac 
disease, infants  <[ADDRESS_178039] 9, 2022, the FDA issued an Emergency Use 
Authorization (EUA) for the emergency use of a lower (2 x 10
7) ID dose of JYNNEOS for 
individuals [ADDRESS_178040] stage of thi s platform trial, several potential dose sparing strategies were considered. 
Use of a reduced dose administered SC  is unlikely to be of comparable immunogenicity to the 
licensed SC r egimen . There were several Phase 1 and 2 trials that evaluated 2 -dose regi mens of 
MVA- BN administered SC four weeks apart (Table 2). Although the 2- dose 5x10
7 TCID 50 SC 
regimen may elicit GMT similar  to that of ACAM2000, the GMT will likely be below that of the 
licensed 2 -dose 1 x 108 TCID 50 MVA- BN regimen.  
 
Table 2 Prior Subcutaneous Dosing Trials 
Reference   1 X107 
TCID 50 2 X107 
TCID 50 5 X107 
TCID 50 1 X108 
TCID 50 Assay  
Vollmar et al,  
Vaccine, 2006  20 Liquid  
formulation  6.4 
(CI not reported)  -- -- 29.3 
(CI not reported)  IHD-J 
PRNT GMT  
Frey at al.  
Vaccine, 2007  Lyophilized 
formulation  -- 347.2  
(161.9, 744.7)  551.5  
(321.5, 946.0)  914.5  
(528.0, 1584)  MVA 
PRNT GMT  
von Krempelhuber  
Vaccine, 2010  Lyophilized 
formulation  -- 5.5 
(3.2, 9.6)  10.3 
(5.8, 18.4)  19.4 
(11.1, 34.2)  IHD-J 
PRNT GMT  
 
A single [ADDRESS_178041]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178042] licensed 2-dose regimen. The pi[INVESTIGATOR_9205] 3 trial demonstrated that a single dose is l ikely 
to provide a significantly lower GMT than the licensed 2- dose MVA -BN regimen, 16.9 [13.7, 20.8] 
as compared to 153.5 [134.3, 175.6], respectively ( Table 3).   
 
Table 3 MVA -BN Compared to ACAM2000 
 
MVA -BN 
(N=185)  ACAM2000  
(N=186)  GMTs ratio  
MVA/ ACAM  
Visit Week  n GMT  95% CI  n GMT  95% CI  Ratio  95% CI  
Plaque Reduction Neutralization Test  
Week 0  185 1.0 [1.0, 1.1]  186 1.0 [1.0, 1.0]  1.008  [0.97, 1.05]  
Week 2  184 16.2 [13.0, 20.1]  184 16.2 [13.1, 20.0]  0.997  [0.74, 1.35]  
Week 4  185 16.9 [13.7, 20.8]  186 79.3 [67.1, 93.8]  0.213  [0.16, 0.28]  
Week 6  185 153.5  [134.3, 175.6]  181 64.7 [54.9, 76.2]  2.372  [1.92, 2.93]  
 
NIAID conducted a Phase [ADDRESS_178043] (now licensed) 2- dose 1 x 108 TCID 50 
MVA- BN SC regimen (liquid formulation) and a 2- dose 2 x 107 TCID 50 MVA- BN ID regimen 
(liquid formulation) and found peak vaccinia virus, Western reserve strain (VV -WR) GMT of 49.5 
(40.0, 61.3) and 59.6 (48.1, 74.0), respectively ( Table 4).21 The 2 -dose 2 x 107 TCID 50 ID regimen 
was non- inferior to the 2 -dose 1 x 108 TCID 50 SC regimen and utilized only one -fifth of the dose.  
These results are supported by a trial evaluating another MVA vaccine (ACAM3000) which showed ID vaccination at 1x10
7 TCID 50 had similar VV -WR GMT to 1x108 TCID 50 administered 
SC or IM.22  
 
Table 4. Prior Intradermal Dosing Compared to Subcutaneous  
Study Visit Day Group   
Lyophilized SC 1x108 
(N=145) GMT [95% CI]  Liquid SC 1x108 
(N=149) GMT [95% CI]  Liquid ID 2x107 
(N=146) GMT [95% CI]  
Day 0  7.5 [,]  7.7 [7.4, 8.0]  7.7 [7.4, 7.9]  
Day 14  10.9 [9.9, 12.0]  10.0 [9.0, 11.1]  10.3 [9.3, 11.3]  
Day 28  10.8 [9.9, 11.9]  9.6 [8.7, 10.6]  10.8 [9.9, 11.9]  
Day 42  77.6 [62.3, 96.7]  45.2 [36.4, 56.2]  54.4 [43.7, 67.8]  
Peak post vaccination 2  87.8 [71.2, 108.3]  49.5 [40.0, 61.3]  59.6 [48.1, 74.0]  
 
Even with the EUA for intradermal MVA -BN being available, Stage 1 of this trial is designed to 
evaluate several unique issues:  
• As vaccine supply is not anticipated to meet the demand in the next year, this trial will 
evaluate dose reduction strategies focused on the ID route, that is, confirming the previously studied ID dose and evaluating one tenth dose of MVA-BN (1x10
7). 
• This trial will also assess differences in safety and tolerability of the ID versus the licensed SC regimen as issues of tolerability have been raised by [CONTACT_154380].  
 While JYNNEOS is available under EUA for individuals younger than [ADDRESS_178044]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178045] sex with men, with a median age of 34 years.  Among global cases with age data 
available, 1.2% are aged 0 -17 years ;23 in the [LOCATION_002], from  May 17 through September 24, 
2022, MPXV infections in persons under 18 years of age accounted for 0.3% of reported cases.24  
Among 55 adolescents aged 13- 17 years, 89% were male, and the most common route of exposure 
was male to male sexual contact (66%). Prior to the global [ADDRESS_178046].  
2.3 Risk/Benefit Assessment  
 
For information regarding risk/benefit assessment for each study stage, see the corresponding appendix.   
3. OBJECTIVES  AND  ENDPOINTS 
 For objectives and endpoints for each study stage, see the corresponding appendix. 
4. STUDY  DESIGN 
4.[ADDRESS_178047] SC regimen in 
healthy, vaccinia -naïve adults 18 to 50 years of age, inclusive, (Stage 1). In Stage [ADDRESS_178048] SC regimen in adults ages 18 to 50, inclusive.   
 In Stage 1, approximately 230 adult participants will be enrolled and randomized to one of three study arms. The two dose sparing strategies include one -fifth (2 x10
7) and one -tenth (1 x107) of 
the standard dose of MVA -BN administered ID on Day 1 and 29 (Arm 1 and 2, respectively). The 
comparator arm (Arm 3) will be the [ADDRESS_178049] (1x108) MVA -BN SC regimen. Stage 1 will 
enroll a 1:1:1 randomization allocation.   In Stage 2, approximately 135 healthy, vaccinia -naïve adults will be enrolled (Arm 4) and will be 
given the standard, licensed regimen of 1x10
8 MVA- BN administered SC on Day 1 and 29 and 
will be combined with adults from Arm 3 (Stage 1)  to be the  comparator  for the primary endpoint , 
non-inferiority testing . Approximately 315 healthy, vaccinia -naïve adolescents will be enrolled and 
given 1x108 MVA- BN administered SC on Days 1 and 29 (Arm 5). The study will have a set target 
enrollment of at least 25% adolescents ages [ADDRESS_178050]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 19 of 147  4.2 Scientific Rationale for Study Design  
The rationale for each of the arms in this study is as follows: 
1. MVA -BN 2 x 107 ID (1/5th dose) on Days 1, 29 (Study Arm 1)  – This regimen matches 
the prior ID dosing and matches the dose authorized in the EUA. This regimen would allow 
for 5 -fold increase in vaccine supply.  
2. MVA -BN 1 x 107 ID (1/10th dose) on Days 1, 29 (Study Arm 2) – This regimen would 
test a larger dose conservation. This regimen would allow for 10- fold increase in vaccine 
supply. 
3. MVA -BN 1 x 108 SC on Days 1, 29 (Study Arms 3, 4, and 5)  – This regimen is the 
licensed dose and route. Arm 3 will be used as a comparator to ID doses of MVA BN (Arms 
1 and 2, Stage 1). Arms 4 (adult) and 5 (adolescent) will be used to evaluate noninferiority of this licensed regimen among adolescents compared to adults (Stage 2). 
4.3 Justification for Dose  
This study will use the FDA -approved, licensed dose 1 x 108 TCID 50 MVA -BN a dministered SC 
on Day 1 and 29 in Stage 2 of the study and as the comparator for the ID doses of MVA -BN in 
Stage 1. It is anticipated that the licensed, 2 -dose SC regimen will be safe and immunogenic in 
adolescents. The ID regimens being evaluated in this study use lower doses  of the licensed vaccine, 
and either match or are one dilution lower than the dose used in the prior ID dosing study (PMID 26143613). Therefore, it is anticipated that these doses administered ID will be safe and immunogenic.   
5. STUDY  POPULATION  
 
For a description of the study population, eligibility criteria, lifestyle considerations, procedures 
for screen failures, recruitment and retention strategies  for each stage see the corresponding 
appendix.   
6. STUDY  PRODUCT 
6.[ADDRESS_178051](s) and Administration  
6.1.[ADDRESS_178052] Description  
JYNNEOS is FDA- approved and licensed as a smallpox and mpox vaccine in the [LOCATION_002]. 
The vaccine, when thawed, is a milky, light yellow to pale white colored suspension that is licensed for subcutaneous injection. JYNNEOS is a live vaccine produced from the strain Modified Vaccinia Ankara- Bavarian Nordic (MVA -BN), an attenuated, non -replicating orthopoxvirus. 
MVA-BN is grown in primary Chicken Embryo Fibroblast (CEF) cells suspended in a serum- free 
medium containing no material of direct animal origin, harvested from the CEF cells, purified, and concentrated by [CONTACT_154381] (TFF) steps including benzonase digestion. Each 0.5 mL dose is formulated to contain 0.5 x 10
8 to 3.95 x 108 infectious  units of MVA -BN 
live virus in 10 mM Tris (tromethamine), [ADDRESS_178053]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178054] -cell DNA (≤ 20 mcg), protein (≤ 500 mcg), benzonase 
(≤0.0025 mcg), gentamicin (≤0.163 mcg), and ciprofloxacin (≤0.005 mcg).  
 
6.1.2 Dosing and Administration 
In this trial, a licensed vaccine is being evaluated (i.e., JYNNEOS) and there is no placebo group 
(Table 5). In Stage 1, use  of the contralateral arm was an option if there is any residual local reaction 
at Day [ADDRESS_178055] 
of the participant in terms of safety or using the same arm (for the second injection) will enable the site to better evaluate reactogenicity (e.g., tattoo on opposite upper arm). If the second vaccination is given in the same arm as the first vaccination, the second injection should be given approximately [ADDRESS_178056] injection site if physically possible.  
 
Table 5 Study Arms  
Stage 1 (Adult) 
Arm  Dose of JYNNEOS (MVA -BN) Route of Administration*  Vaccination Day  
Day 1  Day 29  
1 2 x 107 TCID 50, (0.1 mL)  Intradermal  X X 
2 1 x 107 TCID 50, (0.05 mL)  Intradermal  X X 
3 1 x 108 TCID 50, (0.5 mL)  Subcutaneous  X X 
 
Stage 2 (Adults and Adolescent)  
Arm  Dose of JYNNEOS 
(MVA -BN) Route of Administration*  Vaccination Day 
Day 1  Day 29  
4 (Adult)  1 x 108 TCID 50, (0.5 mL)  Subcutaneous  X X 
5 (Adolescent)  1 x 108 TCID 50, (0.5 mL)  Subcutaneous  X X 
*Subcutaneous is administered in the upper arm , intradermal is administered in the volar aspect (inner side) of 
the forearm.  
 
6.1.[ADDRESS_178057] administration is unsuccessful, another administration will not be attempted.  
 
6.2 Preparation/Handling/Storage/Accountability  
6.2.[ADDRESS_178058]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178059]: JYNNEOS (MVA- BN vaccine)  
The JYNNEOS (MVA- BN vaccine) will be stored and provided by [CONTACT_154382]. Study 
product will be shipped to the clinical research site upon request and approval from DMID. 
 Accountability  
The participating site PI [INVESTIGATOR_119828]. The participating site PI [INVESTIGATOR_119829]’s research pharmacist responsibility for study product accountability. The participating site’s research pharmacist will be responsible for maintaining complete records and documentation of study product receipt, accountability, dispensation, storage conditions, and final disposition of the study products.   Time of vaccine administration to the participant will be recorded on the appropriate data collection 
form (DCF). All study product(s), including the amount of JYNNEOS (MVA -BN vaccine), and 
whether administered or not, must be documented on the appropriate study product accountability record or dispensing log. The sponsor’s monitoring staff will verify the participating site’s study product accountability records and dispensing logs per the DMID -approved clinical monitoring 
plan (CMP).  
 Once all participant dosing is complete, the pharmacy staff should retain or dispose of used study products and complete study product accountability procedures in accordance with site -specific 
standard operating procedures (SOPs). This applies to: 
• used JYNNEOS (MVA- BN vaccine)  vials  
• JYNNEOS (MVA- BN vaccine) cartons  
 
All used vials and cartons may either be sequestered from the unused supplies and retained until study conclusion or until study product accountability has occurred by [CONTACT_154383]. Used syringes should be discarded per usual procedure.   Disposition  
After the study treatment period has ended or as appropriate over the course of the study after study product accountability has been performed, guidance for disposition of unused JYNNEOS (MVA-
BN vaccine) vials will be provided by [CONTACT_122830].   
6.2.[ADDRESS_178060]: JYNNEOS (MVA- BN vaccine)  
JYNNEOS is supplied in a single -dose vial with turquoise and white label for SC injection. Each 
0.5 mL dose is formulated to contain 0.5 x 10
8 to 3.95 x 108 infectious units of MVA -BN live virus 
in 10 mM Tris (tromethamine), [ADDRESS_178061] -cell DNA (≤ 20 mcg), protein (≤ 500 mcg), benzonase (≤ 0.0025 mcg), 
gentamicin (≤0.163 mcg), and ciprofloxacin (≤0.005 mcg). JYNNEOS is a sterile vaccine formulated without preservatives. The vial stoppers are not made with natural rubber latex.   
6.2.[ADDRESS_178062]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178063]: JYNNEOS (MVA- BN vaccine ) 
JYNNEOS should be kept frozen at - 25°C to - 15°C ( -13°F to +5°F) and stored in the original 
package to protect from light. JYNNEOS should not be re -frozen once a vial has been thawed. 
Once thawed, the vaccine may be kept at +2°C to +8°C (+36°F to +46°F) f or 4 weeks. The package 
insert provides additional instructions for the handling and storage of JYNNEOS.  
6.2.4 Preparation  
Each dose (0.5 mL) is supplied in a single -dose vial. Sites should allow the vaccine to thaw and 
reach room temperature before use (about 15 to 30 minutes). After thawing, the total time stored 
at +2°C to +8°C (+36°F to +46°F) should not exceed 4 weeks . Once the vial is punctured and a 
dose is withdrawn, if it is not used in its entirety, it should be stored at +2°C to +8°C (+36°F to +46°F) and discarded within [ADDRESS_178064] puncture. If the unpunctured vial is initially shipped/stored at 2- 8C then i t is stable for up to [ADDRESS_178065] 30 seconds.   For the ID injection (Arm 1), 0.[ADDRESS_178066] (inner side) of the forearm.  
 
For the ID injection (Arm 2), 0.[ADDRESS_178067] of the forearm.  
 
For the SC injection (Arms 3, 4 and 5), 0.5 mL of vaccine will be withdrawn from the vial into a 
sterile syringe and injected into the fatty  subcutaneous tissue of the upper arm. 
 
See the protocol -specific MO P for detailed information on the preparation, labeling, storage, and 
administration for each arm.  
 
6.3 Measures to Minimize Bias: Randomization and Blinding  
6.3.1 Treatment Assignment Procedures  
The randomization procedure will be described in the MOP.  
   
6.3.2 Randomization  
For Stage 1, there will be a 1:1:1 randomization allocation. Randomization will not be stratified. 
Randomized treatment assignments will be generated by a statistician at The Emmes Company, LLC, the Data and Statistical Coordinating Center (SDCC) for this study. Participants will be registered using a web -based application developed by [CONTACT_100415], LLC. Upon entry 
Protocol  22-[ADDRESS_178068]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178069] 25% adolescents ages 12 to 14 years.  
6.3.3 Blinding and Masking Procedures  
This study will not utilize blinding or masking procedures as it is an open- label, non- placebo -
controlled trial. Research laboratories will be blinded to participant study arm for the purposes of 
immunogenicity/efficacy evaluations.  
6.[ADDRESS_178070]. Administration and date, time, and location of injection will be recorded on t he appropriate eCRF.
 
6.5 Concomitant Therapy  
For this platform trial that evaluates use of JYNNEOS vaccine, participants in all stages will be asked to avoid use of medications that might interfere with the evaluation of the immune response to the vaccine unless clinically indicated for a medical condition diagnosed after enrollment. Specific information regarding concomitant therapy for each study stage, see the corresponding appendix.  
7. STUDY  INTERVENTION  DISCONTINUATION  AND  
PARTICIPANT  DISCONTINUATION/WITHDRA WAL  
 For this platform trial, additional individual and study halting criteria were added for stages involving more vulnerable populations for which safety profile is largely unknown (e.g., adolescents).  For each stage, see the corresponding appendix for specific information.  R efer to 
the corresponding appendix for information regarding participants who discontinue study intervention, study withdrawal, and participants lost to follow-up.  
8. STUDY  ASSESSMENTS  AND  PROCEDURES 
 Please see Appendix A  and B  for Sections 8.1 through 8.5. 
 For i nformation regarding study assessments and procedures for each study stage, see the 
corresponding appendix.  
 
8.6 Adverse Events and Serious Adverse Events  
8.6.1 Definition of Adverse Events (AE)  
Protocol  22-[ADDRESS_178071]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178072] medical occurrence associated with the use of an intervention 
in humans, whether or not considered intervention- related (21 CFR 312.32 (a)). An AE can 
therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of medicinal (investigational) product.   Any medical condition that is present at the time the participant is screened will be considered as baseline and not reported as an AE. However, if the severity (i.e., grade) of any pre -existing 
medical condit ion increases, it should be recorded as an AE. 
 Adverse events can be further divided into solicited adverse events and unsolicited adverse events. Solicited adverse events are those for which the study team will specifically query the participant whether they occurred. Unsolicited adverse events are those events that the participant report 
occurring without being queried about the specific event.   
[IP_ADDRESS] Solicited Adverse Events  
Reactogenicity will be especially important to document because of prior studies dem onstrating 
more local (measurement) reactogenicity among participants who received the ID MVA -BN 
vaccine injection. This study will collect the following solicited adverse events based on prior 
studies. This includes local (pain at the site of the injectio n, erythema/redness, induration/swelling, 
pruritis) and systemic (fever, chills, nausea, headache, fatigue, change in appetite, myalgia [exclusive of the injection site], and arthralgia) reactogenicity. In addition, there is an expectation that some partic ipants will develop skin discoloration and nodules which will be reported as AEs 
and not collected on the memory aid and followed through to resolution. For this study, the following toxicity grading scale is used: 
“FDA Guidance for Industry, Toxicity Grading Scale for Healthy Adults and Adolescent 
Volunteers Enrolled in Preventive Vaccine Clinical Trials ” as a reference.  
 Of note, pruritis/itching, arthralgia, chills, and change in appetite are not included in the FDA toxicity table. However, the FDA Guidance allows for addition of other signs and symptoms as 
follows:  
Mild:      No interference with activity  
Moderate:     Some interference with activity  
Severe:      Prevents daily activity  
Potentially Life Threatening:   ER visit or hospi[INVESTIGATOR_059]  
 
[IP_ADDRESS] Unsolicited Events  
Unsolicited events are all AEs spontaneously reported by [CONTACT_4538]/or in response to an 
open question from study personnel or revealed by [CONTACT_4171], physical examination, or other 
diagnostic procedures.    
8.6.2 Definition of  Serious Adverse Events  
An adverse event or suspected adverse reaction is considered "serious" if, in the view of either the 
investigator or sponsor, it results in any of the following outcomes (21 CFR 312.32 (a)):  
Protocol  22-[ADDRESS_178073]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 25 of 147  • death  
• a life -threatening adverse event* 
• inpatient hospi[INVESTIGATOR_1081] 
• a persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions, or  
• a congenital anomaly/birth defect.  
 Important medical events that may not result in death, be life -threatening, or require hospi[INVESTIGATOR_6721], based upon appropriate medical judgment, they may jeopardize the patient or particip ant and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, convulsions that do not result in inpatient hospi[INVESTIGATOR_059], etc.  
 * An adverse event is considered “life -threatening” if, in the view of either the investigator or 
sponsor, its occurrence places the patient or participant at immediate risk of death. It does not include grade [ADDRESS_178074] caused death.   
8.6.3 Classification of an Adverse Event 
The determination of seriousness, severity and causality will be made by [CONTACT_63689]- site investigator 
or other staff as listed on the delegation log. Any potential grade 3 or 4 AE should be evaluated 
by [CONTACT_154384] a medical evaluation of AEs. This includes but is not limited to physicians, physician assistants, and nurse practitioners.   
[IP_ADDRESS] Severity of Event  
All AEs or SAEs will be assessed for severity, according to the toxicity grading scale, FDA 
Guidance for Industry, Toxicity Grading Scale for Healthy Adults and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials . For adverse events (AEs) not included in the 
protocol-defined grading scale, the following guidelines will be used to describe severity.   
Mild (Grade 1): Events that are usually transient and may require only minimal or no 
treatment or therapeutic intervention and generally do not interfere with the participant’s usual activities of daily living.  
Moderate (Grade 2) : Ev
 ents that are usually alleviated with additional specific therapeutic 
intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. Severe (Grade 3) : E
 vents interrupt usual activities of daily living, or significantly affects 
clinical status, or may require intensive therapeutic intervention. Severe events are usually incapacitating.  
Life-threatening (Grade 4) : E
 xtreme limitation in activity, significant assistance required; 
significant medical intervention/therapy required, hospi[INVESTIGATOR_154334].  
 
[IP_ADDRESS]
 Relationship to Study Intervention 
For each reported adverse event or reaction, the Principal Investigator [INVESTIGATOR_154335]: 
Protocol  22-[ADDRESS_178075]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 26 of 147   
Related  – The AE is known to occur with the study intervention, there is a reasonable 
possibility that the study intervention caused the AE, or there is a temporal relationship between the study intervention and event. Reasonable possibility means that there is evidence to suggest a causal relationship between the study intervention and the AE. Not Related  – T
 here is not a reasonable possibility that the administration of the study 
intervention caused the event, there is no temporal relationship between the study intervention and event onset, or an alternate etiology has been established. 
 
8.6.5
 Adverse Event Reporting  
[IP_ADDRESS] Investigators Reporting of AEs 
All clearly related signs, symptoms, and results of diagnostic procedures performed because of an 
AE should be grouped together and recorded as a single diagnosis or AE term, if available. If the AE is a laboratory abnormality that is part of a clinical condition or syndrome, it should be recorded as the syndrome or diagnosis rather than the individual laboratory abnormality. Each AE will also be described in terms of duration (start and stop date), severity, association with the study product, action(s) taken, and outcome. 
 
AEs characterized as intermittent require documentation of onset and duration of each epi[INVESTIGATOR_1865].  All AEs will be assessed for severity, relatedness to study vaccine (see Section [IP_ADDRESS] and Section 
[IP_ADDRESS]) and seriousness (see S ection 8.3.2) by [CONTACT_9154] [INVESTIGATOR_11637]-investigator. 
 All AEs will be captured on the appropriate data collection form. Information to be collected for AEs includes event term or description, date of onset, assessment of severity, relationship to study 
product, and alternate etiology (assessed only by [CONTACT_8703] a diagnosis and listed on the Form FDA 1572 as an investigator), date of resolution, seriousness, and outcome. AEs occurring during the trial collection and reporting period will be documented appropriately regardless of relationship.   
[IP_ADDRESS] Special Reporting of Adverse Events  
Protocol specified Adverse Events of Special Interest ( AESIs ) will be reported within 24 hours of 
the site awareness of the AESI to the DMID Pharmacovigilance Group via the mechanism 
described below for SAE reporting (see Section [IP_ADDRESS]).  
 
 
8.6.6 Serious Adverse Event Reporting  
[IP_ADDRESS] Investigators Reporting of SAEs 
Any AE that meets a protocol- defined serious criterion must be submitted immediately (within 24 
hours of site awareness) on an SAE form to the DMID Pharmacovigilance Group, at the following address: 
  
DMID Pharmacovigilance Group Clinical Research Operations and Management Support (CROMS)  
[ADDRESS_178076]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 27 of 147  SAE Hot Line: 1 -[PHONE_889] (US) or [PHONE_2619] (outside US) 
SAE FAX Number: [PHONE_2620] (US) or [PHONE_2621] (outside US) 
SAE Email Address: [EMAIL_1393] 
 In addition to the SAE form, select SAE data fields must also be entered into the SDCC system. See the protocol-specific MOP for details regarding this procedure.   Other supporting documentation of the event may be requested by [CONTACT_154385]. The DMID Medical Monitor will review and assess the SAE for regulatory reporting and potential impact on study partic ipant safety and 
protocol conduct.  At any time after completion of the study, if the site principal investigator [INVESTIGATOR_29353]-investigator becomes aware of an SAE that is suspected to be related to study product, the site principal investigator [INVESTIGATOR_29353]- investigator will report the event to the DMID 
Pharmacovigilance Group.  
[IP_ADDRESS] Regulatory Reporting of SAEs 
Following notification from the site Principal Investigator [INVESTIGATOR_29353]-investigator, DMID, 
as the IND sponsor, will report any  Suspected Unexpected Serious Adverse Reaction ( S[LOCATION_003]R ) to 
the FDA as an IND safety report. DMID will report an AE as a suspected unexpected adverse event only if there is evidence to suggest a causal relationship between the study intervention and the AE.   The Sponsor must ensure the event meets all three of the definitions: 
• Suspected adverse reaction.  
• Serious. 
• Unexpected.  
 Both serious and unexpectedness are important, but the event will be reported only if there is evidence to suggest a causal relationship b etween the drug and the adverse event, such as:  
• A single occurrence of an event that is uncommon and known to be strongly associated with drug exposure.  
• One or more occurrences of an event that is not commonly associated with drug exposure but is otherwise uncommon in the population exposed to the drug.  
• On review as an aggregate analysis when the occurrence is higher than the historical control.  
 DMID wi ll report to the FDA any unexpected fatal or life -threatening suspected adverse reaction 
as soon as possible, but in no case later than 7 calendar days after the sponsor’s initial receipt of the information. If the event is not fatal or life -threatening the IND safety report will be submitted 
within [ADDRESS_178077]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 28 of 147   
DMID will su bmit an IND safety report to the FDA and will notify all participating site Principal 
Investigators (i.e., all Principal Investigators to whom the sponsor is providing drug under its IND(s) or under any Principal Investigator’s IND(s) of potential serious risks from clinical studies or any other source, as soon as possible. SAEs that are not S[LOCATION_003]Rs will be reported to the FDA at least annually in a summary format which includes all SAEs.   
8.6.[ADDRESS_178078] their 
safety or influence their choice to participate or continue participating in the study.  
8.6.8 Reporting of Pregnancy 
Pregnancy is not an AE. However, any pregnancy that occurs during study participation (through 
Day 365 Stage 1, and Day 394 for Stage 2) should be reported to the sponsor on the appropriate DCF. Pregnancy should be followed for safety and outcome. This follow -up will include pregnancy 
outcome (termination, pre -term birth, term birth)  and newborn outcome (live birth, fetal demise, 
stillbirth; presence of any congenital anomalies). No in -person visits will be required for pregnancy 
outcome determination.  
8.7 Unanticipated Problems  
8.7.1 Definition of Unanticipated Problems (UP)  
The Department of Health and Human Services Office for Human Research Protections (OHRP) c
onsiders unanticipated problems (UPs) involving risks to participants or others to include, in 
general, any incident, experience, or outcome that meets all of  the fol lowing criteria:  
• Unexpected in terms of nature, severity, or frequency given (a) the research procedures that are described in the protocol -related documents, such as the Institutional Review Board 
(IRB) -approved research protocol and informed consent, parental permission and assent 
documents; and (b) the characteristics of the participant population being studied; and  
• Related or possibly related to participation in the research (“possibly related” means there is a reasonable possibility that the incident, experience, or outcome may have been caused by [CONTACT_3459]); and  
• Suggests that the research places participants or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized. 
 Incidents arising from noncompliance with study procedures should be reported as protocol deviations (see Section 8.1.1).  An incident that qualifies as both a UP and a protocol deviation 
should be reported as both.   
8.7.[ADDRESS_178079] 
(IRB) and to the SDCC.  
Protocol  22-[ADDRESS_178080]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 29 of 147   
The UP report will include the following information: 
• Protocol identifying information: protocol title and number, PI’s name, and the I RB project 
number; 
• A detailed description of the event, incident, experience, or outcome;  
• An explanation of the basis for determining that the event, incident, experience, or outcome represents an UP;  
• A description of any changes to the protocol or other  corrective actions that have been taken 
or are proposed in response to the UP. 
 To satisfy the requirement for prompt reporting, UPs will be reported using the following timeline:  
 
• UPs that are SAEs will be reported to the IRB and to the SDCC/study sponsor within 24 hours of the investigator becoming aware of the event.  
• Any other UP will be reported to the IRB and to the SDCC/study sponsor within a timeline 
defined according to the relevant policies.  
• UPs will be collected through the end of the study. 
 
8.7.3 Reporting Unanticipated Problems to Participants  
Participants will be informed of any UPs that will potentially influence their participation in this 
trial. 
 
9. STATISTICAL  CONSIDERATIONS 
 
For statistical considerations for each study stage, see the corresponding appendix.  
10. SUPPORTING  DOCUMENTATION  AND  OPERATIONAL  
CONSIDERATIONS 
10.1 Regulatory, Ethical, and Study Oversight Considerations  
This study will be conducted in conformity with the principles set forth in The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Participants of Research (US 
National Commission for the Protection of Human Participants of Biomedical and Behavioral Research; April 18, 1979), and the federal policy for the Protection of Human Participants codifie d 
in 45 CFR Part 46, 21 CFR Part 50 (Protection of Human Participants), and the ICH E6(R2).  An OHRP -registered IRB will review and approve this protocol, associated informed consent, 
parental permission and assent documents, recruitment materials, and handouts or surveys intended for the participants, prior to the recruitment, screening and enrollment of participants. The IRB review shall be in accordance with 45 CFR 46 and 21 CFR 50, 21 CFR 56 (IRBs), and other federal, state, and local regulations and policies, as applicable.  
Protocol  22-[ADDRESS_178081]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 30 of 147  Each institution engaged in this research will hold a current Federal wide Assurance (FWA) issued 
by [CONTACT_19819] (OHRP) for federally funded research. and provide 
the FWA number to DMID. Each site principal investigator [INVESTIGATOR_154336] d at his/her research site(s).  
 Any amendments to the protocol or informed consent, parental permission and assent documents will be approved by [CONTACT_106526]. IRB review and approval will occur at least annually throughout enrollment and follow -up of participants, in accordance with applicable 
regulations and the requirements of the IRB/IEC. The participating site PI [INVESTIGATOR_154337], as applicable to the IRB policy.  DMID must r eceive the documentation that verifies IRB/IEC approval for this protocol, informed 
consent, parental permission and assent documents and associated documents, prior to the recruitment, screening and enrollment of participants, and any IRB approvals for continuing review or amendments as required by [CONTACT_122830].   
10.1.1 Informed Consent Process  
 
For information regarding the informed consent and assent, where applicable, process for each study stage, see the corresponding appendix.  
10.1.2 Study Termination and Closure  
Section  7, Study Intervention Discontinuation and Participant Discontinuation/Withdrawal, 
describes the temporary halting of the study. This study may be prematurely termi nated if there is 
sufficient reasonable cause, including but not limited to: 
• Determination of unexpected, significant, or unacceptable risk to participants 
• Results of interim efficacy or futility analysis  
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or evaluable 
• Regulatory authorities’ determination  
• Sponsor’s determination 
 
If the study is prematurely terminated, the Principal Investigator (PI) will promptly inform study participants and the Institutional Review Board (IRB) and regulatory authorities as applicable. Study participants will be contact[INVESTIGATOR_530], as applicable, and be informed of changes to study visit schedule. The PI [INVESTIGATOR_154338] -up for the participants, as necessary. The sponsor 
will notify regulatory authorities as applicable.    
10.1.[ADDRESS_178082] by [CONTACT_3486], their staff, and 
the sponsor(s) and their agents. This confidentiality is extended to cover clinical information 
relating to participants, test results of biological samples and genetic tests, and all other information generated during participation in the study. No identifiable information concerning participants in 
Protocol  22-[ADDRESS_178083]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178084] (IRB), and/or regulatory agencies may inspect all documents and records required to be maintained by [CONTACT_093], including but not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the participants in this study. The clinical study site will permit access to such records.  
 All source records including electronic data will be s tored in secured systems in accordance with 
institutional policies and federal regulations. All study data and research specimens that leave the site (including any electronic transmission of data) will be identified only by a coded number that cannot be linked to a participant.  As this research is funded by [CONTACT_18121], it is covered by [CONTACT_154386] a Certificate of Confidentiality. By [CONTACT_122842], researchers cannot be forced to disclose or provide, in any Federal, State, or local civil, criminal, administrative, legislative, or other 
proceeding, the name [CONTACT_122867], document, or biospecimen that 
contains identifiable, sensitive information about the individual and that was created or compi[INVESTIGATOR_5829] d 
for purposes of the research, unless such disclosure or use is made with the consent of the individual to whom the information, document, or biospecimen pertains.  The Certificate cannot be used to resist a demand for information from personnel of the [LOCATION_002] Government that is used for auditing or evaluation of federally funded projects, like this study, or for information that must be released in order to meet the requirements of the FDA.  A Certificate of Co nfidentiality does not prevent the participant from voluntarily releasing 
information about themselves or their involvement in this research. If any person or agency obtains 
a written consent to receive research information, then the researchers may not use the Certificate to withhold that information.   The Certificate of Confidentiality does not prevent the researchers from reporting without the participant’s consent, information that would identify the participant as a participant in the research project regarding matters that must be legally reported including child and elder abuse, sexual abuse, or wanting to harm themselves or others.   The release of individual private information or specimens for other research will only occur if consent was obtained from the individual or the parent(s) or LAR of the adolescent participants to whom the information, document, or biospecimen pertains, or  for the purposes of other research 
that the release is in compliance with applicable Federal regulations governing the protection of human participants in research.  
     
Protocol  22-[ADDRESS_178085]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 32 of 147  10.1.4 Secondary Use of Stored Specimens and Data  
 
[IP_ADDRESS] Samples for Secondary Research  
Repository Research Sample  
To participate in this study, adult participants and the parent or LAR of adolescent participants will 
be asked for consent for storage of samples for secondary use. Samples will be stored indefinitely 
at a DMID -designated storage facility. Each sample will be encoded (labeled) only with a barcode 
and a unique tracking number to protect participant confidentiality. Secondary research with coded samples and data may occur, however, participant confidentiality will be maintained as described for this protocol. An IRB review of the secondary research using coded specimens is required.  Repository Research Samples, upon written request and approval from DMID and any approvals required by [CONTACT_779], may be shared for secondary research with investigators at the participating site, with researchers at other sites or other institutions, or company- designated research 
laboratories. The samples will not be sold or used directly for production of any commercial product. DMID will authorize shipment from the repository.  Reports from secondary research will not be kept in the participants’ health records or shared with participants, unless required by [CONTACT_2371]. Reports will not be sent to the specimen repository. The participant’s decision for secondary research can be changed at any time by [CONTACT_154387]. If the participant changes his/her decision, the samples will be destroyed if the samples have not been used for research or released for a specific research project.  
 
[IP_ADDRESS] Data Sharing for Secondary Research 
Data from this study may be used for secondary research. Individual participant data collected 
during the trial  that are sufficient to reanalyzed primary and secondary endpoints will be made 
available after deidentification.  The SAP and Analytic  Code will also be made available. This data 
will be available  following publication, with no end date.  The data will be made available to 
researchers who provide a methodologically sound proposal. The data will be available for any 
purpose outlined in the approved proposal. Proposals should be directed to DMID. To gain access, data requestors will need to sign a data access agr eement. The investigator may request removal of 
data on individual study participants from NIH data repositories in the event that a research participant withdraws or changes his or her consent. However, data that have been distributed for 
approved research use cannot be retrieved. 
 
10.1.5 Key Roles and Study Governance 
This is a multi- site clinical trial and as such, all study team members and roles are listed in the 
Manual of Procedures (MOP). 
 
10.1.[ADDRESS_178086]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178087] of the trial is in compliance with the currently approved protocol/amendment(s), International Council for Harmonisation (ICH), Good Clinical Practice, and with applicable regulatory requirement(s) and sponsor requirements.   
 Monitoring for this study will be overseen by [CONTACT_18127]/DMID and conducted by [CONTACT_18127]/DMID contractors. Details of clinical site monitoring are documented in a Clinical Monitoring Plan (CMP). The CMP describes in detail who will conduct the monitoring, at what frequency monitoring will be done, at what level of detail monitoring will be performed, and the distribution of monitoring reports. Monitoring visits will include, but are not limited to, review of regulatory files, investigational product  administration and accountability records, eCRFs, informed consent, 
parental permission and assent forms, medical and laboratory reports, site study storage records, training records, and protocol and GCP compliance. Site monitors will have access to each  
participating site, study personnel, and all study documentation according to the NIAID or DMID -
approved site monitoring plan.  Study monitors will meet with site principal investigators (or 
designee) to discuss any problems and outstanding issues and will document site visit findings and discussions.   
10.1.8 Quality Assurance and Quality Control 
Quality control (QC) and quality assurance (QA) activities are essential to the safety of 
participants, and the reliability of study data. Each site participating in the study is responsible for integrating quality control checks throughout the study and implementing a QA Checklist or Clinical Quality Management Plan (CQMP). The site will conduct the following:   
1. Routine internal QC and QA activities for the purposes of measuring, documenting and reporting study conduct, protocol adherence, human participants’ protections, and reliability of the protocol- driven data collected.  
2. Processes for addressing data quality issues (i.e., collecting, recording), and reporting findings in a timely manner.  
3. Identify systemic issues (e.g., protocol or human participant protections non- compliance), 
and implementation and evaluation of Corrective and Preventative Action Plan (CAPA) procedures, if applicable. 
 
10.1.[ADDRESS_178088] Keepi[INVESTIGATOR_007]  
[IP_ADDRESS] Data Collection and Management Responsibilities 
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the 
site investigator. The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the data reported. All source documents should be completed in a neat, legible 
manner to ensure accurate interpretation of data.  
 
Protocol  22-[ADDRESS_178089]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 34 of 147  [IP_ADDRESS] Data Coordinating Center / Biostatistician Responsibilities  
The data coordinating center for this study will be responsible for data management, quality review, 
analysis, and reporting of the study data. Adverse events and medical history will be coded according to the MedDRA dictionary. Concomitant medications will be coded according to the WHO Drug dictionary. At the end of the study, a copy of all datasets including annotated case report forms and data dictionary will be provided to DMID.   A separate Study Data Standardization Plan (SDSP) will be developed which  describes the 
technical recommendations for the submission of human study data and related information in a standardized electronic format throughout product development.  
[IP_ADDRESS] Data Capture Methods 
Clinical research data, including, but not limited to, AE/SAEs , concomitant medications, medical 
history, physical assessments will be abstracted from the source documentation and/or collected 
on source document worksheet by [CONTACT_154388] a [ADDRESS_178090] protection and internal quality checks, such as automatic range checks, 
to identify data that appear inconsistent, incomplete, or inaccurate.  
 The IND Sponsor is responsible for review of data collection tools and processes, and review of data and reports.  Study data will be collected on paper CRFs and then entered into the eCRF or data will be entered directly into the eCRF.    
[IP_ADDRESS] Study Record Retention  
For information  regarding study record retention for each study stage, see the corresponding 
appendix. 
 
[IP_ADDRESS] Source Records  
Source data are all information, original records of clinical findings, observations, or other 
activities documented in a clinical trial necessary for t he reconstruction and evaluation of the trial. 
Each participating site will maintain appropriate medical and research records for this trial, in compliance with ICH GCP, regulatory, and institutional requirements. Data recorded in the electronic case repor t form (eCRF) derived from source documents should be consistent with the 
data recorded on the source documents. Data entered directly into the eCRFs will be considered the source document. All source documents should be completed in a neat, legible manner  to ensure 
accurate interpretation of data.  
 Interview of participants is sufficient for obtaining medical history. Solicitation of medical records from the participant’s primary care provider is not required.    
Protocol  22-[ADDRESS_178091]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 35 of 147  10.1.10 Protocol Deviations 
A protocol deviation is any noncompliance with the clinical trial protocol, any process that is noted 
in the protocol and refers to details in the MOP, or GCP requirements.   The noncompliance may be either on the part of the participant, the investigator, or the study site staff. Following a deviation(s), corrective actions should be developed by [CONTACT_3483]. All individual protocol deviations will be addressed in participant study records.   It is the responsibility of the site principal investigator [INVESTIGATOR_154339], or within five working days of the scheduled protocol -required activity. All deviations 
must be promptly reported to DMID per the protocol deviation reporting procedures. Protocol deviations must be sent to the local IRB/IEC per their guidelines. The site principal i nvestigator 
and personnel are responsible for knowing and adhering to their IRB requirements.   
10.1.11 Publication and Data Sharing Policy 
[IP_ADDRESS] Human Data Sharing Plan 
All NIH protocols are required to have a Data Sharing Plan describe provisions for protecting the 
participants’ privacy and the confidentiality of the data. This study will be conducted in accordance 
with the following publication and data sharing policies and regulations: National Institutes of Health (NIH) Public Access Policy, which ensures that the public has access t
o the published results of NIH funded research. It requires scientists to submit final peer -reviewed 
journal manuscripts that arise from NIH funds to the digital archive PubMed Central  upon 
acceptance for publication.  
 A
s of January 2018, all clinical trials supported by [CONTACT_12242].gov, no later than [ADDRESS_178092] participant. Results of all clinical trials supported by [CONTACT_18121], generally, need to be submitted no later than 12 m onths 
following the primary completion date. As part of the result posting, a copy of this protocol and a copy of the Statistical Analysis Plan will be posted on ClinicalTrials.gov.   
[IP_ADDRESS] Genomic Data Sharing Plan 
Not Applicable. 
 
[IP_ADDRESS] Publication  
This study will c omply with the NIH Public Access Policy, which ensures that the public has access 
to the published results of NIH funded research. As such, the final peer -reviewed journal 
manuscripts will be accessible to the public on PubMed Central no later than [ADDRESS_178093]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178094] (PREP Act). The PREP Act applies under the ter ms of the PREP Act 
declaration in place for smallpox/orthopoxvirus countermeasures for activities conducted pursuant to federal agreements or federal programs (ref: www.federalregister.gov/documents/2015/12/09/2015-[ZIP_CODE]/smallpox- medical -
countermeasures -amendment). JYNNEOS is used under an IND for mpox pursuant to a federal 
agreement/program and is therefore covered under the PREP Act. The PREP Act covers persons (such as manufacturers, distributers, program planners, and other qualified persons who prescri be, 
administer or dispense study product) are immune from liability from the administration, or use of a covered countermeasure, such as JYNNEOS. The PREP Act provides immunity for covered persons from liability, unless the injury was caused by [CONTACT_154389].   The PREP Act also established the Countermeasures Injury Compensation Program (CICP) to provide compensation for serious injuries or death that occur as the direct result of the administration or use of certain countermeasures. Any requests for compensation must be filed within one year of the administration or use of the covered countermeasure. Requests for Benefits must be made to the Health Resources and Services Administration’s (HRSA) Countermeasures 
Injury Compensation Program (http://www.hrsa.gov/cicp/) by [CONTACT_154390] a Request for Benefits Form 
and all required medical records and supporting documentation. Additional information on filing a Request for Benefits is available on the CICP’s website at http://www.hrsa.gov/cicp/. Compensation may then be available for reasonable and necessary medical benefits, lost wages and/or death benefits to eligible individuals for certain injuries in accordance with regulations published by [CONTACT_154391] (found at 42 CFR part 110).  If an in dividual suffers a serious physical injury or death from the administration or use of a covered 
countermeasure in this study, the individual, the individual’s legal or personal representative, the administrator/executor of a deceased individual’s estate, o r certain survivors may request benefits 
from the CICP. A serious physical injury means an injury that warranted hospi[INVESTIGATOR_059] (whether 
Protocol  22-[ADDRESS_178095]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 37 of 147  or not the person was actually hospi[INVESTIGATOR_057]) or that led to a significant loss of function or disability. 
The CICP is the payer of last resort. This means that it only covers expenses or provides benefits that other third -party payers (such as health insurance, the Department of Veterans Affairs, or 
Workers’ Compensation programs) do not have an obligation to pay.  If the Secretary of HHS does not make a final determination on the individual’s request within [ADDRESS_178096] is reduced by [CONTACT_92229]’s compensation available to the injured individual. Awards for non- economic damages, such as pain, suffering, 
physical impairment, mental anguish, and loss of consortium are also limited. If the individual accepts compensation, or if there is no willful misconduct, then the individual does not have a tort claim that can be filed in a US Federal or a State court.
Protocol  22-[ADDRESS_178097]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178098]  
HR Heart Rate  
HRSA  Health Resources and Services Administration  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Conference on Harmonisation  
ICMJE  International Committee of Medical Journal Editors  
ID Intradermal  
IEC Independent or Institutional Ethics Committee  
IND Investigational New Drug Application  
IRB Institutional Review Board  
ISO International Organization for Standardization  
ITT Intention -To-Treat  
LAR  Legal Authorized Representative  
MAAE  Medically Attended Adverse Event  
Protocol  22-[ADDRESS_178099]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 39 of 147  MedDRA  Medical Dictionary for Regulatory Activities  
MITT  Modified Intent to Treat  
MOP  Manual of Procedures  
MPXV  Monkeypox Virus  
N Number (typi[INVESTIGATOR_33891])  
NDA  New Drug Application  
NI Non - Inferior  
NIAID  National Institute of Allergy and Infectious Diseases  
NIH National Institutes of Health  
OHRP  Office for Human Research Protections  
PHI Protected Health Information  
PI [INVESTIGATOR_154340]  22-[ADDRESS_178100]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 40 of 147  10.4 Protocol Amendment History 
 
Versio
n Date  Description of 
Change  Brief Rationale  
6.0 8/31/[ADDRESS_178101] in Stage 2 will be provided by [CONTACT_122830]. 
5.0 4/13/2
023 Allow  Day 57 visit in  
Stage 2 to be done by [CONTACT_648]/virtual visit in certain scenarios.  
-Added that a Day 43 
targeted physical exam (at least assessment of vaccination site) is required  
 
-JYNNEOS MVA-
BN vaccine thaw time increased from 
12 hours to 4 weeks.  -Will allow for phone/virtual visit at Day 57 if no 
ongoing vaccine site skin changes  at Day 43 visit 
-Per FDA approval of labeling change dated 
4/14/2023 https://www.fda.gov/media/166224/download?utm_medium=email&utm_source=govdelivery 
4.0 2/28/[ADDRESS_178102]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 41 of 147  3.0 1/13/[ADDRESS_178103] dose regimen of JYNNEOS in adolescents ages 12 to 17 years, inclusive compared to adults. 
2.0 9/22/[ADDRESS_178104]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 42 of 147  11. REFERENCES  
1. Pan American Health Organization. Mpox (monkeypox) outbreak - 2022. 
(https://www.paho.org/en/mpox-monkeypox-outbreak-
2022#:~:text=On%2023%20July%202022%2C%20the,of%20International%20Concern
%20(PHEIC)).  
2. Centers for Disease Control and Prevention. 2022 Mpox Outbreak Global Map. 
(https://www.cdc.gov/poxvirus/monkeypox/response/2022/world-map.html ). 
3. Outbreak News Today. England: Monkeypox case confirmed, Patient had recent travel 
history from Nigeria. (https://outbreaknewstoday.com/england-monkeypox- case-
confirmed -patient -had-recent -travel -history- from -nigeria-[ZIP_CODE]/ ). 
4. McCollum AM, Damon IK. Human monkeypox. Clin Infect Dis 2014;58(2):260-7. DOI: 
10.1093/cid/cit703. 
5. Grant R, Nguyen LL, Breban R. Modelling human- to-human transmission of monkeypox. 
Bull World Health Organ 2020;98(9):638-640. DOI: 10.2471/BLT.19.242347. 
6. Gong Q, Wang C, Chuai X, Chiu S. Monkeypox virus: a re-emergent threat to humans. 
Virol Sin 2022. DOI: 10.1016/j.virs.2022.07.006. 
7. Rimoin AW, Mulembakani PM, Johnston SC, et al. Major increase in human monkeypox 
incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci U S A 2010;107(37):[ZIP_CODE]-7. DOI: 10.1073/pnas.[PHONE_3454]. 
8. World Health Organization. Emergence of monkeypox in West Africa and Central Africa, 
1970-2017. Wkly Epi[INVESTIGATOR_75313] 2018;93(11):125-32. (https://www.ncbi.nlm.nih.gov/pubmed/29546750).  
9. Centers for Disease Control and Prevention. Multistate outbreak of monkeypox-- Illinois, 
Indiana, and Wisconsin, 2003. MMWR Morb Mortal Wkly Rep 2003;52(23):537-40. (https://www.ncbi.nlm.nih.gov/pubmed/12803191).  
10. Erez N, Achdout H, Milrot E, et al. Diagnosis of Imported Monkeypox, Israel, 2018. 
Emerg Infect Dis 2 019;25(5):980-983. DOI: 10.3201/eid2505.190076. 
11. Yong SEF, Ng OT, Ho ZJM, et al. Imported Monkeypox, Singapore. Emerg Infect Dis 
2020;26(8):1826-1830. DOI: 10.3201/eid2608.191387. 
12. Rao AK, Schulte J, Chen TH, et al. Monkeypox in a Traveler Returning from Nigeria - 
Dallas, [LOCATION_007], July 2021. MMWR Morb Mortal Wkly Rep 2022;71(14):509-516. DOI: 10.[ZIP_CODE]/mmwr.mm7114a1. 
13. Vaughan A, Aarons E, Astbury J, et al. Human- to-Human Transmission of Monkeypox 
Virus, [LOCATION_008], October 2018. Emerg Infect Dis 2020;26(4):782-785. DOI: 10.3201/eid2604.191164. 
14. Hobson G, Adamson J, Adler H, et al. Family cluster of three cases of monkeypox 
imported from Nigeria to the [LOCATION_008], May 2021. Euro Surveill 2021;26(32). DOI: 10.2807/1560-7917.ES.2021.26.32.2100745. 
15. Mauldin MR, McCollum AM, Nakazawa YJ, et al. Exportation of Monkeypox Virus 
From the African Continent. J Infect Dis 2022;225(8):1367-1376. DOI: 10.1093/infdis/jiaa559. 
16. Yinka-Ogunleye A, Aruna O, Dalhat M, et al. Outbreak of human monkeypox in Nigeria 
in 2017-18: a clinical and epi[INVESTIGATOR_154341]. Lancet Infect Dis 2019;19(8):872-879. DOI: 10.1016/S1473-3099(19)[ZIP_CODE]-4. 
Protocol  22-[ADDRESS_178105]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178106] and 
Central Africa, 1970-2017. MMWR Morb Mortal Wkly Rep 2018;67(10):306-310. DOI: 
10.[ZIP_CODE]/mmwr.mm6710a5. 
18. Constantino AK. Health officials confirm first U.S. case of monkeypox virus this year in 
[LOCATION_005].  CNBC Health & Science, 2022.  
19. Department of Health and Human Services. Determination that a public health emergency exists. (https://aspr.hhs.gov/legal/PHE/Pages/monkeypox-4Aug22.aspx ). 
20. Vollmar J, Arndtz N, Eckl KM, et al. Safety and immunogenicity of IMVAMUNE, a 
promising candidate as a third generation smallpox vaccine. Vaccine 2006;24(12):2065-70. DOI: 10.1016/j.vaccine.2005.11.022. 
21. Frey SE, Wald A, Edupuganti S, et al. Comparison of lyophilized versus liquid modified 
vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vacc inia-naive subjects. Vaccine 2015;33(39):5225-34. DOI: 
10.1016/j.vaccine.2015.06.075. 
22. Wilck MB, Seaman MS, Baden LR, et al. Safety and immunogenicity of modified 
vaccinia Ankara (ACAM3000): effect of dose and route of administration. J Infect Dis 2010;201(9):1361-70. DOI: 10.1086/651561. 
23. World Health Organization. Multi-country outbreak of mpox, External situation report 
#11. Emergency Situational Update. Geneva, Switzerland: December 1, 2022. (https://www.who.int/publications/m/item/multi-country-outbreak -of-mpox --external -
situation -report--11---1- december -2022).  
24. Hennessee I SV, McArdle CE, et al.  . Epi[INVESTIGATOR_154342] <18 Years with Monkeypox — [LOCATION_002], May 17–September 24, 2022. MMWR Morb Mortal Wkly Rep  2022(71):1407–1411. DOI: http://dx.doi.org/10.[ZIP_CODE]/mmwr.mm7144a4. 
25. Hutin W, R. J., Malfait, P., Pebody, R., Loparev, V. N., Ropp, S. L., Rodriguez, M., 
Knight, J. C., Tshioko, F. K., Khan, A. S., Szczeniowski, M. V., & Esposito, J. J.  . Outbreak of Human Monkeypox, Democratic Republic of Congo, 1996 to 1997. . Emerging Infectious Diseases 2001;7(3):434–438. DOI: https://doi.org/10.3201/eid0703.017311. 
26. Ježek Z, Szczeniowski M, Paluku KM, Mutombo M. Human Monkeypox: Clinical Features of 282 Patients. The Journal of Infectious Diseases 1987;156(2):293-298. DOI: 10.1093/infdis/156.2.293. 
27. US Food and Drug Administration. Summary Basis for Regulatory Action 
(https://www.fda.gov/media/131802/download).  
28. Overton ET, Lawrence SJ, Wag ner E, et al. Immunogenicity and safety of three 
consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial. PLoS One 2018;13(4):e0195897. DOI: 10.1371/journal.pone.0195897. 
29. US Food and Drug Administration. Fact Sheet for Healthcare Providers Administering 
Vaccine: Emergency Use Authorization of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Non -replicating) for Prevention of Monkeypox Disease in Individuals 
Determined to Be at  High Risk for Monkeypox Infection. 2022. 
30. Elizaga ML VS, Marovich MA, Sato AH, Lawrence DN, Chaitman BR, Frey SE, Keefer MC; MVA Cardiac Safety Working Group. . Prospective surveillance for cardiac adverse events in healthy adults receiving modified va ccinia Ankara vaccines: a systematic 
review. . PLoS One 2013;8(1):e54407. DOI: 10.1371/journal.pone.0054407. 
Protocol  22-[ADDRESS_178107]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 44 of 147  31. Scriba TJ, Tameris, M., Mansoor, N., Smit, E., van der Merwe, L., Isaacs, F., Keyser, A., 
Moyo, S., Brittain, N., Lawrie, A., Gelderbloem, S., Veldsman, A., Hatherill, M., 
Hawkridge, A., Hill, A.V.S., Hussey, G.D., Mahomed, H., McShane, H. and Hanekom, W.A., . Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. . Eur J Immunol 2010;40:279-290. (https://doi.org/10.1002/eji.200939754).  
32. Anywaine Z BH, Anzala O, Mutua G, Sirima SB, Eholie S, et al. . Safety and 
immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA- BN-Filo Ebola vacci nation 
in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial. PLoS Medicine   2022;19(1):e1003865. (https://doi.org/10.1371/journal.pmed.1003865).  
33. Afolabi MO ID, Manno D, et al. Safety and immunoge nicity of the two -dose 
heterologous Ad26.ZEBOV and MVA- BN-Filo Ebola vaccine regimen in children in 
Sierra Leone: a randomised, double-blind, controlled trial. Lancet Infect Dis 2022;22:110-122. 
34. Suter M, Meisinger- Henschel C, Tzatzaris M, et al. Modified vaccinia Ankara strains 
with identical coding sequences actually represent complex mixtures of viruses that 
determine the biological properties of each strain. Vaccine 2009;27(52):7442-50. DOI: 
10.1016/j.vaccine.2009.05.095. 
35. Stittelaar KJ, Kuiken T,  de Swart RL, et al. Safety of modified vaccinia virus Ankara 
(MVA) in immune -suppressed macaques. Vaccine 2001;19(27):3700-9. DOI: 
10.1016/s0264-410x(01)[ZIP_CODE]-5. 
36. Overton ET, Stapleton J, Frank I, et al. Safety and Immunogenicity of Modified Vaccinia 
Ankara- Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human 
Immunodeficiency Virus -Infected Individuals: An Open- Label, Controlled Clinical Phase 
II Trial. Open Forum Infect Dis 2015;2(2):ofv040. DOI: 10.1093/ofid/ofv040. 
37. Greenberg R N, Overton ET, Haas DW, et al. Safety, immunogenicity, and surrogate 
markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV -
infected subjects. J Infect Dis 2013;207(5):749-58. DOI: 10.1093/infdis/jis753. 
38. Overton ET, Lawr ence SJ, Stapleton JT, et al. A randomized phase II trial to compare 
safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS. Vaccine 2020;38(11):2600-2607. DOI: 10.1016/j.vaccine.2020.01.058. 
39. von Sonnenburg F, Perona P, Darsow U, et al. Safety and immunogenicity of modified 
vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis. Vaccine 2014;32(43):5696-702. DOI: 10.1016/j.vaccine.2014.08.022. 
40. Greenberg RN, Hurley MY, Dinh DV, et al. A Multicenter, Open-Label, Controlled 
Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18 -40 Year Old Subjects with Diagnosed Atopic Dermatitis. PLoS One 
2015;10(10):e0138348. DOI: 10.1371/journal.pone.0138348. 
41. Cassimatis DC, Atwood JE, Engler RM, Linz PE, Grabenstein JD, Vernalis MN. 
Smallpox vaccination and myopericarditis: a clinical review. J Am Coll Cardiol 2004;43(9):1503-10. DOI: 10.1016/j.jacc.2003.11.053. 
42. Department of Health and Human Services. 46.[ADDRESS_178108]  2023   
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 45 of 147  (https://www.hhs.gov/ohrp/sites/default/files/ohrp/sachrp/mtgings/2013%20March%20Mt
g/approvedexpeditedreviewcategories.pdf ). 
43. von Krempelhuber A, Vollmar J, Pokorny R, et al. A randomized, double-blind, dose-
finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine 2010;28(5):1209- 16. DOI: 
10.1016/j.vaccine.2009.11.030. 
44. Pi[INVESTIGATOR_154343], Hahn M, Lee HS, et al. Phase [ADDRESS_178109] Smallpox. N Engl J Med 2019;381(20):1897-1908. DOI: 10.1056/NEJMoa1817307. 
Protocol  22-[ADDRESS_178110]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 46 of 147   
APPENDIX  A – STAGE 1: DOSE SPARING STUDY IN ADULTS  
 
Stage 1 began enrollment on September 7, 2022 and completed enrollment on October 12, 2022.  
This appendix contains Version 2.0 dated September 22, 2022 which is also found on the study website .
TABLE  OF CONTENTS  
TABLE OF CONTENTS  ..................................................................................................................... 46 
1.1 Synopsis .........................................................................................................................50  
1.2 Schedule of Activities  (SOA)  .........................................................................................52  
1.3 Study Schema  .................................................................................................................53  
2. INTRODUCTION  ....................................................................................................................... 53 
2.1 Study Rationale  ..............................................................................................................53  
2.2 Background ....................................................................................................................53  
2.3 Risk/Benefit Assessment  ................................................................................................[ADDRESS_178111](s) and Administration  .............................................................................[ADDRESS_178112]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 47 of 147  6.1.4  Dose Modifications ................................................................................................66  
6.1.5  Criteria  for Redosing  ..............................................................................................66  
6.2 Preparation/Handling/Storage/Accountability ...............................................................[ADDRESS_178113]: JYNNEOS (MVA- BN 
vaccine)  [ADDRESS_178114]: JYNNEOS  (MVA -BN vaccine)  ...............67  
6.2.4  Preparation  .............................................................................................................67  
6.3 Measures  to Minimize  Bias:  Randomization and Blinding  ............................................68  
6.3.1  Treatment  Assignment Procedures  .........................................................................68  
6.3.2  Randomization .......................................................................................................68  
6.3.3  Blinding and Masking Procedures  .........................................................................68  
6.4 Study Intervention Compliance  ......................................................................................68  
6.5 Concomitant Therapy  .....................................................................................................68  
6.5.1  Rescue Medicine  ....................................................................................................69  
7. STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  ............................................................................................... [ADDRESS_178115] Values or 
Abnormal Clinical Findings During Screening .....................................................................72  
8.1.2  Sick Visit ................................................................................................................72  
8.2 Immunogenicity Assessments  ........................................................................................73  
8.2.1  Immunogenicity/Efficacy  Evaluations  ...................................................................[ADDRESS_178116] of the Trial .....................................................74  
8.4 Adverse Events and Serious Adverse Events  .................................................................74  
8.4.1  Definition  of Adverse Events  (AE)  ........................................................................[ADDRESS_178117]  (AESI)  ............................................................80  
8.4.9  Reporting of Pregnancy  ..........................................................................................80  
8.5 Unanticipated  Problems  .................................................................................................80  
8.5.1  Definition  of Unanticipated  Problems (UP) ...........................................................[ADDRESS_178118]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178119]  OF TABLES  
Table 1  Schedule of Activities  (SOA)  ............................................................................................52  
Table 2 Study Schema  ....................................................................................................................53  
Table 3 Prior Subcutaneous Dosing Trials  .....................................................................................54  
Table 4 MVA -BN Compared  to ACAM2000  ................................................................................55  
Table 5 Prior Intradermal  Dosing Compared  to Subcuteanous  ......................................................55  
Table 6 Study Arms  .......................................................................................................................66  
Table 7:  Power  calculations  ...........................................................................................................82  
Table 8:  Standard  deviation  estimates  ............................................................................................82  
Table 9:  Standard  deviation  estimates  ............................................................................................[ADDRESS_178120]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178121]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178122]  
Africa.  To prevent further spread  of this outbreak, MVA- BN vaccine is being offered  to individuals 
at high risk. However, there is a global vaccine shortage and increasing vaccine supply will take 
time. This study will evaluate dose sparing strategies to extend the vaccine supply during this global 
public health crisis.  
 
Study  Design  
This study is a Phase 2 randomized, open- label, non- placebo controlled, multi -site clinical trial that 
will evaluate the immunogenicity and safety of two, dose sparing strategies including one - fifth 
(2x107) and one- tenth  (1x107) of the standard  dose of MVA- BN (JYNNEOS)  administered 
intradermally (ID) on Day 1 and 29 (Arm 1 and 2, respectively), compared with the standard, 
licensed regimen of 1x108 MVA- BN administered subcutaneously (SC) on Day 1 and 29 (Arm 3). 
At least 210 healthy, vaccinia -naïve adults 18 to 50 years of age will be enrolled and randomized 
1:1:1 to one of three study arms. There will be eight study visits (plus an optional screening visit) with the last visit at approximately one year after the first study vaccination.  Participants  reporting  monkeypox- like illness  and who have a laboratory -confirmed  monkeypox 
(i.e., a positive diagnostic test for monkeypox) will be seen at a sick visit. 
 
Primary  Objectives  
• To determine if peak (Day 43) humoral immune responses following an ID regimen 
of 2 x 107 TCID 50 MVA- BN are non- inferior to the licensed  regimen  of 1 x 108 
MVA- BN administered SC.  
• To determine if peak (Day 43) humoral immune responses following an ID regim en 
of [ADDRESS_178123] of Objectives/Endpoints, see corresponding section  of the protocol.  
 
Inclusion Criteria  
See inclusion criteria  in corresponding section  of the protocol.  
 
Exclusion Criteria  
See exclusion criteria  in corresponding section  of the  protocol.  
 Study Phase  
Phase [ADDRESS_178124]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 51 of 147  The study population will be healthy, vaccinia- naïve,  non-pregnant, non- breastfeeding  adults 18 to 
50 years of age. Participants with stable chronic medical conditions including those with controlled 
HIV infection  can participate.  The study will attempt to enroll a representative study population that 
is proportional to those affected by [CONTACT_154392].  
 
Sites  
Up to 10 US clinical  research  sites.  
 Study  intervention  
There will be three study arms in which JYNNEOS will be administered by [CONTACT_154393] 1 and 29. JYNNEOS  is live vaccine produced from  the strain  Modified Vaccinia Ankara-
Bavarian Nordic (MVA -BN), an attenuated orthopoxvirus, that is non- replicating in human cells. 
It is FDA -approved and licensed as a smallpox and monkeypox vaccine in the [LOCATION_002]. 
 Study  Durati on 
This study will take approximately [ADDRESS_178125] from  study activation  to the final 
participant’s last study visit.  
 Participant Duration  
It will take approximately  one year for  a participant to  complete  their participation  in the study. 
 
Safety  
The trial will use study and individual pausing rules.  See corresponding section  for details.  This 
trial will use a Data Safety Monitoring Board (DSMB) for objective oversight of the study and 
review for any study pause.   
Protocol  22-[ADDRESS_178126]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 52 of 147  1.2 Schedule  of Activities (SOA) 
The trial will include the following activities  and procedures at each study visit.  Only  procedures 
that contribute to participant eligibility and study objectives and endpoints are included. R efer to 
Manual of Procedures (MOP) for detailed description of study activities. 
Table 1 Schedule  of Activities  (SOA) 
 
 
 
 
 
 
 
Procedures  
Optional 
Screening  Visit 
Day -7 to -1 
Enrollment  / Baseline 
Visit 1 Day 1  
Visit  2 
Day 15 +/- 3 day 
Visit  3 
Day 29 +/- 3 days 
Visit  4 
Day 43 +/- 3 days 
Visit  5 
Day 57 +/- 3 days 
Visit  6 Day 90 +/- 5 
days 
Visit  7 
Day 181 +/- 7 days 
Visit  8 
Day 365 +/ - 14 days 
Sick/Unscheduled 
Visit 6 
Informed  consent  X X1         
Demographics  X X1         
Medical  history  X X1 X X X X X X X X 
Randomization   X         
Vaccine  administration   X  X       
Targeted  physical 
exam  X X1 X2 X2 X2 X2 X2 X2 X2 X2 
Vital  signs  
X X1 X2 X2 X2 X2 X2 X2 X2 X2 
Concomitant 
medication  review  X X1 X X X X X3 X3  
X 
SAE/  MAAEs  4   
All SAE/MAAEs,  Days  1 through  57 Only related 
SAE/MAAEs  
Days  58 -181  
X4 
Unsolicited  AEs4  Day 1 through  Day 29 and Day 29 through  
Day 57    X4 
Solicited  (Local  and 
Systemic) AEs   Day [ADDRESS_178127] 5 X X1  X       
Blood  volume  per visit (ml)  32 20 20 32 20 20 20 20 20 
Blood  volume  total (ml)  32 52 72 104 124 144 164 184 204 
1 If there  is no screening  visit,  these  activities  should  be conducted  at the Day 1 visit prior  to randomization. Temperature 
should be collected on Day 1 and 29 pre -vaccination for all participants.  
2 A targeted (symptom -driven)  physical exam will be  done at  screening (i.e., screening visit or Day 1), on Days 15, 29,  
and 43 (at least assessment  of vaccination  site and presence  of skin discoloration  and nodules  will be done),  and as 
needed in all other visits if interim change in medical status reported by [CONTACT_3445]. Vital signs will be done at screening 
and on Day 1 and 29 prior to vaccination and on an as needed basis during all other visits.  
3 After  Day 57, only concomitant  medications  that are associated  with a related  SAE  or MAAE  (detected  through Day 
181) and clinically relevant to report, will be recorded in the CRF. An exception to this rule for recording concomitant medications is for sick visits. During sick visits, concomitant medications will be colle cted.  
4 If SAE/MAAE  or unsolicited  AE are reported  during a sick visit and within  the reporting  window,  it will be reported 
as AE. See more information about collection of AEs in the safety section of the protocol.  
Protocol  22-[ADDRESS_178128]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178129]  will be done  at the screening  visit (if conducted) and on Day [ADDRESS_178130] a laboratory -confirmed monkeypox will be seen at  a sick 
visit.  An unscheduled  visit may also occur  for reasons  including,  but not limited  to, AE follow  up, blood draw, or early 
termination final visit.  
 
1.3 Study  Schema  
Table 2 Study  Schema  
 
Arm Dose  of JYNNEOS  (MVA -BN) Route  of Administration*  Vaccination  Day 
Day 1 Day 29 
1 2 x 107 TCID 50, (0.1 mL) Intradermal  X X 
2 1 x 107 TCID 50, (0.05  mL) Intradermal  X X 
3 1 x 108 TCID 50, (0.5 mL) Subcutaneous  X X 
*Subcutaneous  is administered  in the upper arm , intradermal  is administered  in the volar  aspect  (inner  side)  of the 
forearm.  
 
 
2. INTRODUCTION  
2.1 Study  Rationale  
On July 23, 2022, WHO declared the 2022 monkeypox outbreak a public health emergency of 
international concern (PHEIC). Since t he first case of monkeypox was detected in the [LOCATION_006] in a 
returning traveler from Nigeria on May 6, 2022, as of September 2022 the outbreak has rapi[INVESTIGATOR_154344] >[ADDRESS_178131], the  number of 
confirmed monkeypox cases in the U.S. surpassed that of any other country. To mitigate the 
consequences of this outbreak, monkeypox vaccine is being offered to individuals considered to be at high risk. However, there is a global vaccine shortage and increasing the supply will take time.  
This study will evaluate vaccine dose sparing strategies  to extend  the limited  supply during this 
global public health crisis. 
 
2.2 Background  
Monkeypox is a reemerging infectious disease caused by [CONTACT_154379] (MPXV), a large 
double- stranded DNA virus belonging to the genus, Orthopoxvirus .[ADDRESS_178132]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178133] 
been 36,589 confirmed monkeypox cases in 92 countries; most cases have been from 85 non- endemic countries including 11,890 confirmed cases in the [LOCATION_002].  Vaccinat ion is being used as a mitigation strategy in the current monkeypox outbreak for those 
exposed to and those deemed to be at higher risk of being exposed to monkeypox. There is one FDA -approved vaccine for monkeypox: JYNNEOS Modified Vaccinia Ankara -Bavarian Nordic 
(MVA -BN). A second vaccine, ACAM2000 is likely effective but is not FDA -approved for 
monkeypox and associated with moderate risk of myocarditis and pericarditis (5.7 cases per 1,000 
vaccinated) as well as encephalomyelitis, progressive vaccinia, generalized vaccinia, and ocular  
complications.  ACAM2000 should not be given to people with weakened  immune  system, eczema, 
cardiac disease, infants <[ADDRESS_178134] 9, 
2022, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the emergency use of a lower (2 x 10
7) ID dose of JYNNEOS  for individuals 18 years  of 
age and older determined  to be at high risk for monkeypox infection.  
 
There are several potential dose sparing strategies we considered. Use of a reduced dose 
administered SC is unlikely to be of comparable immunogenicity to the licensed SC regimen. There were several Phase 1 and 2 trials that evaluated 2 -dose regimens of MVA -BN administered SC four 
weeks apart ( Table 3). Although the 2- dose 5x10
7 TCID 50 SC regimen may  elicit GMT  similar  to 
ACAM2000, the GMT will likely  be below that of the licensed  2-dose 1 x 108 MVA- BN regimen .  
Table 3 Prior Subcutaneous  Dosing  Trials  
 
Reference   1 X107 
TCID 50 2 X107 
TCID 50 5 X107 
TCID 50 1 X108 
TCID 50 Assay  
Vollmar  et al, 
Vaccine,  2006  15 Liquid 
formulation  6.4 
(CI not reported)  -- -- 29.3 
(CI not reported)  IHD-J PRNT  
GMT  
Frey at al. 
Vaccine,  2007  Lyophilized 
formulation  -- 347.2  
(161.9,  744.7)  551.5  
(321.5,  946.0)  914.5  
(528.0,  1584)  MVA  PRNT  
GMT  
von Krempelhuber 
Vaccine, 2010  Lyophilized 
formulation  -- 5.5 
(3.2, 9.6) 10.3 
(5.8, 18.4)  19.4 
(11.1,  34.2)  IHD-J PRNT  
GMT  
 
A single [ADDRESS_178135] licensed 2 -dose regimen. The pi[INVESTIGATOR_9205] 3 trial demonstrated that a single dose is likely 
to provide  a significantly  lower  GMT  than the licensed  2-dose MVA- BN regimen,  16.9 [13.7, 20.8] 
as compared to 153.5 [134.3, 175.6], respectively ( Table 4).  
Protocol  22-[ADDRESS_178136]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 55 of 147   
Table 4 MVA -BN Compared  to ACAM2000  
 
 MVA -BN 
(N=185)  ACAM2000 
(N=186)  GMTs ratio 
MVA/  ACAM  
Visit  Week  n GMT  95% CI n GMT  95% CI Ratio  95% CI 
Plaque  Reduction  Neutralization  Test 
Week  0 185 1.0 [1.0, 1.1] 186 1.0 [1.0, 1.0] 1.008  [0.97,  1.05]  
Week  2 184 16.2 [13.0,  20.1]  184 16.2 [13.1,  20.0]  0.997  [0.74,  1.35]  
Week  4 185 16.9 [13.7,  20.8]  186 79.3 [67.1,  93.8]  0.213  [0.16,  0.28]  
Week  6 185 153.5  [134.3,  175.6]  181 64.7 [54.9,  76.2]  2.372  [1.92,  2.93]  
 
NIAID  conducted a Phase [ADDRESS_178137]  (now licensed)  2-dose 1 x 108 TCID 50 
MVA- BN SC regimen  (liquid formulation) and a 2-dose 2 x 107 TCID 50 MVA- BN ID regimen 
(liquid formulation) and found peak vaccinia virus, Western reserve strain (VV -WR) GMT of 49.5 
(40.0, 61.3) and 59.6 (48.1, 74.0), respectively ( Table 5).16 The 2 -dose 2 x 107 TCID 50 ID regimen 
was non-inferior to the 2-dose 1 x 108 TCID 50 SC regimen and utilized only one-fifth of the dose. 
These results are supported by a trial evaluating another MVA vaccine (ACAM3000) which showed ID vaccination at 1x10
7 TCID 50 had similar VV -WR GMT  to 1x108 TCID 50 administered 
SC or IM.17 
 
Table 5 Prior Intradermal  Dosing  Compared  to Subcutaneous  
 
Study  Visit Day Group  
 Lyophilized SC 1x108 
(N=145)  GMT [95%  CI] Liquid SC 1x108 (N=149)  
GMT  [95%  CI] Liquid ID 2x107 (N=146)  
GMT  [95%  CI] 
Day 0 7.5 [,] 7.7 [7.4, 8.0] 7.7 [7.4, 7.9] 
Day 14 10.9 [9.9, 12.0]  10.0 [9.0, 11.1]  10.3 [9.3, 11.3]  
Day 28 10.8 [9.9, 11.9]  9.6 [8.7, 10.6]  10.8 [9.9, 11.9]  
Day 42 77.6 [62.3,  96.7]  45.2 [36.4,  56.2]  54.4 [43.7,  67.8]  
Peak  post vaccination  2 87.8 [71.2,  108.3]  49.5 [40.0,  61.3]  59.6 [48.1,  74.0]  
 Even  with the EUA for intradermal  MVA- BN being  available,  this trial is designed to evaluate 
several unique issues: 
• As vaccine supply is  not anticipated  to meet  the demand  in the next year,  this trial will 
evaluate dose reduction strategies focused on the ID route, that is, confirming the previously studied ID dose and evaluating one tenth dose of MVA-BN (1x10
7). 
• This trial will also assess differences in safety and tolerability of the ID versus the licensed  SC regimen  as issues of tolerability  have been  raised  by [CONTACT_154394].  
 
2.3 Risk/Benefit  Assessment  
2.3.[ADDRESS_178138]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 56 of 147  The potential risks  to the participants  in the study are those related  to venipuncture and 
reactogenicity as well as possible reactions to the vaccine.  
 
Venipuncture  
Venipuncture may cause transient  mild discomfort and/or fainting. Bruising at the site of the 
venipuncture may occur but can be prevented or lessened by [CONTACT_154395].  Infection at the site is possible but highly unlikely with the use of aseptic 
technique.  
Adverse Reactions  
MVA- BN administered  SC was approved by [CONTACT_154396]  24, 2019.
[ADDRESS_178139] vaccination.  There were  mostly  local  and systemic  
reactogenicity  and rare cases  of allergy/hypersensitivity  observed. Within  [ADDRESS_178140] common solicited  local  (injection site)  reactions  
among 2,943 smallpox vaccine -naïve healthy  adult participants  included pain (84.9%), redness  
(60.8%), swelling  (51.6%),  induration (45.4%), and itching  (43.1%). The most common solicited  
systemic  adverse  reactions  were  muscle pain (42.8%),  headache  (34.8%), fatigue (30.4%), nausea  
(17.3%), and chills  (10.4%).  In a large clinical  trial involving 3,[ADDRESS_178141] dose 
(79.3% versus 69.9%).19 
 
A
n analysis of serious adverse events (SAEs) among the 7,[ADDRESS_178142] 1 dose of JYNNEOS identified 
only four SAEs  (0.05%) in which  a causal  relationship  could not be ruled  out. All were non- fatal 
SAEs  and included Crohn’s disease,  sarcoidosis, extraocular  muscle  paresis,  and throat tightness 
(angioedema). The trial that had the related angioedema had three other post- vaccination 
hypersensitivity reactions which were non-serious and judged to related to the vaccination. 
 As with all injectable  vaccines,  there  is a risk of an allergic  reaction  or an anaphylactic event.  To 
mitigate the risk, individuals with known allergy or history of anaphylaxis or other serious adverse reaction to a vaccine or vaccine products will not be eligible to participate in the study. In addition, sites must observe participants for [ADDRESS_178143]. Howe ver, the participant  will be encouraged not to 
withdraw from the study so that they may be followed for safety and immunogenicity until the end of the study.  
Intradermal  Route  of Administration  
In a Phase 2 clinical trial that compared the ID and SC administration of the liquid formation of MVA- BN, no participants in the Liquid SC dose group experienced a severe systemic reaction and 
20.4% experienced  a moderate systemic  reaction  following the first vaccination, and 1.9% of 
Protocol  22-[ADDRESS_178144]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 57 of 147  participants experienced severe systemic reactions and 16.6% experienced moderate systemic 
reactions following the second vaccination.16 In the Liquid ID dose group, 3.1% of participants 
experienced a severe systemic reaction and 24.1% experienced moderate systemic reactions followi ng the first vaccination, and 0.7% experienced a severe systemic reaction and 15.0% 
experienced  moderate systemic  reactions  following  the second vaccination.  Fatigue was the most 
common systemic reaction reported in both groups after both vaccinations, reported by 35.9% in the Liquid SC dose group and 41.4% in the Liquid ID dose group after the first vaccination, and 33.1%, and 29.4% of participants  in the Liquid SC, and Liquid ID dose groups, respectively  after 
the second vaccination.  Pain at the injection site occurred in 65.4% and 91.0% of participants in the Liquid ID group and the SC group, respectively. Itchiness was the most prevalent local reaction in the Liquid ID group, reported by 89.0% of participants after either vaccination compared to 48.5% in the Liquid SC 
group. Vaccine site discoloration (hyperpi[INVESTIGATOR_371]) was seen in 122 (63.9%) participants in the Liquid ID group and all but three of these events were graded as mild (Grade 1). In contrast, only seven (4.2%) participants in the Liquid SC group had discoloration at the vaccine  site and all but 
one event  was Grade 1. Nodule formation  at the vaccine site occurred  at a similar frequency of 
participants in the Liquid ID and Liquid SC group; 35 (18.3%) and 34 (20.4%) participants developed a nodule, respectively.  The original protocol (and report) used a more conservative grading scale for erythema and induration than the FDA's current guidance document, “Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials”. When NIAID re-analyzed  the data using the FDA’s  current  toxicity  grading scale,  12% of participants  in the ID group 
and 7.2% in the SC group experienced moderate/severe erythema following the first vaccination, and 59.5% in the ID group and 31.2% in the SC group following the second vaccination. Systemic 
reactogenicity was similar across the two arms.  
 
Risk  During  Pregnancy  
There were four developmental toxicity studies that evaluated the effect of JYNNEOS on fetal a nd 
postnatal development and found no vaccine- related  fetal malformations  or adverse effects on 
postnatal development. JYNNEOS has  not been  evaluated  in preclinical studies for carcinogenicity 
or mutagenicity.  No safety  signals were  observed  in [ADDRESS_178145]  Feeding  Infant  
It is not known whether JYNNEOS is excreted in human milk. Data are not available to assess the  
effects  of JYNNEOS  in the breastfed  infant or on milk production/excretion. For this reason, woman 
who are breastfeeding will not be eligible to participate in this study.  
Risk  to Children  and Adolescents  
Protocol  22-[ADDRESS_178146]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178147] not been  established  in individuals less than 18 
years of age. For this reason, this study will enroll only adults 18 to 50 years of age. 
 
Risk  to Individuals  with  Chronic  Diseases  
JYNNEOS does not replicate in human cell lines and therefore the vaccine can be safely administered  to immunocompromised individuals. Safety  has been  demonstrated  in clinical  trials 
and studies involving severely immunocompromised animals
20,21 and humans with HIV 
infection.22-24 The safety of JYNNEOS in HIV -infected individuals was evaluated in an open label  
trial that included 351 HIV-infected  smallpox  vaccine -naïve participants,  131 HIV-infected 
participants who previously received smallpox vaccine, 88 non- HIV-infected smallpox vaccine - 
naïve participants, and 9 non- HIV-infected participants who had previously received a smallpox 
vaccine.22 HIV -infected participants had CD4 counts ≥ 200 and ≤ 750 cells/μL at study entry. 
 Among smallpox  vaccin e-naïve participants,  solicited  local  and systemic  adverse reactions  were 
reported at similar or lower frequencies in HIV -infected participants than in non- HIV-infected 
participants. Frequencies of other solicited local and systemic adverse reactions were similar to those reported in other trials.
23,[ADDRESS_178148] year or their viral load is not well -
controlled with antiretroviral therapy ( ART).  
 Individuals with atopic dermatitis (AD) are not able to receive replicating smallpox vaccines including ACAM2000. However, two clinical trials have shown that they can safely be given JYNNEOS.
25,26 The larger of the two studies was a multicenter, open -label clinical trial that 
evaluated the safety of JYNNEOS in 350 smallpox vaccine -naïve participants either with active or  
a history of AD and in 282 participants  without AD.26 The proportion of participants  reporting 
solicited local and systemic adverse reactions was similar between the arms, except for redness (61.2% with AD vs. 49.3% without AD), swelling (52.2% with AD vs. 40.8% without AD), chills (15.9% with AD vs. 7.8% without AD) and headache (47.2% with AD vs. 34.8% without AD). However, most adverse events were mild to moderate in severity. In this study, individuals with 
AD are eligible to participate.  
 
Cardiac Adverse Events  of Special  Interest  (AESI)  
During the 2002 -2004 smallpox vaccination campaign initiated by [CONTACT_154397] 
(DoD) and Department of Health and Human Services (DHHS) to protect military personnel  and 
civilian  first-responders, there were  high rates  of pericarditis  and myocarditis  reported  among those 
vaccinated  with Dryvax. Similarly,  high rates  were detected  after receipt of ACAM2000.
[ADDRESS_178149] vaccination. In 22 
studies, cardiac AESI s were reported to occur in 1.3% (95/7,093) of JYNNEOS recipi[INVESTIGATOR_154345] 
0.2% (3/1,206) of placebo recipi[INVESTIGATOR_154346]ïve. The higher proportion of JYNNEOS recipi[INVESTIGATOR_154347] t-
vaccination elevation of troponin I, the clinical significance of which is unknown.  Among the cardiac AESIs reported, there were six, non- serious cases (0.08%) deemed causally 
related to JYNNEOS vaccination including tachycardia, electrocardiogram (ECG) T wave inversion, unspecified ECG abnormality, ECG ST segment elevation, ECG T wave abnormality, and palpi[INVESTIGATOR_814]. These data are consistent with findings from a randomized, double -blind, placebo-
Protocol  22-[ADDRESS_178150]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 59 of 147  controlled Phase 3 trial that evaluated the immunogenicity and safety of three consecutive  
production lots of MVA- BN. In that trial, eight out of 3,003 (0.3%) participants  who received at 
least one dose of MVA -BN had a cardiac AESI. Of these events, two of the eight were considered 
possibly related to MVA -BN vaccination; one participant had a right bundle branch block on ECG, 
and the other participant had clinical symptoms consistent with acute pericarditis but had a negative 
cardiac work -up. This same participant had positive serology to Coxsackie B virus suggesting that 
an acute viral infection may have been the cause of their symptoms. Given these data, we will not be monitoring for cardiac AESI during this study.  However,  we will be monitoring  AE, MAAE,  and SAE  that will allow  us to detect  symptomatic 
cardiac conditions. 
 
2.3.2 Known  Potential  Benefits  
JYNNEOS  was licensed  in 2019 based  on pre-clinical  studies and clinical  trial data showing that 
the vaccinia virus -specific (VV -WR) geometric mean titer (GMT) elicited by [CONTACT_154398]- inferior to that elicited by [CONTACT_154399]2000; ACAM2000 was licensed based on 
non-inferiority  to Dryvax. Participation  in this study may result  in protection against  monkeypox 
during this current outbreak. However, participation may also provide no direct  benefit to the 
participant  if they develop antibodies to vaccinia virus and/or monkeypox virus that are not fully 
protective. Society may benefit from the identification of dose sparing regimens that could be used  
during the current  global vaccine shortage.  Additional supportive data on ID dosing may be used to 
inform the public health response to the current outbreak. 
 
2.3.[ADDRESS_178151]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 60 of 147  3. OBJECTIVES  AND  ENDPOINTS  
 
OBJECTIVES  ENDPOINTS  
(OUTCOME  MEASURES)  
Primary   
To determine if peak (Day 43) humoral immune 
responses following  an ID regimen  of 2 x 107 
TCID 50 MVA- BN are non-inferior to the licensed  
regimen  of 1 x 108 TCID 50 MVA- BN administered 
SC Vaccinia  virus  specific  PRNT  GMT  at Day 43 
To determine if peak  (Day 43)  humoral immune 
responses following  an ID regimen  of 1 x 107 
TCID 50 MVA- BN are non-inferior to the licensed  
regimen  of 1 x 108 TCID 50 MVA- BN administered 
SC Vaccinia  virus  specific  PRNT  GMT  at Day 43 
Secondary   
To determine  if individual  peak  humoral  immune 
responses following each ID regimen are non - 
inferior to the licensed regimen administered SC  Individual  peak  GMT  through  Day 365 
To evaluate humoral immune responses of each 
ID regimen  (separately)  compared  to licensed  SC 
regimen each study day.  Vaccinia  virus  specific  PRNT  GMT  at Study  Day 1, 
15, 29, 43, 57, 90, 181, and 365  
To evaluate  the kinetics  of the humoral  immune 
responses of  each ID regimen (separately) 
compared to licensed SC regimen through Day 
365 Vaccinia  virus  specific  PRNT  half-life (t ½) 
To compare relative safety among study arms as 
assessed by [CONTACT_154400] 
14 days after each vaccination, unsolicited adverse 
events for 28 days after each vaccination, and 
serious adverse events (SAE) and medically 
attended  events (MAAE)  from  Day 1 through Day 
57, and related SAE/MAAEs through Day 181  Frequency,  severity,  and relatedness  of solic ited 
systemic and local AE for 14 days after each 
vaccination.  
Frequency  severity,  and relatedness of unsolicited 
AEs in each study arm for 28 days after each 
vaccination.  
Frequency  and relatedness of MAAE  and SAEs  in 
each study arm.  
Frequency  of withdrawals  or discontinuation of 
vaccination in each study arm  
Exploratory   
To evaluate  other  measures  of the humoral 
immune responses for each regimen  Results  from  additional  immunologic  assays  for 
vaccinia and other related viruses.  
To evaluate  humoral  immune  responses  of each ID 
regimen (separately) compared to licensed dose 
administered SC to monkeypox virus.  Monkeypox  virus  specific  PRNT  GMT  at Day [ADDRESS_178152]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178153] 210 participant s will be 
enrolled  and randomized  to one of three study arms.  The two dose sparing strategies  include one- 
fifth (2 x107) and one -tenth (1 x107) of the standard dose  of MVA- BN administered ID  on Day 1 
and 29 (Arm 1 and 2, respectively). The comparator arm (Arm 3) will be the [ADDRESS_178154] (1x108) 
MVA- BN SC regimen.  
 
The study will enroll a 1:1:1 randomization allocation. Participants will not be stratified by [CONTACT_154401], demographic characteristics or HIV infection status; however,  these data will be collected 
during screening and enrollment. Each participant may be screened either in a separate  visit in the 
[ADDRESS_178155] vaccination.  
 
4.2 Scientific  Rationale  for Study  Design  
The rationale for  each of the arms  in this  study is as follows:  
1. MVA -BN 2 x 107 TCID 50 ID (1/5th  dose)  on Days  1, 29 (Study  Arm  1) – This regimen  
matches the prior ID dosing and matches the dose authorized in the EUA. This regimen 
would allow for 5-fold increase in vaccine supply. 
2. MVA -BN 1 x 107 TCID 50 ID (1/10th dose)  on Days  1, 29 (Study  Arm  2) – This regimen  
would test  a larger  dose conservation. This regimen  would allow  for 10- fold increase in 
vaccine supply.  
3. MVA -BN 1 x 108 TCID 50 SC on Days 1, 29 (Study  Arm  3) – This regimen  is the licensed  
dose and route and will be used as a comparator. 
 
4.3 Justification  for Dose  
This study will use the FDA -approved, licensed dose 1 x 108 TCID 50 MVA -BN a dministered SC 
on Day 1 and 29 as the comparator for the ID doses of MVA -BN. The ID regimens being evaluated 
in this study use lower doses of the licensed vaccine, and either match or are one dilution lower than the dose used in the prior ID dosing study (PMID  26143613). Therefore,  it is anticipated  this 
range is safe and immunogenic. 
 
5. STUDY  POPULATION  
This study will enroll healthy, non- pregnant, non- breastfeeding adults [ADDRESS_178156] applicability of the study findings. To this end, the goal will be to enroll:  
Protocol  22-[ADDRESS_178157]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 62 of 147   
• at least  30% female participants,  
• at least 20% African  American/Black  participants,  
• at least 20% Hispanic participants.  
 
These are enrollment goals and will not be a deviation if these are not ultimately  met. Sites  will be 
chosen based on projected ability to enroll the representative study population. Enrollment will  be 
monitored and adjusted  at individual sites to pursue these goals while  also enrolling this study 
quickly to inform public health decisions. 
 Participant Inclusion and Exclusion Criteria must be confirmed by [CONTACT_154402]. If there  is any uncertainty, the PI [INVESTIGATOR_119820]  a potential 
participant is eligible for study enrollment. No exemptions are granted on Inclusion/Exclusion Criteria.  
 
5.[ADDRESS_178158] meet all  the following criteria:  
 
1. Individuals 18 - 50 years of age inclusive at the  time of consent.  
2. Able  to read  the written  informed  consent, states  willingness  to comply with  all study 
procedures, and is anticipated to be available for all study visits. 
3. Agreement  to adhere  to Lifestyle  Considerations (defined  in section  5.4) during the study.  
4. Females  of reproductive potential who  have sexual  intercourse with  males  must agree to 
use highly effective contraception for at least 1 month prior to signing ICF and through 
Day 57. 
Note:  See MOP  for definitions  and list of  highly effective contraception  
5. In good general  health  as evidenced  by [CONTACT_115033], physical examination, and 
clinical judgement of the investigator to be in stable state of health.  
Note:  Participants with pre- existing  stable chronic medical  conditions defined as conditions not 
requiring significant change in therapy or hospi[INVESTIGATOR_154348] [ADDRESS_178159]  6 months, report 
a CD4 count of greater than 350 cells/µL and no AIDS- defining illness in the last year.  
 
5.2 Exclusion  Criteria  
An individual who meets  any of the following criteria  will be excluded  from  participation  in this 
study:  
1. Ever  received  a licensed  or an investigational smallpox  or monkeypox vaccine.  
Note:  this includes Dryvax,  Acam2000, LC 16 m8, MVA -based vaccine  candidate or licensed 
vaccines, and Jynneos, Imvamune or Imvanex) 
Protocol  22-[ADDRESS_178160]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178161] monkeypox in the 3 weeks prior to signing ICF  
4. Immunocompromised as determined  by [CONTACT_093]  
5. Recent  or current  use of any immunosuppressing medications  in the 4 weeks  prior to 
signing ICF. 
Note: topi[INVESTIGATOR_2855], ophthalmic, inhaled, intranasal and intraarticular corticosteroids are acceptable,  
but receipt  of ≥20 mg/day of prednisone or equivalent for ≥[ADDRESS_178162]  feeding.  
7. Received  or plans to  receive  a live  vaccine in  the 4 weeks  prior to  signing ICF  and 4 
weeks after each vaccination  
8. Received  or plans to receive any  other vaccine in  the 2 weeks  prior to  signing ICF 
through Day 43. 
9. Received  experimental  therapeutic agent  or vaccine in the 3 months prior to signing ICF.  
10. Has known allergy  or history of anaphylaxis or other serious adverse  reaction  to a 
vaccine or vaccine products.  
Note:  this includes individuals with history of severe allergic  reaction  to gentamicin, ciprofloxacin, 
chicken or egg protein. 
11. Has tattoos,  scars,  or other  marks  which  would, in  the opi[INVESTIGATOR_871], 
interfere with assessment of the vaccination site.  
12. Has any medical  disease  or condition that,  in the opi[INVESTIGATOR_154349]-investigator, precludes study participation. 
Note: this includes acute, subacute, intermittent, or chronic medical disease or condition that would 
place the participant at an unacceptable risk of injury, render the  participant unable to meet  the 
requirements  of the protocol, or may interfere  with the evaluation of responses or the parti cipant’s 
successful completion of this trial.  
 
5.2.[ADDRESS_178163] received smallpox vaccination during the smallpox eradication campaign.  
Because the effects  on the fetus  are not known, pregnant individuals will not be eligible for the 
trial (see Risk/Benefit Assess ment Section). In addition, individuals who are breastfeeding will 
not be eligible because it is not known if JYNNEOS is excreted in the breastmilk. Adolescents and children will not be  included in this trial because  there is no safety or  efficacy  data on the ID  route 
of administration in  this population. Should the outcome of this trial be deemed acceptable, 
additional trials may be initiated, including those in other populations.  
 
5.[ADDRESS_178164]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 64 of 147  impaired participants, adolescents, and children.  
5.4 Lifestyle Considerations  
During this study, participants  are asked  to: 
• Follow public health  guidance on preventing monkeypox infection  and notify the clinical  site 
if exposed to an individual with monkeypox. 
• Contact  [CONTACT_154403] a  study sick visit. 
• Refrain  from receiving a live  vaccine from  enrollment through Day 57. 
• Refrain  from receiving  any other vaccine through Day 43. 
• Decline participation  in another study evaluating  investigational vaccines  through Day  181.  
• Decline participation  in another study evaluating  an investigational MVA- based  vaccine 
through end of trial. 
 
Of note, participants  may enroll in non-interventional, observational studies (e.g., natural  history 
study of monkeypox). However, concurrent participation in this trial and observational studies can 
only occur if the recommended blood collection volumes are not exceeded. 
 
5.[ADDRESS_178165] been completed, the investigator or designee is to review  the 
inclusion/exclusion criteria and determine the participant’s eligibility for the study. The following information will be collected on screen failures: demographics (age, screen number, sex, ethnicity,  
and race)  and reason(s)  for ineligibility.  Participants  who  are found to  be ineligible will be told the 
reason for ineligibility.  
 A participant may be re- screened once if a protocol eligibility criterion that is not met at the initial 
time of screening, will be met by [CONTACT_154404] a later date (e.g., a vaccine was received with in 
exclusionary window at first screening  that would not be in the exclusionary window at a later 
rescreen).  
 
5.[ADDRESS_178166]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178167] while  taking 
part in this trial. Procedures and treatment for clinical care may be billed to the participant, participant’s insurance or third party. 
 
6. STUDY  PRODUCT  
6.[ADDRESS_178168](s) and Administration  
6.1.[ADDRESS_178169]  Description  
JYNNEOS is FDA-approved for adults and licensed as a smallpox and monkeypox vaccine in the 
[LOCATION_002]. The vaccine, when thawed, is a milky, light yellow to pale white colored suspension that is licensed for subcutaneous injection. JYNNEOS is a live vaccine produced from the strain 
Modified Vaccinia Ankara- Bavarian Nordic (MVA -BN), an attenuated, non- replicating 
orthopoxvirus. MVA- BN is grown in primary  Chicken Embryo Fibroblast (CEF)  cells suspended in 
a serum -free medium containing no material of direct animal origin, harvested from the CEF cells, 
purified, and concentrated by [CONTACT_154381] (TFF) steps including benzonase  
digestion. Each  0.5 mL dose is formulated  to contain 0.5 x 10
8 to 3.95 x 108 infectious units of 
MVA- BN live virus in 10 mM Tris (tromethamine), [ADDRESS_178170] -cell DNA (≤ 20 mcg), protein (≤ 500 mcg), 
benzonase (≤0.0025 mcg), gentamicin (≤0.163 mcg), and ciprofloxacin (≤0.005 mcg).  
 
6.1.2 Dosing  and Administration  
In this trial, a licensed  vaccine  is being evaluated  (i.e., JYNNEOS)  and there is no placebo  arm. Use 
of the contralateral arm is an option if there is any residual local reaction at Day [ADDRESS_178171]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 66 of 147  Table 6 Study  Arms  
 
Arm  Dose  of JYNNEOS  (MVA -BN) Route  of Administration*  Vaccination  Day 
Day 1 Day 29 
1 2 x 107 TCID 50, (0.1 mL) Intradermal  X X 
2 1 x 107 TCID 50, (0.05  mL) Intradermal  X X 
3 1 x 108 TCID 50, (0.5 mL) Subcutaneous  X X 
*Subcutaneous is administered  in the deltoid  region, intradermal is administered  in the volar aspect  (inner side) 
of the forearm.  
 
6.1.[ADDRESS_178172] administration  is unsuccessful, another  administration  will not be attempted.  
 
6.2 Preparation/Handling/Storage/Accountability  
6.2.[ADDRESS_178173]:  JYNNEOS  (MVA -BN vaccine)  
The JYNNEOS  (MVA -BN vaccine)  will be stored  and provided by [CONTACT_154405]. Study 
product will be shipped to the clinical research site upon request and approval from DMID. 
 
Accountability  
The participating site PI [INVESTIGATOR_154350]. The participating  site PI [INVESTIGATOR_154351]’s research pharmacist responsibility for study product accountability. The participating  site’s  research  pharmacist  will be responsible for maintaining  complete  records  and 
documentation of study product receipt, accountability, dispensation, storage conditions, and final disposition of the study products.  Time of vaccine administration to the participant will be recorded on the appropriate data collection form (DCF). All study product(s), including the amount of JYNNEOS (MVA -BN vaccine),  and 
whether  administered  or not, must be documented on the appropriate study product accountability 
recor d or dispensing log. The sponsor’s monitoring staff will verify the participating site’s study 
product accountability records and dispensing logs per the DMID - approved clinical monitoring 
plan (CMP).  
 Once all participant  dosing is complete,  the pharmacy  staff should retain  or dispose of used study 
products and complete study product accountability procedures in accordance with site -specific 
standard operating procedures (SOPs). This applies to: 
Protocol  22-[ADDRESS_178174]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 67 of 147  • used and unused JYNNEOS  (MVA -BN vaccine) vials 
• JYNNEOS  (MVA -BN vaccine)  cartons  
 
All used vials and cartons may either be sequestered from the unused supplies and retained until 
study conclusion or until study product accountability has occurred by [CONTACT_154406].  Used  syringes should be discarded 
per usual procedure. 
Destruction  
After the study treatment period has ended or as appropriate over the course of the study after study product accountability has been performed, disposition of unused and used JYNNEOS (MVA -BN vaccine) vials can be destroyed on -site following applicable site procedures. A 
certificate  of destruction or documentation of destruction  should be provided to the sponsor and 
retained in the Pharmacy Binder once completed.  
6.2.[ADDRESS_178175]: JYNNEOS (MVA -BN 
vaccine)  
JYNNEOS  is supplied in  a single-dose vial with  turquoise and white  label  for SC injection.  Each  
0.5 mL dose is formulated to contain 0.5 x 10
8 to 3.95 x 108 infectious units of MVA -BN live virus 
in 10 mM Tris  (tromethamine),  [ADDRESS_178176]- cell DNA (≤ 20 mcg),  protein (≤ 500 mcg),  benzonase (≤0.0025 mcg), 
gentamicin (≤0.163 mcg), and ciprofloxacin (≤0.005 mcg). JYNNEOS is a sterile vaccine 
formulated without preservatives. The vial stoppers are not made with natural rubber latex.  
6.2.[ADDRESS_178177]:  JYNNEOS  (MVA -BN vaccine)  
JYNNEOS should be kept frozen at - 25°C to -15°C ( -13°F to +5°F) and stored in the original 
package to protect  from  light.  JYNNEOS  should not be re-frozen  once  a vial has been  thawed. Once 
thawed, the vaccine may be kept at +2°C to +8°C (+36°F to +46°F) for 12 hours. The package 
insert provides additional instructions for the handling and storage of JYNNEOS. 
 
6.2.4 Preparation  
Each dose (0.5 mL) is supplied in a single -dose vial. Sites should allow the vaccine to thaw and 
reach  room temperature before  use (about 15 to 30 minutes).  After  thawing, the total time stored at 
+2°C to +8°C (+36°F  to +46°F) should not exceed 12 hours. Once the vial is punctured and a dose 
is withdrawn, if it is not used in its entirety, it should be stored at +2°C to +8°C (+36°F to +46°F) 
and discarded within [ADDRESS_178178] puncture. If the unpunctured vial is initially shipped/stored  
at 2-8C then it is stable  for up to [ADDRESS_178179] 30 seconds. 
 
• For the ID injection  (Arm  1), 0.[ADDRESS_178180] (inner side) of the 
forearm.  
Protocol  22-[ADDRESS_178181]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 68 of 147   
• For the ID injection  (Arm  2), 0.[ADDRESS_178182] of the forearm. 
 
• For the SC injection  (Arm  3), 0.5 mL of vaccine will be withdrawn  from  the vial into a 
sterile syringe and injected into the fatty tissue over the deltoid area. 
 
See the protocol- specific  MOP  for detailed  information  on the preparation, labeling, storage,  and 
administration for each arm.  
 
6.3 Measures  to Minimize  Bias:  Randomization  and Blinding  
6.3.1 Treatment  Assignment  Procedures  
The randomization procedure will be described  in the MOP.  
 
6.3.2 Randomization 
There will be a 1:1:1 randomization allocation. Randomization will not be stratified. Randomized 
treatment assignments will be generated by a statistician at The Emmes Company, LLC, the Statistical and Data Coordinating Center (SDCC) for this study. Partic ipants will be registered  
using a web-based  application  developed  by [CONTACT_154407], LLC.  Upon entry of 
demographic data and confirmation of eligibility for the trial, the participant will be enrolled and randomized. The randomization procedure will be described in more detail in the MOP.  
 
6.3.3 Blinding  and Masking  Procedures  
This study will not utilize blinding or masking procedures as it is an open- label, non- placebo - 
controlled trial. Research  laboratories  will be blinded to participant  study arm for the purposes of 
immunogenicity/efficacy evaluations.  
 
6.[ADDRESS_178183]. Administration and date, time, and location 
of injection will be recorded on the appropriate eCRF. 
 
6.5 Concomitant  Therapy  
At screening (i.e., the screening visit or Day 1 visit if the screening visit is not conducted), participants  will be asked  about receipt  of immunosuppressive therapy, experimental  therapeutic 
agents and vaccines, other medications, and vaccines. At each subsequent study visit through Day 57, new concomitant medication(s)  and changes  to existing  medications  will be recorded  as well as 
receipt o f a vaccine. For this study, concomitant medications to be reported in the Case Report 
Form (CRF) are prescription drugs, over-the-counter medications, and supplements. Concomitant me
 dications  taken  and vaccines  received  in the [ADDRESS_178184]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178185] laboratory -confirmed monkeypox 
(illness). During sick visits, c oncomitant medications and treatment will be  collected.  
 Medications  that might interfere with the evaluation  of the immune  response to MVA- BN should 
not be used by [CONTACT_93308]-reporting period unless clinically  indicated  as part 
of the participant’s health care for a condition diagnosed after enrollment. This would include any 
systemic immunosuppressant medication that may impact the immunogenicity endpoints. In the event medical conditions dictate the use of these medications, parti cipants are encouraged to obtain 
adequate care, comply with the course of therapy as prescribed by [CONTACT_154408]. 
 
6.5.1 Rescue Medicine  
Not applicable.  
 
7. STUDY  INTERVENTION  DISCONTINUATION  AND  
PARTICIPANT  DISCONTINUATION/WITHDRAWAL 
7.1 Halting Criteria  and Discontinuation  of Study  Intervention  
7.1.1 Study  Halting  Criteria  
The study will be paused  for safety  analysis  if any of the following events  occur:  
1. One (1) participant experiences  a SAE  after the administration  of the vaccine that  is 
considered related to the vaccine.  
2. One (1) participant  experiences  a Grade 4 solicited  AE after  the administration  of the 
vaccine that is considered related to the vaccine.  
3. Three  (3) or more participants  experience  a Grade  3 or higher unsolicited  AE coded  to 
the same Preferred Term based on the medical dictionary for Regulatory Activities (MedDRA) that are deemed related to the vaccine.  
In the event  a halting  rule is met, an unscheduled safety  analysis  by [CONTACT_154409]. Further administration of the vaccine, including a second dose, is suspended for all participants until an assessment by [CONTACT_154410]. 
 
[IP_ADDRESS] Sentinel  Participant  Halting  Rules  
Not Applicable.  
 
[IP_ADDRESS] Cohort Halting  Rules  
Not Applicable.  
Protocol  22-[ADDRESS_178186]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 70 of 147   
7.1.2 Individual  Halting  Criteria  
If a single participant  meets  an individual halting  criterion,  this will not halt the whole study but 
halts the participant’s involvement in terms of the administration of the second dose of the vaccine. 
However, while the participant is discontinued from receipt of vaccine, they should be encouraged to remain in the study to monitor safety and evaluate immunogenicity until the end of the study.  
4. Any participant  experiences  laryngospasm, bronchospasm or anaphylaxis within  24 hours 
after the administration of the vaccine that is considered related to the vaccine within the 24 hours after vaccination. 
5. Any participant  experiences  generalized  urticaria (defined  as urticarial  lesions occurring 
at more than two body parts) within [ADDRESS_178187] of the participant. The participant could be withdrawn from the study at any time during the trial. 
 
7.1.3 Follow up for participants  that discontinued study  intervention  
Discontinuation from vaccination administration does not mean discontinuation from the study, and remaining study procedures should be completed as indicated by [CONTACT_4690]. If a clinically significant finding is identified (including, but not limited to changes from baseline) after  
enrollment,  the investigato r or qualified  designee will determine  if any change in participant 
management is needed.  
 The second  vaccination  will not be given, but other  follow up visits  will continue, if the participant: 
• Becomes  pregnant.  
• Develops monkeypox (symptomatic  disease)  after the first vaccination  
• Meets  an exclusion  criterion  for participation  in the study (either  newly  developed  or not 
previously recognized) that precludes further study participation. 
If a participant meets an exclusion criterion after enrollmen t/randomization and first dose, it does 
not necessarily mean the participant cannot receive the second dose of JYNNEOS. The decision of 
what “precludes further study participation” depends on what exclusion criteria are met, with a focus 
on what is best for participant safety.  The most likely  exclusion criteria  to be met are participants  
that receive a licensed vaccine after randomization (i.e., exclusion criteria 7 and 8).  If a participant  
receives  an off-study vaccine during the study- defined  restricted  time periods (i.e., as defined in 
exclusion criteria and Section 5.4), receipt of the off - s
 tudy vaccine should be reported as a 
deviati on. The participant can receive the second study vaccination if the investigator determines 
that the participant is otherwise eligible to receive the second MVA -BN in this trial.  
 
There is no reactogenicity threshold for  administration of  the second dose of vaccine, that is the 
Protocol  22-[ADDRESS_178188]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178189] vaccination.  Participants  may decline the second vaccination  due to 
residual reactogenicity at the Day 29 visit and will be discontinued from the study intervention. However, the participant will remain in the study and followed for safety and immunogenicity through Day 365 unless they withdraw from the study.  
The data to be collected at  the time of study int ervention discontinuation will  include:  
• Reason  for discontinuation study vaccination  including, but not limited  to, unacceptable 
(intolerable) reactogenicity, new medical condition identified that places participant at 
risk, participant unwillingness to have second vaccination. 
• Confirmation  of willingness  to remain  in the study and  understanding of study schedule . 
Participant Withdrawal from the Study and Replacement Participants  are free to withdraw from  
participation  in the study at any time upon request.  An investigator may withdraw a participant 
from the study if the participant: 
• Has an AE or other  medical  condition that  continued participation  in the study would not 
be in the best interest of the participant. 
• Is lost to follow- up 
 
The reason for participant discontinuation or withdrawal from the study, whether the decision was made by [CONTACT_154411], and the extent of the withdrawal (i.e., whether participant  
withdrew from  all components of research  study or  just the study intervention) will be recorded on 
the CRF. If the participant agrees, every attempt will be made to follow all AEs through resolution (return to baseline) or until defined as stable. The investigator will inform the participant that already collected data will be retained and analyzed for this study even if the participant withdraws from this study. Biospecimens collected will still be used to analyze the study endpoints.  Participants  who withdraw,  or are withdrawn  from  this study, or are lost to follow-up after signing 
the ICF and administration of the study product will not be replaced. 
7.[ADDRESS_178190] to follow-up if he or she fails to return for two scheduled visits  
and is unable to be contact[CONTACT_154412].  Extensive effort (i.e., 
generally three documented contact [CONTACT_154413], e- mail, etc., made on separate  
occasions)  will be made to  locate or  recall  the participant,  or at  least to determine  the participant’s 
health status. These efforts will be documented in the participant’s study file. 
 
8. STUDY  ASSESSMENTS  AND  PROCEDURES  
8.1 Screening  Procedures  
In this study, screening assessments can occur in an optional screening visit on Day –7 to –1, or at Visit [ADDRESS_178191] vaccination. At the time of the screening assessment, the participant  
will be provided with detailed  study information  and written  informed  consent will be obtained. The 
following assessments are performed to determine eligibility requirements as specified in the inclusion and exclusion criteria:  
Protocol  22-[ADDRESS_178192]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 72 of 147  • Obtain  demographic data. 
• Obtain  monkeypox exposure history in the 3 weeks prior to  signing ICF.  
• Review  vaccination  history, including any  experimental  vaccines,  and determine receipt 
of exclusionary vaccine(s):  
o Live vaccine in the prior 4  weeks  or an  inactivated  vaccine in the prior 2 weeks.  
o Licensed  or investigation smallpox  or monkeypox vaccine.  
• Obtain medical history. Ask specifically about worsening of any chronic medical 
condition or hospi[INVESTIGATOR_154352] [ADDRESS_178193] the following 
medical conditions: 
o HIV infection  
o History  of monkeypox, cowpox or vaccinia infection  
o History  of anaphylaxis or severe adverse reaction  to a vaccine  or vaccine product  
o History  of allergy  to gentamicin,  ciprofloxacin, chicken  or egg protein  
o History  of keloid scar formation  
• Review  medications  and therapi[INVESTIGATOR_154353]  [ADDRESS_178194]  on the 
appropriate CRF and determine receipt of exclusionary medication(s):  
o Experimental  therapeutic  agent  (or vaccine)  in the 3 months prior to consent  
o Use of immunosuppressing drugs prior to consent.  
• Perform  targeted  physical examination  and inspect  arms  for smallpox  vaccination  scar 
• Measure vital signs (H eart rate (H R), Blood pressure ( BP), and  oral temperature).  
• Review  of birth  control history with  female participants.  
o C ounsel participants  to use adequate birth  control methods required  during the 
trial to avoid pregnancy. 
o Do serum  or urine  pregnancy  test (in participants  of childbearing potential)  
• Review  inclusion and  exclusion criteria.  
The overall  eligibility  of the participant  to participate  in the study will be assessed  once all screening 
values are available. The screening process can be suspended prior to complete assessment at any time if exclusions are identified by [CONTACT_3476].  
Study participants  who  qualify for inclusion will be enrolled.  
 
8.1.[ADDRESS_178195] 
Values or Abnormal Clinical Findings During Screening  
 
A participant  may be re-screened  once if a protocol eligibility  criterion  that is not met at the initial 
time of screening, will be met by [CONTACT_154404] a later date. No participant may be screened more than twice due to a screening failure result.  Participants  will be provided the results  of pregnancy testing  and abnormal  clinical  findings 
necessitating follow -up at the discretion of the participating site PI [INVESTIGATOR_29353]- investigator.  
8.1.2 Sick Visit  
Participants with signs and symptoms consistent with monkeypox (e.g., vesicular or pustular lesions, fever, chills, lymphadenopathy, malaise, myalgias, headache, or respi[INVESTIGATOR_1856]) during the study are asked to call the study site. Those who have laboratory -confirmed monkeypox  
will be evaluated  at the clinical  site; those who have not been  tested  will be asked  to have a 
Protocol  22-[ADDRESS_178196]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178197] done. During the visit, the participant will be asked about the current illness (e.g., 
onset date, treatment received) and for information about the diagnostic testing that was done. 
Participants will have a targeted physical examination done, and a blood sample will be taken. For more information about this visit, see the MOP and the CRF. 
 
8.2 Immunogenicity Assessments  
8.2.1 Immunogenicity/Efficacy  Evaluations  
Prior comparator studies used the Bavarian Nordic (BN) Vaccina virus Western Reserve strain (VV-WR) plaque reduction neutralizing antibody (PRNT) assay and enzyme -linked 
immunosorbent assay  (ELISA)  to evaluate  immunogenicity. 
16,23,[ADDRESS_178198] a minimum of 4 timepoints (i.e., at least Days 1, 29, 43, 90 from Days 1, 15, 29, 43, 57, 90, 181 and 365). This study will also measure a monkeypox virus specific PRNT and will test a minimum of 2 timepoints  (Days  1 and 43). The monkeypox PRNT  assay  is not yet developed, and therefore  this 
endpoint is as an exploratory endpoint. Additional timepoints for each will be evaluated as able (given lab throughput and cost). 
 
8.2.2 Exploratory Assessments  
Additional assessments of humoral immunity  including ELISAs  may be performed  on samples from 
this trial.  
 
8.3 Safety and Other Assessments  
Study procedures are specified in the SOA and more detailed information as needed is provided in the MOP. A study clinician, licensed to make medical diagnoses and listed on the Form FDA 1572 as the pa rticipating  site PI [INVESTIGATOR_29353]-investigator, will be responsible for all study- related 
medical decisions.  
• Medical  history  
o A complete medical history will be obtained by [CONTACT_154414]  (i.e., the screening  visit or on Day 1 if no screening  visit is conducted). 
o An interim medical history will be obtained by [CONTACT_154415]. Any changes 
since the previous clinic  visit will be noted. The  interim medical  history should 
include an assessment for adverse events and new medical conditions. 
• Physical  examination  
o A symptom- directed  (targeted)  physical exam  will be performed  if indicated  by 
[CONTACT_9870].  
• Reactogenicity  Assessments 
o Reactogenicity  assessments of solicited  systemic  reactogenicity  occurring from 
the time  of each  vaccination  through [ADDRESS_178199] each  vaccination  will include 
fever, chills, nausea, headache, fatigue, change in appetite, myalgia, and 
arthralgia.  
o Assessment s of solicited local (injection site) reactogenicity occurring from the 
time of each  vaccination  through [ADDRESS_178200]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 74 of 147  at injection site, erythema/redness, induration/swelling, and pruritis at site.  
o Any ongoing events  at Day  15 will be followed at  subsequent visits  in order to 
note a resolution date. See Memory Aid section below on measurement of 
ongoing erythema/redness and/or induration/swelling. 
• Memory  Aid 
o All participants will complete a Memory Aid to document local and systemic 
reactogenicity from time of each vaccination through [ADDRESS_178201] each 
vaccination  (Days  1-[ADDRESS_178202] vaccination  and Days  29-43 for the second 
vaccination).  
o Memory  Aids  will be reviewed  with the participants  for any solicited  reactions,  as 
well as unsolicited AEs and SAEs. 
o The vaccination  injection  site will be examined  at all visits  until  symptoms 
resolve.  
o For those with no residual  systemic  or local  reactogenicity  at the Day 15 or Day 
43 visit, no more data is collected by [CONTACT_154416]. 
o For those with ongoing systemic  and/or local  reactogenicity  at Day  15 or Day 43 
visit, they will be asked to do the following: 
 Measure erythema/redness  and/or induration/swelling and record  in the 
Memory Aid until it has resolved, if applicable. 
 Record  end date of all  other signs and symptoms  
o Nodules and  hyperpi[INVESTIGATOR_154354],  and not collected  in the Memory  Aid to 
avoid double counting these events which tend to develop at end of second week 
as a post- inflammatory reaction.  
• Assessment  of tolerability  
o On Day  15 and Day  43, the participants  will be asked  several  global assessment 
questions to evaluate how well the vaccine is tolerated. 
• Vital signs  
o Vital sign measurements will include systolic and dia stolic BP, HR, and oral 
temperature.  Vital signs will be measured  at timepoints  specified  in the SOA.  
• Clinical laboratory evaluations  
o Serum  or urine  pregnancy  test will be performed  locally  by [CONTACT_154417] [ADDRESS_178203].  
 
8.4 Adverse  Events and Serious  Adverse  Events  
8.4.1 Definition  of Adverse Events  (AE)  
Protocol  22-[ADDRESS_178204]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178205] medical occurrence associated with the use of an intervention  
in humans, whether  or not considered  intervention- related  (21 CFR  312.32 (a)). An AE can 
therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of medicinal (investigational) product.  
 Any medical  condition that is present  at the time the participa nt is screened  will be considered  as 
baseline and not reported as an AE. However, if the severity (i.e., grade) of any pre -existing medical 
condition increases, it should be recorded as an AE. 
 
Adverse events can be further divided into solicited adverse events and unsolicited adverse events. Solicited  adverse events  are those for which  the study team  will specifically  query the participant 
whether they occurred. Unsolicited adverse events are those events that the participant report occurring without being queried about the specific event. 
 
[IP_ADDRESS] Solicited  Adverse Events  
Reactogenicity will be especially important to document because of prior studies demonstrating more local (measurement) reactogenicity among participants who received the ID MVA -BN 
vacci ne injection. In this study, we will collect the following solicited adverse events based on 
prior studies. This includes local (pain at the site of the injection, erythema/redness, induration/swelling, pruritis) and systemic (fever, chills, nausea, headache, fatigue, change in appetite, myalgia [exclusive of the injection site], and arthralgia) reactogenicity. In addition, we expect  that some participants  will develop  skin discoloration and nodules which  will be reported as 
AEs and not collected on the memory aid and followed through to resolution. For this study, we will use the following toxicity grading scale: “FDA  Guidance for Industry, Toxicity  Grading Scale for Healthy Adults and Adolescent Volunteers 
Enrolled in Preventive Vaccine Clinical Trials ” as a reference.  
 Of note, pruritis/itching, arthralgia, chills, and change in appetite are not included in the FDA toxicity  table.  However,  the FDA Guidance allows  for addition of other  signs and symptoms as 
follows:  
 
Mild:  No interference  with activity  
Moderate:  Some  interference  with activity  
Severe:  Prevents  daily  activity  
Potentially  Life Threatening:  ER visit or  hospi[INVESTIGATOR_059]  
 
[IP_ADDRESS] Unsolicited  Events  
Unsolicited  events  are all AEs  spontaneously reported  by [CONTACT_4538]/or  in response to an 
open question from study personnel or revealed by [CONTACT_4171], physical examination or other 
diagnostic procedures. 
 
8.4.2 Definition  of Serious  Adverse Events  
An adverse  event  or suspected  adverse reaction  is considered  "serious" if,  in the view  of either the 
Protocol  22-[ADDRESS_178206]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 76 of 147  investigator or sponsor, it results in any of the following outcomes (21 CFR 312.32 (a)): 
• death  
• a life-threatening adverse event*  
• inpatient hospi[INVESTIGATOR_707]  
• a persistent  or significant incapacity  or substantial disruption of the ability  to conduct 
normal life functions, or 
• a congenital anomaly/birth  defect.  
 
Important medical events that may not result in death, be life -threatening, or require hospi[INVESTIGATOR_154355], based  upon appropriate medical  judgment, they may jeopardize 
the patient or participant and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, convulsions that do not result in inpatient hospi[INVESTIGATOR_059], etc.  
 * An adverse event  is considered  “life-threatening” if, in the view  of either  the investigator or 
sponsor, its occurrence places  the patient  or participant  at immediate  risk of death.  It does not 
include grade [ADDRESS_178207] caused death. 
 
[IP_ADDRESS] Definition  of Medically  Attended  Adverse Events  (MAAE)  
A medically attended adverse event (MAAE) is an unsolicited AE that results in unscheduled medical  attention  such as a hospi[INVESTIGATOR_154356] 24 hours, an emergency  room visit,  or an 
otherwise unscheduled healthcare visit for any reason. All SAEs and MAAEs will  be collected from 
Day 1 through Day 57, and all SAE/MAAEs related to the vaccine through Day 181. 
 
[IP_ADDRESS] Definition  of Suspected  Unexpected  Serious  Adverse  Reactions  (S[LOCATION_003]R)  
A S[LOCATION_003]R  is a SAE  that is considered  related  to study product and unexpected.  
 Unexpectedness  to study product will be determined  by [CONTACT_154418].  
 
8.4.3 Classification  of an Adverse Event  
The determination  of seriousness,  severity,  and causality  will be made by [CONTACT_63689]-site investigator or 
other staff as listed on the delegation log. Any potential grade 3 or 4 AE should be evaluated by [CONTACT_154384] a medical ev
aluation  of AEs.  This includes but is not limited  to physicians, physician assistants,  and nurse 
practitioners.  
 
[IP_ADDRESS] Severity  of Event  
All AEs or SAEs will be assessed  for severity, according  to the toxicity  grading scale,  FDA 
Guidance for Industry, Toxicity  Grading Scale for Healthy Adults and Adolescent  Volunteers 
Enrolled in Preventive Vaccine Clinical Trials . For adverse events (AEs) not included in the 
Protocol  22-[ADDRESS_178208]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 77 of 147  protocol-defined grading scale, the following guidelines will be used to describe severity. 
 Mild (Grade 1) :
  Events that are usually transient and may require only minimal or no treatment  or 
therapeutic intervention and generally  do not interfere  with the participant’s usual activities of daily 
living.  Moderate (Grade 2) : E
 vents that are usually alleviated with additional specific therapeutic  
intervention. The event  interferes  with usual activities  of daily  living, causing discomfort but poses 
no significant or permanent risk  of harm  to the research  participant.  
 Severe (Grade 3) : E
 vents interrupt usual activities of daily living, or significantly affects clinical 
status, or may require intensive therapeutic intervention. S evere events are usually incapacitating.  
 Life-
threatening (Grade  4): Extreme  limitation  in activity,  significant assistance required; 
significant medical intervention/therapy required, hospi[INVESTIGATOR_154334]. 
 
[IP_ADDRESS] Relationship  to Study  Intervention  
For each reported  adverse event  or reaction,  the Principal  Investigator [INVESTIGATOR_154357]:  Related  
– The AE is known to occur with the study intervention, there is a reasonable possibility  
that the study intervention  caused  the AE, or there is a temporal  relationship between the study 
intervention and event. Reasonable possibility means that there is evidence to suggest a causal relationship between the study intervention and the AE.   Not Related  
– There is not a reasonable possibility that the administra tion of the study intervention 
caused the event, there is no temporal relationship between the study intervention and event onset, or an alternate etiology has been established.  
 
8.4.4 Time  Period  and Frequency  for Event  Assessment  and Follow- Up 
For this study:  
• Systemic  and local  solicited  adverse events  will be  collected  from  Day  1 through Day  15, 
and Day 29 through Day 43. However, participants with ongoing systemic and/or local reactogenicity at Day 15 or Day 43 visit, will be asked to measure erythema/redness and/or 
induration/swelling until it has resolved, if applicable, and record end date of all other signs and symptoms. 
• Unsolicited  adverse events  will be collected  from  Day 1 through Day  29, and Day  29 
through Day 57. 
• All Serious adverse  events  (SAEs) and MAAEs  will be collected  from  Day  1 through 
Day 57, and all SAE/MAAEs related to the vaccine through Day 181. 
• All SAEs  will be followed through resolution or until the site  investigator deems  the 
event to be chronic or the participant is stable.  
• AEs will be followed through resolution.  
 
Protocol  22-[ADDRESS_178209]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 78 of 147  8.4.5 Adverse Event  Reporting  
[IP_ADDRESS] Investigators Reporting  of AEs 
All clearly related  signs, symptoms, and results of diagnostic procedures performed because of an  
AE should be grouped together  and recorded as a single diagnosis  or AE term,  if available. If the 
AE is  a laboratory abnormality that  is part of a clinical  condition or syndrome, it should be  
recorded  as the syndrome or diagnosis rather  than the individual laboratory abnormality. 
Each AE will also be described in terms of duration (start and stop date), severity, association with 
the study product, action(s) taken, and outcome. 
 AEs characterized  as intermittent require  documentation  of onset and duration of each epi[INVESTIGATOR_17110]. All 
AEs will be assessed for severity, relatedness to study vaccine (see Section 8.4.3), and seriousness 
(see section 8.4.2) by [CONTACT_9154] [INVESTIGATOR_11637]-investigator.  All AEs will be captured  on the appropriate data collection  form.  Information  to be collected  for 
AEs includes event term or description, date of onset, assessment of severity, relationship to study product, and alternate etiology (assessed only by [CONTACT_154419] a 
diagnosis and listed on the Form FDA 1572 as an investigator), date of resolution, seriousness, and 
outcome. AEs occurring during the trial collection and reporting period will be documented 
appropriately regardless of relationship. 
 
[IP_ADDRESS] Special  Reporting  of Adverse Events  
Not applicable.  
 
8.4.6 Serious  Adverse Event Reporting  
[IP_ADDRESS] Investigators Reporting  of SAEs  
Any AE that meets  a protocol- defined  serious criterion  must be submitted  immediately  (within 24 
hours of site awareness) on an SAE form to the DMID Pharmacovigilance Group, at the following address:  
 
DMID  Pharmacovigilance Group  
Clinical Research  Operations and Management  Support  (CROMS)  
[ADDRESS_178210]. Suite  650 Bethesda, MD 
[ZIP_CODE], [LOCATION_003] SAE  Hot Line:  [PHONE_2618] (US) or [PHONE_2619] (outside US) 
SAE  FAX  Number: [PHONE_2620] (US) or [PHONE_2621] (outside US) 
SAE  E
mail Address: [EMAIL_1393]  
 In addition to the SAE  form,  select  SAE  data fields  must also be entered  into the SDCC  system. 
See the protocol-specific MOP for details regarding this procedure.  Other  supporting documentation of the event  may be requested  by [CONTACT_122831]. The DMID Medical Monitor will review a nd 
assess the SAE for regulatory reporting and potential impact on study participant safety and 
Protocol  22-[ADDRESS_178211]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178212], the site 
principal investigator [INVESTIGATOR_29353]- investigator will report the event to the DMID 
Pharmacovigilance Group. 
 
[IP_ADDRESS] Regulatory Reporting  of SAEs  
Following notification from the site Principal Investigator [INVESTIGATOR_29353]-investigator, DMID, as the IND  sponsor, will report  any S[LOCATION_003]R  to the FDA  as an IND  safety  report. DMID will  report  
an AE as a suspected  unexpected  adverse  event  only if there  is evidence to suggest a causal 
relationship between the study intervention and the AE. 
 
The Sponsor must ensure the event  meets  all three of  the definitions:  
• Suspected  adverse reaction.  
• Serious.  
• Unexpected.  
Both serious and unexpectedness  are important,  but the event  will be reported  only if there  is 
evidence to suggest a causal relationship between the drug and the adverse event, such as: 
• A single occurrence  of an event  that is uncommon and  known to  be strongly associated 
with drug exposure. 
• One or more occurrences  of an even t that  is not commonly  associated  with  drug exposure 
but is otherwise uncommon in the population exposed to the drug. 
• On review  as an aggregate analysis  when  the occurrence is higher than the historical 
control.  
 
DMID  will report  to the FDA  any unexpected  fatal or life-threatening  suspected  adverse  reaction 
as soon as possible, but in no case later than 7 calendar days after the sponsor’s initial receipt of the information. If the event is not fatal or life -threatening the IND safety report will be submitted 
within [ADDRESS_178213].  
DMID  will submit an IND safety  report to the FDA  and will notify all participating  site Principal 
Investigators (i.e., all Principal Investigators to whom the sponsor is providing drug under its 
IND(s) or under any Principal Investigator’s IND(s) of potential serious risks from clinical studies or any other source, as soon as possible. SAEs that are not S[LOCATION_003]Rs will be reported to the FDA at least annually in a summary format which includes all SAEs. 
 
8.4.[ADDRESS_178214]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178215]  (AESI)  
There are no pre -specified  AESI  for this trial.  
 
8.4.9 Reporting  of Pregnancy  
Pregnancy  is not an AE. However,  any pregnancy  that occurs  during study participation  (through 
Day 365) should be reported to the sponsor on the appropriate DCF. Pregnancy should be followed 
for safety and outcome. This follow -up will include pregnancy outcome (termination, pre -term 
birth, term birth) and newborn outcome (live birth, fetal demise, stillbirth; presence of any congenital anomalies). No in-person visits will be required for pregnancy outcome determination.  
 
8.5 Unanticipated  Problems  
8.5.1 Definition  of Unanticipated Problems  (UP)  
The Department  of Health  and Human  Services  Office  for Human  Research  Protections (OHRP) 
considers unanticipated problems (UPs) involving risks to participants or others to include, in general, any incident, experience, or outcome that meets all of the following criteria: 
• Unexpected  in terms  of nature,  severity,  or frequency given (a)  the research  procedures 
that are described in the protocol -related documents, such as the Institutional Review 
Board (IRB) -approved research protocol and informed consent document; and (b) the 
characteristics of the participant population being studied; and 
• Related  or possibly related  to participation  in the research  (“possibly related” means  there 
is a reasonable possibility that the incident, experience, or outcome may have been caused 
by [CONTACT_3459]); and 
• Suggests that the research  places  participants  or others  at a greater  risk of harm  (including 
physical, psychological, economic, or social harm) than was previously known or recognized.  
 
Incidents arising from noncompliance with study procedures should be reported as protocol deviations (see Section  10.1.10).  An incident that qualifies  as both a UP and a protocol deviation 
should be reported as both. 
8.5.2 Unanticipated Problem  Reporting  
The investigator will report unanticipated problems (UPs) to the study sponsor, the reviewing IRB 
and to the SDCC.  
 
The UP report  will include the following information:  
• Protocol identifying information: protocol title  and number, PI’s  name,  and the IRB 
project number; 
• A detailed  description of the event,  incident, experience,  or outcome;  
• An 
explanation of the basis for determining  that the event,  incident, experience,  or 
outcome represents an UP;  
• A description of any  changes  to the protocol or other corrective  actions  that have been 
taken or are proposed in response to the UP. 
Protocol  22-[ADDRESS_178216]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 81 of 147   
To satisfy  the requirement  for prompt reporting, UPs  will be reported  using the following timeline:  
 
• UPs that are serious adverse events (SAEs) will be reported to the IRB and to the 
SDCC/study sponsor within  24 hours of the investigator becoming aware  of the event.  
• Any other UP will be reported  to the IRB and to the SDCC/study sponsor within  a 
timeline defined according to the relevant policies.  
• UPs will be collected  through the end  of the study. 
 
8.5.[ADDRESS_178217] non - 
inferiority  of the 2 x 107 ID regimen  relative  to 1 x 108 SC (standard  dose regimen).  If the [ADDRESS_178218] dose regimen.  
 
Primary  Hypothesis 1 
• At Day [ADDRESS_178219] 1 x 108 MVA- BN SC regimen,  as assessed  by [CONTACT_154420].  
 
Primary  Hypothesis 2 
• At Day  [ADDRESS_178220] 1 x 108 MVA- BN SC regimen, as assessed by [CONTACT_154421].  
Secondary  hypotheses  
• At Day [ADDRESS_178221] 1 x 108 MVA- BN SC regimen,  as assessed  by [CONTACT_154420].  
• A t Day [ADDRESS_178222] 1 x 108 MVA- BN SC regimen,  as assessed  by [CONTACT_154420].  
• The humoral immune  responses, as  assessed  by [CONTACT_154420],  for each ID regimen  will be 
similar to the SC regimen at all study days. [Note, this corresponds to two hypotheses, one for each ID study arm.] 
• The humoral immune  responses, as  assessed  by [CONTACT_154422]-life, for each 
ID regimen will be similar to the SC regimen. [Note, this corresponds to two hypotheses, one for each ID study arm.] 
• The humoral immune  responses, as  assessed  by [CONTACT_154423],  for 
each ID regimen will be similar to the SC regimen at Day  1 and 43. [Note, this 
corresponds to two hypotheses, one for each ID study arm.] 
 
Protocol  22-[ADDRESS_178223]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 82 of 147  9.2 Sample  Size Determination  
Approximately 210 evaluable (mITT) participants (70 per study arm; [ADDRESS_178224] of non-
inferiority)  will provide ample  power for both tests of non- inferiority  with a type I error rate of 0.05 
(Table 7), and assumes, conservatively, that both arms have a standard deviation of 0.6. 
 A sample size of [ADDRESS_178225] of non- inferiority will provide 84% power with the non- 
inferiority (NI) margin of 0.[ADDRESS_178226] deviation of 0.6 in both arms ( Table 8 and 9). Data from prior 
studies by [CONTACT_25715][INVESTIGATOR_154358] 0.[ADDRESS_178227] 
dose regimen for two reasons: 1) the hypothesis test is conditional on rejecting the null hypothesis comparing the [ADDRESS_178228] regimen arm, and 2) the true GMT for the [ADDRESS_178229] SC dose.  In a prior study that compared ID and SC routes of MVA -BN
16, 10% of the randomized participants  
did not receive the second  vaccination.  Therefore,  this trial will enroll up to 231 participants (210 x 
1.1) to have 210 evaluable participants. 
Table 7: Power calculations  
Power calculations for a non- inferiority test of means using unequal variances and two- sided type 
one error rate of 0.05. Non- inferiority margin of 0.5. Assumed standard deviation (on log10 scale) 
of 0.6. 
 
NI margin  Sample  Size 
per arm   
Total  sample  size for NI test  
Power  
0.5 
Log 10(0.5) =- 0.301   
60  
120  
0.78 
0.5 70 140 0.84 
0.5 80 160 0.88 
0.5 85 170 0.90 
0.5 90 180 0.92 
 
 
Table 8: Standard deviation estimates  
Standard  deviation estimates  computed from  Table S4 of Pi[INVESTIGATOR_154359], 201929 
 MVA -BN ACAM2000  Ratio  of 
GMTs  95%  CI 
Week  N GMT  95%  CI SD 
(for 
log 10 
GMT)  N GMT  95%  CI SD 
(for 
log 10 
GMT)  
2 184 16.2 [13.0,  20.1]  0.65 184 16.2 [13.1,  20.0]  0.63 0.997  [0.738,  1.348]  
4 185 16.9 [13.7,  20.8]  0.63 186 79.3 [67.1,  93.8]  0.51 0.213  [0.163,  0.278]  
6 185 153.5  [134.3,  175.6]  0.41 181 64.7 [54.9,  76.2]  0.49 2.372  [1.922,  2.928]  
8 179 118.2  [102.9,135.8]  0.41 183 67.1 [56.9,  79.0]  0.49 1.763  [1.422,  2.185]  
Peak 185 153.5  [134.3,  175.6]  0.41 186 79.3 [67.1,  93.8]  0.51 1.935  [1.562,  2.397]  
 
Protocol  22-[ADDRESS_178230]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 83 of 147   
Table 9: Standard deviation estimates  
Standard  deviation estimates  computed from Frey  et al, 201516 
Study  Visit Day Liquid  SC 1x108 N=149  Liquid  ID 2x107 N=146  
 VV-WR GMT  [95%  CI] SD VV-WR GMT  [95%  CI] SD 
Day 14 10.0 [9.0, 11.1]  0.28 10.3 [9.3, 11.3]  0.27 
Day 28 9.6 [8.7, 10.6]  0.27 10.8 [9.9, 11.9]  0.23 
Day 42 45.2 [36.4, 56.2]  0.59 54.4 [43.7, 67.8]  0.[ADDRESS_178231] 2nd vaccination  49.5 [40.0, 61.3]  0.58 59.6 [48.1, 74.0]  0.[ADDRESS_178232] statistic and 95% two -
sided confidence intervals. The ID -dose regimen will be considered non- inferior if the lower bound 
of the confidence interval (original scale) is no less than half that of the standard dose, giving a non -
inferiority (NI) margin of 0.5 (NI= - 0.301 log10 scale). The selection of this NI margin was based 
on the pi[INVESTIGATOR_9205] [ADDRESS_178233] MVA -BN regimen, which provided an estimated relative  (peak)  
immune  response of approximately 2-t imes  higher for MVA- BN (Table 8). An NI margin of 0.[ADDRESS_178234] as high as what would be 
expected for ACAM2000. 
 If the null hypothesis from analysis 1 is rejected in favor of non- inferiority (i.e., the lower limit of 
the 95% CI of the difference in log of GMTs for 2 x 10
7 TCID 50 MVA- BN ID compared to 1 x 
108 MVA- BN SC is greater  than log(0.5) which  is equal  to -0.301), testing  will proceed  with a 
non- inferiority test of  the [ADDRESS_178235] statistic with 95% confidence interval.  
 
9.3.2 Timing  of An alyses  
[IP_ADDRESS] Interim  Safety  Analyses  
Given the need for rapid review and dissemination of study data for public health reasons, AEs and  
SAEs  may be reviewed  as necessary  outside of DSMB  reviews.  The DSMB  may not need  to meet  
(unless halting  rules  are met),  and materials  will be provided electronically.  Documentation of 
review and any concerns noted will be solicited electronically.  
 The DSMB  will review  separate cumulative  AE data reports  for all participants  within  each arm. 
Given the safety database known for authorized/approved vaccines, there is no routine mandatory review by [CONTACT_154424]. 
 
Protocol  22-[ADDRESS_178236]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 84 of 147  [IP_ADDRESS] Interim  Immunogenicity  Analyses  
Interim data review of immunogenicity may be performed after all participants have comple ted 
Day 181. Analyses will be performed as needed to inform public health decisions. It is recognized 
that the data may not be frozen, but the risk of introducing bias at that point in the trial is considered 
small. The analyses will be provided to the study team. There is no blinded data in this trial. However, research laboratories  will be blinded to participant  study arm for the purposes of 
immunogenicity/efficacy evaluations.  
 Data may be disseminated  to public health  officials  and partners  as needed  and included in 
publications and presentations to inform the global scientific community. 
[IP_ADDRESS] Final  Analyses  
The final efficacy/immunological/safety  outcome(s) may be analyzed  after all data for the primary 
and secondary outcome(s) have been collected and locked.  
 
9.3.[ADDRESS_178237] one dose of study vaccine. Analyses for the safety 
population will include safety  reported  through the end of the study. The modified  intent- to-treat 
(mITT) population includes all participants who received at least one dose of vaccine and contributed both pre- and at least one post- vaccination  venous blood sample  for immunogenicity 
testing for which valid results were reported.  In the final analysis,  protocol deviations will be reviewed  to determine  which  protocol deviations 
may affect  the analysis.  The per protocol (PP) population will then be defined  – and this includes 
all participants in the mITT subset with the following exclusions: 
• Data from all available visits  for participants  found to  be ineligible  at baseline.  
• Data from  all visits  after  the protocol deviations that  are considered to  affect  the science 
(as determined by [CONTACT_154425]). 
• Data from  any visit that  occurs  substantially  out of window.  
 
For the PP and mITT  analyses,  participants  will be analyzed  according to the study product that they 
received.  
 
9.3.[ADDRESS_178238]  the analysis,  a per-protocol (PP) analysis  may 
also be performed.  
Protocol  22-[ADDRESS_178239]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 85 of 147   
Geometric Mean Titers (GMT) and Geometric Mean Fold Rise (GMFR) from baseline of VV - WR 
PRNT  will be calculated,  along with 95% CIs, for all groups, at each timepoint.  Summaries will 
also be displayed graphically. Geometric Mean Titer Ratio, defined as the ratio of each ID arm to the control SC arm, will also be reported at each timepoint, along with 95% CIs. There are no imputations planned for missing  data.  
 A Statistical Analysis Plan (SAP)  will be developed and will detail  the full planned analysis.  
9.3.6 Safety  Analyses 
The safety  outcomes for the three study arms  will be evaluated  including systemic  reactogenicity 
for 14 days after each vaccination, local reactogenicity for 14 days after each vaccination, and unsolicited adverse eve nts for 28 days after each vaccination. All SAEs and MAAE will be 
evaluated from Day 1 through Day 57 of the trial as compared to licensed dose, and all related SAE/MAAEs will be evaluated through Day 181. 
 
[IP_ADDRESS] Reactogenicity  
The number, percentage (observed r ate) and exact two -sided 95% CI for participants reporting each 
solicited  local  (injection  site) reaction  and solicited  systemic  reaction  following vaccination will be 
summarized by [CONTACT_154426], and overall (i.e., after any 
vaccination). In addition, the most severe local and systemic reactions recorded during the follow-up period (i.e., maximum severity) for each participant will be determined and summarized by [CONTACT_154427] (as well as overall) and the resulting number and percentage of participants will be summarized by [CONTACT_86953] (none, mild, moderate,  severe,  life-threatening).  Last,  the daily  severity  of local  and systemic  reactions  will be 
determined for each participant and the proportion of participants having a sign/symptom each day will summarized by [CONTACT_154428]. Rates for any severe (Grade 3 or 4) solicited local or systemic reaction following any vaccination will be compared between study arms. 
 
[IP_ADDRESS] Other Adverse Events  
The number of associated unsolicited AEs, MAAEs and SAEs following vaccine administration is 
expected  to be small. A  complete  listing  of all events  will therefore  be provided, including the nature 
of the event, timing relative to vaccination, severity, duration, and the investigator’s assessment of the likely relationship to vaccination. For each type of AE, the observed rate and exact two- sided 
confidence intervals will be computed for each study arm and listed by [CONTACT_154429]. AEs will be MedDRA
® coded for preferred term and system organ class. Event rates and exact  95% confidence  
intervals  for each  study arm and  the entire  study cohort will be presented, in aggregate  and by 
[CONTACT_61132]® categories.  Related  unsolicited  AEs,  MAAE  and SAEs  rates  will be compared between 
the study arms.  The number, percentage  (observed rate) for participants  that withdrew or discontinued their 
vaccination series due to safety or reactogenicity events will be tabulated. Rates of  
withdrawal/discontinuation  will be compared  between  study arms  using Fisher’s  exact  test.  
 
Protocol  22-[ADDRESS_178240]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 86 of 147  Refer  to the SAP for additional information.  
 
10. SUPPORTING  DOCUMENTATION  AND  OPERATIONAL  
CONSIDERATIONS  
10.1 Regulatory,  Ethical,  and Study  Oversight  Considerations  
This study will be conducted  in conformity  with the principles set forth  in The Belmont Report: 
Ethical Principles and Guidelines for the Protection of Human Participants of Research (US 
National Commission for the Protection of Human Participants of Biomedical and Behavioral 
Research; April 18, 1979), and the federal policy for the Protection of Human Participants codified in 45 CFR Part 46, 21 CFR Part 50 (Protection of Human Participants), and the ICH E6(R2).  
 An OHRP -registered IRB will review and approve this protocol, associated informed consent 
documents, recruitment materials, and handouts or surveys intended for the participants, prior to the recruitment,  screening  and enrollment of participants.  The IRB review  shall  be in accordance 
with 45 CFR 46 and 21 CFR 50, 21 CFR 56 (IRBs), and other federal, state, and local regulations and pol icies, as applicable.  
 Each institution engaged in this research will hold a current Federalwide Assurance (FWA) issued by [CONTACT_154430] (OHRP) for federally  funded research.  and provide  
the FWA  number to DMID.  Each  site principal investigator [INVESTIGATOR_154360]/her research site(s). Any amendments to the protocol or informed consent documents will be approved by [CONTACT_154431]. IRB review and approval will occur at least annually throughout 
enrollment and follow -up of participants, in accordance with applicable regulations and the 
requirements  of the IRB/IEC.  The participating  site PI [INVESTIGATOR_154361], as applicable to the IRB policy. 
 
DMID must receive the documentation that verifies IRB/IEC approval for this protocol, informed consent documents and associated  documents, prior to the recruitment,  screening  and en rollment 
of participants, and any IRB approvals for continuing review or amendments as required by [CONTACT_122830]. 
 
10.1.1 Informed  Consent  Process  
Informed consent is a process that is initiated prior to an individual agreeing to participate in a trial and continuing throughout the individual’s trial participation. Before any study procedures are performed, informed consent will be obtained and documented. Participants will receive a concise and focused presentation of key information about the clinical trial, verbally and with a written 
consent form. The key information about the purpose of the study, the procedures and experimental aspects of the study, study interventions/products, probability for random assignment to treatment groups, risks and discomforts, the expected duration of the participant’s participation in the trial, 
any expected benefits to the participant, and alternative treatments and procedures that may be available to the participant. The explanation will be organized and presented in lay terminology and 
language that facilitates  understanding why one might or might not want to participate.  
 
Protocol  22-[ADDRESS_178241]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178242] (e.g., the 
investigator) for answers to any questions relating to the research project. 
 Information will also include the foreseeable circumstances and/or reasons under which the participant’s participation in the trial may be terminated. The participants will be informed that participation  is voluntary and that they are free to withdraw from  the study for any reason  at any 
time without penalty or loss of benefits to whic h the participant is otherwise entitled.  
 Participants will be informed that records identifying the participant will be kept confidential, and,  
to the extent  permitted  by [CONTACT_29695]/or  regulations, will not be made publicly available 
and, if the results of the trial are published, the participant’s identity will remain confidential. 
Participants will be informed whether private information collected from this research and/or specimens will be used for additional research, even if identifier s are removed. Participants will be 
informed that the monitor(s), auditors(s), IRB, NIAID, and regulatory authority(ies) will be granted direct access to the participant’s original medical records for verification of clinical trial procedures and/or data w ithout violating the confidentiality of the participant,  to the extent  permitted  by [CONTACT_154432], and that, by [CONTACT_2960] a written informed consent form, the 
participant is authorizing such access.  
 Participants  will be allowed  sufficient  time to consider  participation  in this research  trial and can 
discuss this trial with their family, friends or legally authorized representative, or think about it prior to agreeing to participate. 
 
Informed  consent forms  will be IRB-approved, and participants  will be asked  to read and review 
the consent form. Participants must sign the informed consent form prior to starting any study procedures being done specifically for this trial. Once signed, a copy of the informed consent form will be give n to the participant(s) for their records. 
 New information will be communicated by [CONTACT_16541] [INVESTIGATOR_154362].  The informed  consent 
document will be updated, and participants will be re -consented per IRB requirements, if necessary.  
 
[IP_ADDRESS] Requirements  for Permission  by [CONTACT_122781]/Guardians  and Assent  by [CONTACT_63779]  (in case 
of a minor) 
Not applicable.  
 
[IP_ADDRESS] Other Informed  Consent  Procedures  
Participants will be asked for consent to collect blood for the use of residual specimens and samples 
for secondary research. This extra/residual blood and corresponding serum will be used as back -up 
specimens for PP defined assays or designated for secondary  research use and stored indefinitely at 
a designated storage facility. Collection of extra/residual samples during the study will help 
Protocol  22-[ADDRESS_178243]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178244]  (safety and immunological)  of the vaccine on the host response to vaccination. To 
maintain statistical power in follow -on analyses it is important that extra  blood collection and 
secondary research use be included in as many participants as possible, due to the limited  sample  
size per treatment  arm. For this reason,  if participants  choose not to provide permission  for extra  
blood and secondary  research  use, they will not be eligible  for enrollment into the study. 
 
The stored samples will be labeled with barcodes to maintain confidentiality. Research with identifiable samples and data may occur as needed, however, participant confidentiality will be maintained as described for this protocol and with IRB approval. Samples designated for secondary research u se may be used for additional immunological assessments that may include but are not 
limited to antibody epi[INVESTIGATOR_111050], B and T cell repertoire determination, non- traditional immune  
assay  development, determination  of innate immune factors  and the ability  of vaccine -induced 
antibodies to cross -react to different proteins and virus strains. These blood samples might be used 
in new or different immunological laboratory tests, to provide information for the development of new vaccines or therapeutics, or for the studies of monkeypox virus or other related viruses. Samples will not be sold for commercial profit.  
Although the results of any future research may be patentable or have commercial profit, participants will have no legal or financial interest in any commercial development resulting from any future research. There are no direct benefits to the participant for extra specimens collected  or 
from  the secondary  research.  No results  from  secondary  research  will be entered  into the 
participant’s medical  record. Incidental findings will not be shared with the participant, including 
medically actionable incidental findings, unless required by [CONTACT_2371].  Risks are associated with the additional volume of blood collected, such as anemia. Risks for loss  
of privacy and confidentiality  are described  below.  Participants  may withdraw  permission  to use 
samples for secondary use at any time. They will need to contact [CONTACT_154433]. Participants who withdraw consent before the last visit will not have the extra blood drawn for secondary use.  Participants will be asked to consent specifically on primary and secondary research samples. The consent process will include an explanation of the potential risks to the individual participants associated with data submitted to an NIH  data repository and subsequent sharing. 
Data that may potentially identify human participants will not be released in unrestricted databases.  Participants  will be informed  that analytical  methods are associated  with the risk of 
re-identification, even when specimens are de- identified. The consent will include whether 
individual participant data will be shared through a NIH controlled access data repository. 
 
10.1.2 Study  Termination  and Closure  
Section  7, Study Intervention Discontinuation and Participant  Discontinuation/Withdrawal, 
describes the temporary halting of the study. This study may be prematurely  terminated  if there is sufficient  reasonable cause,  including but not 
limited to:  
• Determination  of unexpected, significant,  or unacceptable risk  to participants  
Protocol  22-[ADDRESS_178245]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 89 of 147  • Results  of interim efficacy  or futility  analysis  
• Insufficient  compliance to protocol requirements  
• Data that are not sufficiently  complete  and/or evaluable  
• Regulatory authorities’  determination  
• Sponsor’s determination  
 
If the study is prematurely  terminated,  the Principal  Investigator (PI) will promptly inform  study 
participants and the Institutional Review Board (IRB) and regulatory authorities as applicable.  
 Study participants will be contact[INVESTIGATOR_530], as applicable, and be informed of changes to study visit schedule.  The PI [INVESTIGATOR_154363]- up for the participants,  as necessary.  The sponsor 
will notify regulatory authorities as applicable.  
 
10.1.[ADDRESS_178246] by [CONTACT_3486], their staff, and  
the sponsor(s) and their agents.  This confidentiality  is extended  to cover  clinical  information 
relating to participants, test results of biological samples and genetic tests, and all other information generated during participation in the study. No identifiable information concerning participants in the study will be released to any unauthorized third party. Participant confidentiality will be maintained when study results are published or discussed in conferences. 
 
The study monitor, other authorized representatives of the sponsor, representatives of the Institutional Review Board (IRB), and/or regulatory agencies may inspect all documents and 
records required to be maintained by [CONTACT_093], including but not limited to, medical records  
(office,  clinic,  or hospi[INVESTIGATOR_307]) and pharmacy  records  for the participants  in this study. The clinic al study 
site will permit access to such records.  
 All source records including electronic data will be stored in secured systems in accordance with institutional  policies  and federal  regulations. All study data and research  specimens  that leave the 
site ( including any electronic transmission of data) will be identified only by a coded number  that 
cannot be linked to a participant.  As this research is funded by [CONTACT_18121], it is covered by [CONTACT_154386] a Certificate of Conf identiality. By [CONTACT_122842], researchers cannot be forced to disclose or 
provide, in any Federal, State, or local civil, criminal, administrative, legislative, or other proceeding, the name [CONTACT_122867], document, or biospecimen  that 
contains identifiable,  sensitive  information  about the individual and that was created  or compi[INVESTIGATOR_154364], unless such disclosure or use is made with the consent of the individual to whom the information, document, or biospecimen pertains.  The Certificate  cannot be used to resist  a demand  for information  from  personnel of the United 
States  Government that is used for auditing or evaluation  of federally  funded projects,  like this 
study, or for information that must be released  in order to meet  the requirements of the Federal 
Food and Drug Administration (FDA).  
Protocol  22-[ADDRESS_178247]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 90 of 147  A Certificate of Confidentiality does not prevent the participant from voluntarily releasing 
information  about themselves  or their involvement in this research. If any person  or agency  obtains 
a written  consent to receive research  information, then the researchers  may not use the Certificate 
to withhold that information.  The Certificate of Confidentiality does not prevent the researchers from reporting without the participant’s consent, information that would identify the participant as a participant in the research  
project  regarding  matters  that must be legally  reported  including child  and elder  abuse, sexual abuse, 
or wanting to harm themselves or others.  The release  of individual private information  or specimens  for other research  will only occur  if 
consent was obtained from  the individual to whom  the information, document, or biospecimen 
pertains, or for the purposes of other research that the release is in compliance with applicable 
Federal regulations governing the protection of human participants in research. 
 
10.1.4 Secondary  Use of Stored  Specimens  and Data  
 
[IP_ADDRESS] Samples  for Secondary  Research  
Repository Research  Sample  
To participate in this study, participants will be asked for consent for storage of samples for secondary  use. Samples  will be stored  indefinitely  at a DMID -designated  storage facility.  Each 
sample will be encoded (labeled) only with a barcode and a unique tracking number to protect participant confidentiality. Secondary research with coded samples and data may occur, however, participant confidentiality will be maintained as described for this protocol. An IRB review of the secondary research u sing coded specimens is required. 
 Repository Research  Samples,  upon written  request  and approval from  DMID  and any approvals 
required by [CONTACT_779], may be shared for secondary research with investigators at the participating site, with researchers at other sites or other institutions, or company- designated research 
laboratories. The samples will not be sold or used directly for production of any commercial product. DMID will authorize shipment from the repository.  Reports from secondary research will not be kept in the participants’ health records or shared with participants, unless required by [CONTACT_2371]. Reports will not be sent to the specimen repository. The participant’s decision for secondary research can be changed at any time by [CONTACT_154434].  If the participant changes  his/her decision,  the samples  will be 
destroyed if the samples have not been used for research or released for a specific research project.  
[IP_ADDRESS] Data  Sharing  for Secondary  Research  
Data from this study may be used for secondary research. Individual participant data collected 
during the trial that are sufficient to reanalyzed primary and secondary endpoints will be made available after deidentification. The Statistical Analysis Plan and Analytic Code will also be made  
available.  This data will be available following publication, with no end date.  The data will be made 
available to researchers who provide a methodologically sound proposal. The data will  be available 
for any purpose outlined in  the approved proposal. Proposals should be directed  to DMID. To gain 
Protocol  22-[ADDRESS_178248]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178249] been distributed for approved research use cannot be retrieved. 
 
10.1.5 Key Roles  and Study  Governance  
This is a multi- site clinical  trial and as such, all study team  members  and roles  are listed  in the 
Manual of Procedures (MOP). 
 
10.1.[ADDRESS_178250] of members with appropriate expertise to contribute to the interpreta tion of the data from this trial. The DSMB  will operate under the rules  
of a DMID -approved charter  that will be written  at the organizational meeting of the DSMB. 
Procedures for DSMB reviews/meetings will be defined in the charter.  
 Reports may include enrollment and demographic information  and solicited  and unsolicited 
AE/SAEs.  The DSMB  will review  SAEs  on a regular  basis  and ad hoc during this trial. The 
DMID Medical Monitor will be responsible for reviewing SAEs in real time.  
 
The DSMB  will conduct the following reviews:  
• Approximately Day  22-29 after  study start.  Given  the planned short enrollment period (3 - 
4 weeks) and second dose of vaccine given on day 29, there is a narrow window for review. As such the review will focus on AEs utilizing real time reports where able.  
• Ad hoc meeting:  
o When  trial- level  halting  criteria  are met 
o At the request  of DMID  to review  a potential safety  concern  identified  in the trial.  
• Interim and  final  data  will be shared  with the DSMB,  but the DSMB  does not need  to 
meet to review the final data.  
 
Additional data may be requested by [CONTACT_4318]. The DSMB may receive data in aggregate and presented  by [CONTACT_2890].  The DSMB  may  also be provided with  expected  and observed rates of 
the expected AEs in an unblinded fashion and may request the treatment assignment be unblinded  
for an individual participant  if required  for safety  assessment.  The DSMB  will review grouped and 
unblinded data in the closed session only. As an outcome of each review/meeting, the D SMB will 
make a recommendation as to the advisability of proceeding with study interventions (as applicable), and to continue, modify, or terminate this trial.  T
he DSMB will operate under the rules of a DMID -approved charter that will be written at the 
organizational meeting of the DSMB. At this time, each data element that the DSMB needs to assess will be clearly defined. Procedures for DSMB reviews/meetings will be defined in the charter.  The 
Protocol  22-[ADDRESS_178251]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 92 of 147  DSMB  will review  applicable data to include, but not limited  to, study progress and participant, 
clinical, safety and safety related data. Reports may include enrollment and demographic  
information, medical  history, concomitant medications,  physical assessments, clinical laboratory 
values, dosing compliance, and solicited and unsolicited AE/SAEs. 
 DMID or the DSMB chair may convene the DSMB on an ad hoc basis according to protocol criteria or if there are immediate concerns regarding observations during the course of this trial. The DMID Medical Mo nitor is empowered to stop enrollment and study product administration if  AEs that 
meet  the halting  criteria  are reported.  The DMID  Medical  Monitor will be responsible for reviewing 
SAEs in real time. The DSMB will review SAEs on a regular basis and ad hoc during this trial.  
 
10.1.[ADDRESS_178252] of the trial is in compliance with the currently approved 
protocol/amendment(s), International Council for Harmonisation  (ICH),  Good Clinical Practice, 
and with applicable regulatory requirement(s) and sponsor requirements.  Monitoring for this study will be overseen by [CONTACT_18127]/DMID and conducted by [CONTACT_18127]/DMID 
contractors. Details of clinical site monitoring are documented in a Clinical Monitoring Plan 
(CMP). The CMP describes in detail who will conduct the monitoring, at what f requency 
monitoring will be done, at what level of detail monitoring will be performed, and the distribution of monitoring reports. Monitoring visits will include, but are not limited to, review of regulatory files, investigational product administration a nd accountability records, eCRFs, informed consent 
forms, medical and laboratory reports, site study storage records, training records, and protocol and GCP  compliance.  Site monitors will have access  to each participating site, study personnel, 
and all stu dy documentation according to the NIAID or DMID -approved site  monitoring plan. 
Study monitors will meet  with site principal investigators (or designee) to discuss any problems 
and outstanding issues and will document site visit findings and discussions.  
 
10.1.8 Quality  Assurance and Quality  Control  
Quality control (QC) and quality assurance (QA) activities are essential to the safety of participants, and the reliability of study data. Each site participating in the study is responsible for  
integrating  quality  control checks  throughout the study and implementing  a QA Checklist  or 
Clinical Quality Management Plan (CQMP). The site will conduct the following:  
8. Routine internal  QC and QA activities  for the purposes of measuring, documenting and 
reporting study conduct, protocol adherence, human participants’ protections, and reliability of the protocol- driven data collected.  
9. Processes  for addressing data quality  issues (i.e., collecting,  recording), and reporting 
findings in a timely manner.  
10. Identify  systemic  issues (e.g., protocol or human participant  protections non-compliance), 
and implementation and evaluation of Corrective and Preventative Action Plan (CAPA) procedures, if applicable. 
Protocol  22-[ADDRESS_178253]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178254]  Keepi[INVESTIGATOR_007]  
[IP_ADDRESS] Data  Collect ion and Management  Responsibilities  
Data collection  is the responsibility  of the clinical  trial staff at the site under the supervision of the 
site investigator. The investigator is responsible for ensuring the accuracy, completeness, legibility, 
and timeliness of the data reported. All source documents should be completed in a neat, legible manner to ensure accurate interpretation of data.  
 
[IP_ADDRESS] Data  Coordinating Center / Biostatistician  Responsibilities  
The data coordinating center for this study will be responsible for data management, quality review, analysis, and reporting of the study data. Adverse events and medical history will be coded  
according  to the MedDRA  dictionary. Concomitant medications  will be coded  according to the 
WHO  Drug  dictionary. At the end of the study, a copy of all datasets  including annotated case 
report forms and data dictionary will be provided to DMID.  A separate Study Data Standardization Plan (SDSP) will be developed which describes the 
technical  recommendations  for the submission of human study data and related  information  in a 
standardized electronic format throughout product development. 
 
[IP_ADDRESS] Data  Capture  Methods  
Clinical research  data,  including, but not limited  to, AE/SAEs,  concomitant  medications,  medical 
history, physical assessments will be abstracted from the source documentation and/or collected on 
source document worksheet by [CONTACT_154388]  a [ADDRESS_178255] protection and internal quality  checks,  such as automatic  range checks, to 
identify data that appear inconsistent, incomplete, or inaccurate.  The IND Sponsor is responsible for review  of data collection  tools and processes,  and review  of 
data and reports.  Study data will be collected  on paper  CRFs  and then entered  into the eCRF  or data will be entered 
directly into the eCRF.  
 
[IP_ADDRESS] Study  Record  Retention  
Study related  records,  including the regulatory file, study product accountability  records,  consent 
forms, participant source documents and electronic records should be maintained for a period of [ADDRESS_178256] for the 
indication for which it is being investigated; or, if no application is to be filed or if the application is not approved for such indication, until [ADDRESS_178257]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 94 of 147  the specimens remain in identifiable format, and a minimum of three years  after use of the 
identifiable  specimens  in nonexempt human participant research.  
 
[IP_ADDRESS] Source Records  
Source data are all information, original records of clinical findings, observations, or other activities 
documented in a clinical trial necessary for the reconstruction and evaluation of the trial. Each participating site will maintain appropriate medical and research records for this trial, in compliance with ICH GCP, regulatory, and institutional requirements. Data recorded in the electronic  case 
report  form  (eCRF)  derived  from  source documents should be consistent with the data recorded on 
the source documents. Data entered directly into the eCRFs will be  considered the source document. 
All source documents should be completed in a neat, legible manner to ensure accurate interpretation of data.  Interview of participants  is sufficient  for obtaining medical  history. Solicitation  of medical records 
from the participant’s primary care provider is not required. 
 
10.1.10 Protocol Deviations 
A protocol deviation is any noncompliance with the clinical  trial protocol, any process  that is noted 
in the protocol and refers to details in the MOP, or GCP requirements.  
 The noncompliance may be either  on the part of the participant,  the investigator, or the study site 
staff. Following a deviation(s), corrective actions should be developed by [CONTACT_3483]. All individual protocol deviations will be addressed in participant study records.  
 It is the responsibility  of the site principal  investigator [INVESTIGATOR_154365], or within  five working days of the scheduled  protocol- required  activity.  All deviations must be 
promptly reported to DMID per the protocol deviation reporting procedures. Protocol deviations must be sent to the local IRB/IEC per their guidelines. The site principal investigator [INVESTIGATOR_154366]. 
 
10.1.11 Publication  and Data  Sharing  Policy  
[IP_ADDRESS] Human  Data  Sharing  Plan  
All NIH protocols are required  to have a Data Sharing  Plan describe provisions for protecting the 
participants’ privacy and the confidentiality of the data. This study will be conducted in accordance with the following publication and data sharing policies and regulations: 
 
National Institutes of Health (NIH) Public Access Policy, which ensures that the public has access  
to 
the published results  of NIH funded research.  It requires  scientists  to submit final peer-reviewed  
journal manuscripts that arise from  NIH funds to the digital archive PubMed Central  upon 
acceptance for publication.  
 A
s of January 2018, all clinical trials supported by [CONTACT_71511].gov,  
Protocol  22-[ADDRESS_178258]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178259] participant.  Results  of all clinical trials 
supported by [CONTACT_18121], generally, need to be submitted no later than 12 months following the primary  
completion  date.  As part of the result  posting, a copy of this protocol and a copy of the Statistical 
Analysis Plan will be posted on ClinicalTrials.gov. 
 
[IP_ADDRESS] Genomic  Data  Sharing  Plan  
Not Applicable.  
 
[IP_ADDRESS] Publication  
This study will comply with the NIH Public Access Policy, which ensures that the public has access  
to the published results  of NIH funded research.  As such, the final peer-reviewed  journal 
manuscripts will be accessible to the public on PubMed Central no later than [ADDRESS_178260] (PREP Act). The PREP Act applies under the terms of the PREP Act declaration in place for smallpox/orthopoxvirus countermeasures for activities  conducted 
pursuant to federal agreements or federal pr ograms (ref: 
www.federalregister.gov/documents/2015/12/09/2015- [ZIP_CODE]/smallpox- medical - countermeasures -
amendment). JYNNEOS is used under an IND for monkeypox pursuant to a federal agreement/program and is therefore covered under the PREP Act. The PREP Act covers persons 
Protocol  22-[ADDRESS_178261]  2023     
  
DMID/NIAID/NIH  CONFIDENTIAL  Page 96 of 147  (such as manufacturers, distributers, program planners, and other qualified persons who prescribe, 
administer or dispense study product) are immune from liability from the administration,  or use of 
a covered  countermeasure,  such as JYNNEOS.  The PREP  Act provides immunity for covered  
persons from  liability,  unless  the injury was  caused  by [CONTACT_154389].  
 The PREP Act also established the Countermeasures Injury Compensation Program (CICP) to provide compensation for serious injuries or death that occur as the direct result of the administration or use of certain countermeasures. Any requests for compensation must be filed within one year of the administration or use of the covered countermeasure. Requests for Benefits must be  made to the Health Resources and Services Administration’s (HRSA) Countermeasures  
Injury Compensation Program  (http://www.hrsa.gov/cicp/) by [CONTACT_154390]  a Request for Benefits Form 
and all required medical records and supporting documentation. Additional information on filing a Request for Benefits is available on the CICP’s website at http://www.hrsa.gov/cicp/. Compensation may then be available for reasonable and necessary medical benefits, lost wages and/or death benefits to eligible individuals for certain injuries in accordance with regulations published by [CONTACT_154391] (found at 42 CFR part 110).  If an individual suffers a serious physical injury or death from the administration or use of a covered countermeasure in this study, the individual, the  individual’s legal or personal representative, the 
administrator/executor of a deceased individual’s estate, or certain survivors may request benefits from the CICP. A serious physical injury means an injury that warranted hospi[INVESTIGATOR_059] (whether or not the person was actually hospi[INVESTIGATOR_057]) or that led to a significant loss of function or disability. The CICP is the payer of last resort. This means that it only covers expenses or provides benefits that other third -party payers (such as health insurance, t he Department  of Veterans  Affairs,  or 
Workers’  Compensation programs) do not have an obligation to pay. 
 If the Secretary of HHS does not make a final determination on the individual’s request within [ADDRESS_178262] is reduced by [CONTACT_92229]’s compensation available to the injured individual. Awards for non- economic damages, such as pain, suffering, 
physical impairment, mental anguish, and loss of consortium are also limited. If the  individual 
accepts  compensation, or if there is no willful misconduct, then the individual does not have a tort 
claim that can be filed in a US Federal or a State court.  
Protocol [ADDRESS_178263]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178264]  Dis 2014;58(2):260-7. DOI: 
10.1093/cid/cit703.  
2. Grant  R, Nguyen LL, Breban  R. Modelling human- to-human transmission  of monkeypox. 
Bull World Health Organ 2020;98(9):638-640. DOI: 10.2471/BLT.19.242347.  
3. Gong Q, Wang  C, Chuai X, Chiu S. Monkeypox virus: a re-emer gent threat  to humans. 
Virol Sin 2022. DOI: 10.1016/j.virs.2022.07.006. 
4. Rimoin  AW,  Mulembakani PM, Johnston SC, et al. Major  increase in human monkeypox 
incidence 30 years after smallpox vaccination campaigns cease in the Democratic 
Republic of Congo. Proceedings of the National Academy of Sciences of the [LOCATION_002] of America 2010;107(37):[ZIP_CODE]-7. DOI: 10.1073/pnas.[PHONE_3454]. 
5. Emergence of monkeypox in West Africa and Central Africa, 1970- 2017. Wkly 
Epi[INVESTIGATOR_75313] 2018;93(11):125-32. (https:// www.ncbi.nlm.nih.gov/pubmed/29546750).  
6. Centers  for Disease  C, Prevention. Multistate  outbreak of monkeypox-- Illinois,  Indiana, 
and Wisconsin, 2003. MMWR Morb Mortal Wkly Rep 2003;52(23):537-40. (https://www.ncbi.nlm.nih.gov/pubmed/12803191). 
7. Erez N, Achdout H, Milrot E, et al. Diagnosis of Imported Monkeypox, Israel,  2018. 
Emerging infectious diseases 2019;25(5):980-983. DOI: 10.3201/eid2505.190076. 
8. Yong SEF,  Ng OT, Ho ZJM,  et al. Imported Monkeypox, Singapore. Emerging  infectious 
diseases 2020;26(8):1826-1830. DOI: 10.3201/eid2608.191387. 
9. Rao AK, Schulte J, Chen TH, et al. Monkeypox in a Traveler  Returning from  Nigeria  - 
Dallas,  [LOCATION_007],  July 2021. MMWR  Morb  Mortal  Wkly  Rep 2022;71(14):509-516. DOI: 
10.[ZIP_CODE]/mmwr.mm7114a1.  
10. Vaughan A, Aarons E, Astbury J, et al. Human -to-Human  Transmission  of Monkeypox 
Virus, [LOCATION_008], October 2018. Emerging infectious diseases 2020;26(4):782- 785. DOI: 10.3201/eid2604.191164. 
11. Hobson G, Adamson J, Adler H, et al. Family cluster of three cases of monkeypox imported  from  Nigeria  to the United  Kingdom, May 2021. Euro  Surveill 2021;26(32). 
DOI: 10.2807/1560-7917.ES.2021.26.32.2100745. 
12. Mauldin MR, McCollum AM, Nakazawa YJ, et al. Exportation of Monkeypox Virus From  the African  Continent. The Journal of infectious diseases  2022;225(8):1367-1376. 
DOI: 10.1093/infdis/jiaa559. 
13. Y
inka-Ogunleye A, Aruna  O, Dalhat  M, et al. Outbreak  of human monkeypox in Nigeria 
in 2017- 18: a clinical and epi[INVESTIGATOR_154341]. The Lancet Infectious diseases 
2019;19(8):872-879. DOI: 10.1016/S1473-3099(19)[ZIP_CODE]-4. 
14. Durski KN, McCollum AM, Nakazawa Y, et al. Emergence of Monkeypox - West and 
Central  Africa,  1970-2017. MMWR  Morb  Mortal  Wkly  Rep 2018;67(10):306-310. DOI: 
10.[ZIP_CODE]/mmwr.mm6710a5.  
15. Vollmar J, Arndtz N, Eckl KM, et al. Safety and immunogenicity of IMVAMUNE, a 
promising candidate as a third  generation  smallpox  vaccine.  Vaccine 2006;24(12):2065- 
70. DOI: 10.1016/j.vaccine.2005.11.022. 
16. Frey SE, Wald  A, Edupuganti S, et al. Comparison of lyophilized versus liquid modified 
vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia -naive subjects. Vaccine 2015;33(39):5225- 34. DOI: 
10.1016/j.vaccine.2015.06.075.  
Protocol [ADDRESS_178265]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 98 of 147 
 17. Wilck MB, Seaman MS, Baden LR, et al. Safety  and immunogenicity of modified 
vaccinia Ankara (ACAM3000): effect  of dose and route of administration.  The Journal of 
infectious diseases 2010;201(9):1361-70. DOI: 10.1086/651561. 
18. Food and Drug  Administration.  Summary  Basis  for Regulatory Action 
https://www.fda.gov/media/131802/download. 
(https://www.fda.gov/media/131802/download).  
19. Overton ET, Lawrence  SJ, Wagner  E, et al. Immunogenicity and safety  of three 
consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial. PLoS One 2018;13(4):e0195897. DOI: 10.1371/journal.pone.0195897. 
20. Suter M, Meisinger -Henschel C, Tzatzaris M, et al. Modified vaccinia Ankara strains with 
identical coding sequences actually represent complex mi xtures of viruses that determine  
the biological properties of each strain.  Vaccine  2009;27(52):7442-50. DOI: 
10.1016/j.vaccine.2009.05.095.  
21. Stittelaar  KJ, Kuiken T, de Swart  RL, et al. Safety  of modified  vaccinia virus Ankara 
(MVA) in immune -suppressed macaques. Vaccine 2001;19(27):3700- 9. DOI: 
10.1016/s0264- 410x(01)[ZIP_CODE]- 5. 
22. Overton ET, Stapleton J, Frank I, et al. Safety and Immunogenicity of  Modified Vaccinia 
Ankara- Bavarian Nordic Smallpox Vaccine in Vaccinia- Naive and Experienced Human 
Immunodeficiency Virus -Infected  Individuals: An Open -Label,  Controlled Clinical Phase 
II Trial. Open Forum Infect Dis 2015;2(2). DOI: 10.1093/ofid/ofv040. 
23. Greenberg RN, Overton ET, Haas DW, et al. Safety, immunogenicity, and surrogate markers  of clinical  efficacy  for modified  vaccinia Ankara as a smallpox  vaccine in  HIV- 
infected subjects. The Journal of infectious diseases 2013;207(5):749- 58. DOI: 
10.1093/infdis/jis753.  
24. Overton ET, Lawrence SJ, Stapleton JT, et al. A randomized phase II trial to compare safety  and immunogenicity of the MVA- BN smallpox  vaccine  at various doses  in adults 
with a history of AIDS. Vaccine 2020;38(11):2600- 2607. DOI: 
10.1016/j.vaccine.2020.01.058.  
25. von Sonnenburg F, Perona P, Darsow  U, et al. Safety  and immunogenicity of modified 
vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis. Vaccine 2014;32(43):5696-702. DOI: 10.1016/j.vaccine.2014.08.022. 
26. Greenberg RN, Hurley MY, Dinh DV, et al. A Multicenter, Open -Label, Controlled Phase 
II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE)  in 18-40 Year  Old Subjects with Diagnosed Atopic Dermatitis.  PLoS One 
2015;10(10):e0138348. DOI: 10.1371/journal.pone.0138348. 
27. Cassimatis  DC, Atwood  JE, Engler RM, Linz PE, Grabenstein  JD, Vernalis  MN. 
Smallpox vaccination and myopericarditis: a clinical review. J Am Coll Cardiol 2004;43(9):1503-10. DOI: 10.1016/j.jacc.2003.11.053. 
28. von Krempelhuber A, Vollmar  J, Pokorny R, et al. A randomized, double-blind, dose- 
finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candid ate IMVAMUNE. Vaccine 2010;28(5):1209- 16. DOI: 
10.1016/j.vaccine.2009.11.030.  
29. P
ittman  PR, Hahn  M, Lee HS, et al. Phase [ADDRESS_178266] Smallpox. The New England journal of medicine 2019;381(20):1897-1908. DOI: 10.1056/NEJMoa1817307. 
Protocol [ADDRESS_178267]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 99 of 147 
 APPENDIX  B – STAGE 2: ADOLESCENT AND ADULT NONINFERIORITY 
STUDY  
 
 
Protocol [ADDRESS_178268]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 100 of 147 
 TABLE OF CONTENTS 
 
APPENDIX B – Stage 2: Adolescent and Adult Noninferiority Study  ................................................ 99 
1. Introduction  ................................................................................................................................ 103 
1.1 Study Rationale ............................................................................................................103  
1.2 Background ..................................................................................................................103  
1.3 Risk/Benefit Assessment  .............................................................................................[ADDRESS_178269](s) and Administration...........................................................................[ADDRESS_178270] Description ...................................................................................116  
5.1.2  Dosing and Administration ..................................................................................116  
5.1.3  Dose Modifications ..............................................................................................117  
5.1.4  Criteria for Redosing ............................................................................................117  
5.2 Preparation/Handling/Storage/Accountability .............................................................[ADDRESS_178271] Storage and Stability...............................................................................117  
5.2.4  Preparation  ...........................................................................................................117  
5.3 Measures to Minimize Bias: Randomization and Blinding  .........................................[ADDRESS_178272]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 101 of 147 
 5.3.2  Randomization .....................................................................................................118  
5.3.3  Blinding and Masking Procedures .......................................................................118  
5.4 Study Intervention Compliance ...................................................................................118  
5.5 Concomitant Therapy...................................................................................................118  
6. STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  .......................................................................................... [ADDRESS_178273] 
Values or Abnormal Clinical Findings During Screening ...................................................122  
7.2 Sick Visit  ......................................................................................................................123  
7.3 Additional Study Procedures in Stage 2 ......................................................................123  
7.3.1  Phone Visits .........................................................................................................123  
7.3.2  Photography .........................................................................................................123  
7.4 Immunogenicity Assessments ......................................................................................123  
7.4.1  Immunogenicity/Efficacy Evaluations .................................................................[ADDRESS_178274]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178275]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 103 of 147 
 1. INTRODUCTION  
 
1.1 Study Rationale  
On July 23, 2022, the WHO Director -General  declared that the multi- country outbreak of mpox 
constitutes a Public Health Emergency of International Concern (PHEIC) . Since the first case of 
mpox was detected in the U nited Kingdom in a returning traveler from Nigeria on May 6, 2022, 
the outbreak has rapi[INVESTIGATOR_154367] [ADDRESS_178276] of 2022, the number of confirmed mpox cases in the U.S. surpassed that of any other 
country2,3. To mitigate the consequences of this outbreak in the U.S., JYNNEOS vaccine is being 
offered to individuals considered to be at high risk for acquiring the disease . In Stage 1 of this 
platform study, we evaluated dose sparing strategies in adults because JYNNEOS, the only licensed vaccine for mpox, was in short supply. In Stage 2  of this study, we  will evaluate vaccine 
safety and immunogenicity among adolescents ages 12 to 17 years to extend eligibility to adolescent population, a population that may be at risk if the outbreak persists in 2023.  
1.2 Background  
Mpox is a reemerging infectious disease caused by [CONTACT_154379] (MPXV), a large double -
stranded DNA virus belonging to the genus, Orthopoxvirus .[ADDRESS_178277] been 84,648 confirmed mpox cases worldwide 
inclu ding 29,980 confirmed cases and 2 1 deaths in the [LOCATION_002].2  
 Vaccination is being used as a mitigation strategy in the current mpox outbreak for those exposed to and those deemed to be at higher risk of being exposed to mpox. There is one FDA -approved 
vaccine for mpox: JYNNEOS Modified Vaccinia Ankara -Bavarian Nordic (MVA -BN). A second 
vaccine, ACAM2000, is likely effective but is not FDA -approved for mpox and associated with 
moderate risk of myocarditis and pericarditis (5.7 cases per 1,000 vaccinated) as well as encephalomyelitis, progressive vaccinia, generalized vaccinia, and ocular complications. 
Protocol [ADDRESS_178278]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 104 of 147 
 ACAM2000 should not be given to people with a weakened immune system, eczema, cardiac 
disease, infants <[ADDRESS_178279] 9, 2022, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the emergency use of the licensed SC dose for individuals less than 18 years of age determined to be at high risk for mpox for the emergency use 
of a lower (2 x 10
7 TCID 50) ID dose of JYNNEOS for individuals 18 years of age and older 
determined to be at high risk for MPXV infection. In addition, because of limited vaccine supply, the EUA allowed for the use of a lower (2 x 10
7 TCID 50) ID dose of JYNNEOS for individuals [ADDRESS_178280] sex with men, with a median age of 34 years.  Among global cases with age data available, 1.2% are individuals ages 0-17 years ;
23 in the [LOCATION_002], from  May 17 through September 24, 2022, MPXV infections in 
persons under 18 years of age accounted for 0.3% of reported cases.24  Among 55 adolescents ages 
13-17 years, 89% were male, and the most common route of exposure was through male -to-male 
sexual contact (66%). Prior to the global [ADDRESS_178281] wit h an infected individual.  
 
1.3 Risk/Benefit Assessment  
1.3.1 Known Potential Risks  
The potential risks to the participants in the study are those related to venipuncture and local reactogenicity as well as possible systemic adverse reactions to the vaccine and vaccination procedure.  Venipuncture  
Venipuncture may cause transient mild discomfort and/or fainting. Bruising at the site of the venipuncture may occur but can be prevented or lessened by [CONTACT_154435]. Infection at the site is possible but highly unlikely with the use of aseptic 
technique.  Adverse Reactions  
MVA- BN administered SC was approved by [CONTACT_154436] 24, 2019.
[ADDRESS_178282] vaccination. There were mostly local and systemic reactogenicity and rar e cases of allergy/hypersensitivity  observed. Within [ADDRESS_178283] common solicited local (injection site) reactions among 2,943 smallpox vaccine -naïve healthy adult participants included pain (84.9 %), redness 
Protocol [ADDRESS_178284]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 105 of 147 
 (60.8%), swelling (51.6%), induration (45.4%), and itching (43.1%). The most common solicited 
systemic adverse reactions were muscle pain (42.8%), headache (34.8%), fatigue (30.4%), nausea (17.3%), and chills (10.4%). The majority of these soli cited AEs were mild and moderate severity . 
However , there were severe (Grade3)  solicited AEs the most common being pain in 7.4% of 
participants. In a large clinical trial involving 3,[ADDRESS_178285] dose (79.3% versus 
69.9%).
28 
 An analysis of serious adverse events (SAEs) among 7,[ADDRESS_178286] 1 dose of JYNNEOS identified 
only four SAEs (0.05%) in which a causal relationship could not be ruled out. All were non- fatal 
SAEs and included Crohn’s disease, sarcoidosis, extraocular muscle paresis, and throat tightness (angioedema). The trial that had the related angioedema had three other post -vaccination 
hypersensitivity reactions which were non-serious and judged to be related to the vaccine.   As with all injectable vaccines, there is a risk of an allergic reaction or an anaphylactic event. To mitigate the risk, individuals with known allergy or history of anaphylaxis or other serious adverse reaction to a vaccine or vaccine products will not be eligible to participate in the study. In addition, sites must observe participants for [ADDRESS_178287] Feeding Infant  
It is not known whether JYNNEOS is excreted in human milk. Data are not available to assess the effects of JYNNEOS in the breastfed infant or on milk production/excretion. For this reason, woman wh o are breastfeeding will not be eligible to participate in this study.  
  
Protocol [ADDRESS_178288]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178289] 9, 2022, for the use of a 2- dose 1 x 10
8 regimen of JYNNEOS 
administered subcutaneously for prevention of mpox disease in individuals younger than 18 years of age who were at high risk for MPXV infection.
29 The EUA was based on “safety and 
effectiveness data from clinical trials in adults and efficacy data from animal challenge studies and historical data with use of live vaccinia virus (smallpox vaccine) in pediatric populations”.  Per  the 
EUA, the vaccination provider was responsible for mandatory reporting to the Vaccine Adverse Event Reporting System (VAERS) of all serious adverse events (ir respective of attribution to 
vaccination); cases of cardiac events, including myocarditis and pericarditis; and cases of thromboembolic events and neurovascular events following vaccination with JYNNEOS. The FDA initially required cardiac screening and prospective monitoring for cardiac events in all early clinical trials of MVA -BN vaccine. A review of six Phase 1 trials conducted between 2004 and 
2012 found no myo/pericarditis cases that met the CDC case definition and were judged to be related to vaccine in [ADDRESS_178290] one dose of MVA -BN.
30  Moreover, the MVA 
vector has been studied in multiple adolescent and pediatric populations in other vaccine trials with no serious safety concerns identified.
31-33 
 Risk to Individuals with Chronic Diseases  JYNNEOS does not replicate in human cell lines and therefore the vaccine can be safel y 
administered to immunocompromised individuals. Safety has been demonstrated in clinical trials and studies involving severely immunocompromised animals
34,35 and humans with HIV 
infection.36-38 The safety of JYNNEOS in HIV- infected individuals was evaluated in an open label 
trial that included 351 HIV -infected smallpox vaccine -naïve participants, 131 HIV -infected 
participants who previously received smallpox vaccine, 88 non- HIV-infected smallpox vaccine -
naïve participants , and 9 non- HIV-infected participants who had previously received a smallpox 
vaccine.36 HIV -infected participants had CD4 counts ≥ 200 and ≤ 750 cells/μL at study entry.  
Among smallpox vaccine -naïve participants, solicited local and systemic adverse reactions were 
report ed at similar or lower frequencies in HIV -infected participants than in non- HIV-infected 
participants. Frequencies of other solicited local and systemic adverse reactions were similar to those reported in other trials.
37,[ADDRESS_178291] year or their viral load is not well -
controlled with antiretroviral therapy (ART) (see Section 5.1).  
 Individuals with atopic dermatitis (AD) are not able to receive replicating smallpox vaccines including ACAM2000. However, two clinical trials have shown that they can safely be given JYNNEOS.
39,40 The larger of the two studies was a multicenter, open -label clinical trial that 
evaluated the safety of JYNNEOS in 350 smallpox vaccine -naïve participants either with active 
or a history of AD and in 282 participants without A D.40 The proportion of participants reporting 
solicited local and systemic adverse reactions was similar between the arms, except for redness (61.2% with AD vs. 49.3% without AD), swelling (52.2% with AD vs. 40.8% without AD), chills (15.9% with AD vs. 7.8% without AD) and headache (47.2% with AD vs. 34.8% without AD). 
Protocol [ADDRESS_178292]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178293] (AESI)  
During the 2002- 2004 smallpox vaccination campaign initiated by [CONTACT_154437] 
(DoD) and Department of Health and Human Services (DHHS) to protect military personnel and civilian first- responders, there were high rates of pericarditis and myocarditis reported among 
those vaccinated with Dryvax. Similarly, high rates were detected after receipt of ACAM2000.
[ADDRESS_178294] vaccination. In 22 
studies, cardiac AESIs were reported to occur in 1.3% (95/7,093) of JYNNEOS recipi[INVESTIGATOR_154345] 0.2% (3/1,206) of placebo recipi[INVESTIGATOR_154346]ïve. The higher proportion of JYNNEOS recipi[INVESTIGATOR_154368] -
vaccination elevation of troponin I, the clinical significance of which is unknown.   Among the cardiac AESIs reported, there were six, non- serious cases (0.08%) deemed causally 
related to JYNNEOS vaccination including tachycardia, electrocardiogram (ECG) T wave inversion, unspecified ECG abnormality, ECG ST segment elevation, ECG T wave abnormality, and palpi[INVESTIGATOR_814]. These data are consistent with findings from a randomized, double -blind, 
placebo -controlled Phase 3 trial that evaluated the immunogenicity and safety of three consecutive 
production lots of MVA -BN. In that trial, eight out of 3,003 (0.3%) participants who received at 
least one dose of MVA -BN had a cardiac AESI. Of these events, two of the eight were considered 
possibly related to MVA -BN vaccination; one participant had a right bundle branch block on ECG, 
and the other participa nt had clinical symptoms consistent with acute pericarditis but had a 
negative cardiac work -up. This same participant had positive serology to Coxsackie B virus 
suggesting that an acute viral infection may have been the cause of their symptoms. Given these  
data, we are not monitoring for cardiac AESI during Stage 1 of this study which involves adults ages 18 to 50 years, inclusive. However, in Stage 2, which involves adolescent participants, monitoring for protocol specified AESI (see Section  [IP_ADDRESS]) will be part of the study as less is 
known about the product’s safety profile in this population. In addition, an exclusion criterion for adolescents an d adults with relevant cardiac history that could place them at risk was added in 
Stage 2.  In Stage 1 and Stage 2, the occurrence of AE, MAAE, and SAE will be monitored allowing detection of symptomatic cardiac events as well as cases of thromboembolic events and neurovascular events following vaccination with JYNNEOS.  
 
1.3.2 Known Potential Benefits
 
JYNNEOS was licensed in 2019 based on pre -clinical studies and clinical trial data showing that 
the vaccinia virus -specific (VV -WR) geometric mean titer (GMT) elicited by [CONTACT_154438] -inferior to that elicited by [CONTACT_154399]2000; ACAM2000 was licensed based on 
non-inferiority to Dryvax. Participation in this study may result in protection against mpox during 
this current outbreak.  However, participation may also provide no direct benefit to the participant 
and/or if they develop an immune response to vaccinia virus the immune response may not be fully 
protective against mpox. Data from Stage [ADDRESS_178295]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178296] of benefit for individual subjects (45 CFR 46.405). Risk to participants will be minimized by [CONTACT_154439].  
2. OBJECTIVES  AND  ENDPOINTS 
 
Table 1 Stage 2 Objectives and Endpoints  
OBJECTIVES  ENDPOINTS  
(OUTCOME MEASURES)  
Primary   
To determine if peak (Day 43) humoral immune 
responses in adolescents ages 12 to 17 years are 
non-inferior to adults after receipt of a 2 -dose SC 
regimen of 1 x 108 TCID 50 MVA- BN. 
 Vaccinia virus specific PRNT GMT  at Day 43  
 
To describe safety of a 2 -dose 1 x 108 TCID 50 
MVA-BN regimen administered SC in 
adolescents ages 12 to 17 years. Frequency and severity of solicited systemic and 
local AE for 7 days after each vaccination.  
Frequency severity, and relatedness of unsolicited 
AEs for 28 days after each vaccination.  
Frequency and description of protocol specified 
AESIs f rom Day 1 through 210. 
Frequency and description of related MAAEs from Day 1 through 210.  
Frequency and relatedness of SAEs for durat ion 
of the study.  
Frequency and description of withdrawals and 
discontinuations of vaccination.  
 
Secondary   
To evaluate humoral immune responses at 
baseline, prior to the second vaccination, and 
following receipt of the 2-dose SC regimen of 1 x 
108 TCID 50 MVA-BN in adolescents compared to 
adults on each study day.  
 Vaccinia virus specific PRNT GMT at  Study Day  
1, 29, 43, 210, and 394  
 
To evaluate the kinetics of the humoral immune 
responses to the 2 -dose SC regimen of 1 x 108 
TCID 50 MVA-BN in adole scents and adults 
through Day 365 after the second dose is administered.  
 Vaccinia virus specific PRNT half -life (t ½)  
 
Protocol [ADDRESS_178297]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178298] SC regimen in adults ages 18 to 50, inclusive .  Approximately 135 healthy, 
vaccinia- naïve adults will be enrolled in a comparator arm (Arm 4)  and will be given the standard, 
licensed regimen of 1x108 TCID 50 MVA- BN administered SC on Day 1 and 29. These adults (Arm 
4) will be combined with the [ADDRESS_178299] SC 
regimen in  Stage 1 (Arm 3) . Together, this will be the comparator group for non- inferiority testing  
for the primary endpoint. Approximately 315 healthy, vaccinia- naïve adolescents will be enrolled 
and given 1x108 TCID 50 MVA- BN administered SC on Days 1 and 29 (Arm 5). The study will 
have a set target enrollment of at least 25% adolescents ages 12 to 14 years, inclusive, to ensure 
that adequate numbers of younger adolescents are enrolled. Participants will be followed as outlined in the Schedule of Activities ( Table 2):  
Protocol [ADDRESS_178300]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 110 of 147 
 Table 2 Stage 2 Schedule of Activities (S OA)  
Procedures   Optional 
Screening  
Visit   
Day -7 to 
-1  Visit 1 
Enroll 
Baseline  
Day 1  
  Visit 
2 
Day 
8 +/- 
1 
day   
Visit 
3 
Day 
29 +/ - 
3 
days   Visit 4  
Day 
36 +/ - 
1 day Visit 5   
Day 43 
+/- 3 
days    Visit 6  
Day 57 
+/- 3 
days  6  Visit 7 
Day 90 
+/- 5 
days  6 Visit 8  
Day 210 
+/- 7 
days   Visit 9   
Day 394 
+/- [ADDRESS_178301] 
second 
vaccination      7 +/-1 
days 14 +/ -3 
days 28 +/ -3 
days 61 +/ -5 
days  181 +/ -
7 days  365 +/ -
14 days   
Informed 
consent and 
assent where 
appropriate   X  X1      
    
            
Demographics   X  X1      
                
Medical history   X  X1  X X  X X  X  X  X  X  X  
Vaccine 
administration     X    X                
Targeted 
physical exam   X  X1  X2  X2  X2 X2  X2  X6 X2  X2  X2  
Vital signs   X  X1  X2 X2  X2 X2  X2  X6 X2  X2  X2  
Concomitant 
medicine 
review  3 X  
  X  
  X X  
  X X 
 X  
  X 
  X  
   X  
 X  
  
SAE4      All SAE , Day 1 through 394   X4  
Protocol 
specified AESI 
and related 
MAAE  4  Protocol specified AESI and related MAAEs, Day 1 through 210  X4 
Unsolicited 
AEs4     Unsolicited AEs, Day 1 through Day 57  
        X4  
Solicited (Local 
and Systemic) 
AEs  Day [ADDRESS_178302] 5   X  X1     X                
Maximum 
blood volume 
per visit (ml)  8   15 
    
 15   
15     15  15  
Maximum 
blood volume 
total (ml) 8  15   
30  
45   60 75  
Blood 
collection visits 
8    X    
X    
X      X  X    
  
1 If there is no screening visit, these activities should be conducted at the Day 1 visit prior to enrollment .  
2 A targeted (symptom -driven) physical exam will be done at screening (i.e., screening visit or Day 1), on Days 8, 
29, 36, and 43 (at least assessment of vaccination site and presence of skin reactogenicity will be done), and as 
needed in all other visits if interim change in medical status reported by [CONTACT_3445]. Vital signs (temperature, blood 
Protocol [ADDRESS_178303]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 111 of 147 
 pressure and heart rate) will be done on Day 1 and 29 prior to vaccination. However, if the re was a separate 
screening visit and vital signs (temperature, BP, and HR) were done at that visit, only a temperature is needed on 
Day 1.  Vital signs can be done at other visits on an as needed basis.   
3 For Stage 2, after Day 57, only concomitant medic ations that are associated with a protocol specified AESI  or related 
MAAE through Day 210, and all  SAE through Day 394  and clinically relevant to report, will be recorded in the CRF. 
In addition, d uring sick visits concomitant medications will be collected.  
4 If SAE/MAAE /AESI  or unsolicited AE are reported during a sick visit or unscheduled visit and within the reporting 
window, it will be reported. See more information about collection of AEs in the safety section of the protocol.  See section [IP_ADDRESS]  for additional details on AESIs.  
[ADDRESS_178304] will be done at the screening visit (if conducted) and on Day [ADDRESS_178305] ed 
virtually  via video teleconference (e.g., Zoom, FaceTime) if deemed necessary. If an in -person visit is deemed 
necessary, site may do vital signs and a physical examination on an as needed basis.  
[ADDRESS_178306] blood drawn on Days 1, 29, 43, 210 and 394. For Stage 2, a minimally acceptable 
blood volume on Day 1 and on Day 43 is set at 5- mL of whole blood (SST for serum), regardless of age. Should the 
site not be able to collect that blood before the first vaccination, the participant will not be permitted to continue. 
Maximum blood draw at the pre -specified visits in Stage 2 is 15 mL  
 
3.2 Scientific Rationale for Study Design  
The rationale for each of the study arms in Stage 2 are as f ollows: 
 
1 x 108 TCID 50 MVA -BN SC on Days 1, 29 (Study Arms 4, and 5)  – This regimen is the licensed 
dose and route for adults ages 18 and above. Arms 4 (adult) and 5 (adolescent) will be used to evaluate noninferiority of this regimen among adolescents compared to adults.
 
3.[ADDRESS_178307] 25% adolescent participants ages [ADDRESS_178308]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178309] DMID Medical Officers to discuss. No exemptions are granted on Inclusion/Exclusion Criteria. 
4.[ADDRESS_178310] meet the following inclusion criteria:   
1 Adult ages 18 to 50 years inclusive at the time of consent ; OR  
Adolescent ages 12 to 17 years inclusive at the time of consent.  
2 Adult participant is able to read the written informed consent, states willingness to comply 
with all study procedures and is anticipated to be available for all study visits ; OR  
Parent(s)/Legal Authorized Representative (LAR)(s) of the participating adolescent is able 
to read and provides written informed permission and participating adolescent provides 
assent as appropriate for age or development and approved by [CONTACT_1744]. Adolescent s tates 
willingness to comply with all study procedures and is anticipated to be available for all 
study visits.  
3 Adult participant is able to understand and agrees to adhere to Lifestyle Considerations 
(section 5.4) during the study; OR  
Parent(s)/LAR(s) of the participating adolescent is able to understand and states willingness 
to comply with Lifestyle Considerations ( section 5.4).  
[ADDRESS_178311] 1 month prior to signing ICF and agrees to 
use acceptable method of contraception through Day 57. 
 Note: See MOP for definitions and list of acceptable method of contraception 
 
5 In good general health as evidenced by [CONTACT_9870], physical examination, and clinical 
judgement of the investigator to be in stable state of health.  
 
Note:  Participants with pre -existing stable chronic medical conditions defined as conditions 
not requiring significant change in therapy or hospi[INVESTIGATOR_154348] [ADDRESS_178312] 6 months, report a CD4 count 
of greater than 350 cells/µL and no AIDS- defining illness in the last year.  
 
4.[ADDRESS_178313]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 113 of 147 
 For Stage 2 of the study, an individual who meets any of the following criteria will be excluded 
from participation in this study . Of note, the only difference s between  exclusion criteria in  Stage 
1 and Stage 2 is criterion 8 and the addition of criterion 13: 
1. Ever received a licensed or an investigational smallpox or mpox vaccine. 
Note: this includes Dryvax, Acam2000, LC 16 m8, MVA -based vaccine candidate or 
licensed vaccines, and Jynneos, Imvamune or Imvanex) 
2. Any history of mpox, cowpox, or vaccinia infection. 
3. Close contact [CONTACT_154440] 3 weeks prior to signing ICF 
4. Immunocompromised as determined by [CONTACT_093]  
5. Recent or current use of any immunosuppressing medications in the 4 weeks prior to 
signing ICF.  
Note: topi[INVESTIGATOR_2855], ophthalmic, inhaled, intranasal and intraarticular corticosteroids are acceptable, but receipt of ≥20 mg/day of prednisone or equivalent for ≥[ADDRESS_178314] feeding. 
7. Received or plans to receive a live vaccine or a ny COVID -19 vaccine in  the 4 weeks  before 
or after each study vaccination. 
8. Received or plans to receive any other vaccine in the one week before or after each study vaccination.  
9. Received experimental therapeutic agent or vaccine in the 3 months prior to signing ICF.  
10. Has known allergy or history of anaphylaxis or other serious adverse reaction to a vaccine or vaccine products.  
Note: this includes individuals with history of severe allergic reaction to gentami cin, 
ciprofloxacin, chicken or egg protein. 
11. Has tattoos, scars, or other marks which would, in the opi[INVESTIGATOR_871], interfere with assessment of the vaccination site.  
12. Has any medical disease or condition that, in the opi[INVESTIGATOR_154369]-investigator, precludes study participation. 
Note:  this includes acute, subacute, intermittent, or chronic medical disease or 
condition that would place the participant at an unacceptable risk of injury, render the 
participant unable to meet the requirements of the protocol, or may interfere with the 
evaluation of responses or the participant’s successful completion of this trial. 
13. Adolescent or adult participant has a history of myocarditis/pericarditis or a history of 
structural congenital heart defect/cardiac dysrhythmia that, in the opi[INVESTIGATOR_871], poses increased risk to the participant. 
14. Adolescent or adult participant has a history of COVID -19 ( with positive test for SARS -
CoV-2) in the [ADDRESS_178315] study vaccination. 
Note: This includes positive rapid antigen test, polymerase chain reaction (PCR) assay, 
or other nucleic acid amplification (NAAT) test  including those performed by [CONTACT_154441]. 
Protocol [ADDRESS_178316]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178317] received smallpox vaccination during 
the smallpox eradication campaign. Because the effects on the fetus are not known, pregnant individuals will not be eligible for the trial (see Risk/Benefit Assessment Section). In addition, individuals who are breastfeeding will not be eligible because it is not known if JYNNEOS is excreted in the breastmilk. Stage 2 of the study will also enroll healthy non- pregnant, non-
breastfeeding adolescents ages 12 to 17 years, inclusive. Should the outcome of  this trial be 
deemed acceptable, additional trials may be initiated, including those in other populations.  Given that safety of MVA -BN among adolescents ages 12 to 17 years is largely unknown and 
myocarditis and pericarditis were found to be associated with vaccination with ACAM2000 and Dryvax, replicating smallpox vaccines, adolescents with a history of myocar ditis/pericarditis or a 
history of structural congenital heart defect/cardiac dysrhythmia that, in the opi[INVESTIGATOR_871], poses increased risk to the participant will not be eligible to participate.  
4.[ADDRESS_178318] benefit to the participant (45 CFR 46.405) given that MPXV continues to cause disease in the U.S., and may spread into additional populations, including sexually active adolescents. Adolescents will be recruited from communities that represent the general population that attend the clinics associ ated with the institution for research sites, or individuals who respond to advertisements 
posted publicly. 
4.4 Lifestyle Considerations  
During Stage 2 of this study, participants are asked to: 
• Follow public health guidance on preventing mpox infection and not ify the clinical site if 
exposed to an individual with mpox. 
• Contact [CONTACT_154442] a positive MPXV diagnostic test to schedule a study sick visit. See Section 8.2 and the 
MOP.  
• Contact [CONTACT_154443] -19 illness (with positive test for SARS -CoV-
2 including those performed at home by [CONTACT_2299]) during the study.  
• Refrain from receiving a live vaccine or COVID -19 vaccine in the 4 weeks before or after each 
study vaccination.  
• Refrain from receiving any other vaccine in the one week before or after each study vaccination.  
• Decline participation in an other study evaluating investigational vaccines through Day [ADDRESS_178319]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 115 of 147 
 • Decline participation in another study evaluating an investigational mpox vaccine, smallpox 
vaccine, or MVA-based vaccine through end of trial. 
 Of note, participants may enroll in non- interventional, observational studies (e.g., natural history 
study of mpox). However, concurrent participation in this trial and observational studies can only occur if the recommended blood collection volumes as specified by [CONTACT_154444].
[ADDRESS_178320] been completed, the investigator or designee is to review the inclusion/exclusion criteria and determine the participant’s eligibility for the study. The following information will be collected on screen failures: demographics (age, screen number, sex, ethnic ity, 
and race) and reason(s) for ineligibility. Participants who are found to be ineligible will be told the reason for ineligibility.  
 A participant may be re -screened once if a protocol eligibility criterion that is not met at the initial 
time of screening, will be met by [CONTACT_154404] a later date (e.g., a vaccine was received within exclusionary window at first screening that would not be in the exclusionary window at a later rescreen).  
 
4.[ADDRESS_178321]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178322] while taking 
part in this trial. Procedures and treatment for clinical care may be billed to the participant, participant’s insurance or third party.  
  
5. STUDY  PRODUCT 
5.[ADDRESS_178323](s) and Administration  
5.1.[ADDRESS_178324] Description  
JYNNEOS is FDA-approved and licensed for adults as a smallpox and mpox vaccine in the United 
States. The vaccine, when thawed, is a milky, light yellow to pale white colored suspension that is licensed for subcutaneous injection. JYNNEOS is a live vaccine produced from the strain Modified Vaccinia Ankara -Bavarian Nordic (MVA -BN), an attenuated, non- replicating orthopoxvirus. 
MVA- BN is grown in primary Chicken Embryo Fibroblast (CEF) cells suspended in a serum -free 
medium containing no material of direct animal origin, harvested from the CEF cells, purified, and concentrated by [CONTACT_154381] (TFF) steps including benzonase digestion. Each 0.5 mL dose is formulated to contain 0.5 x 10
8 to 3.95 x 108 infectious units of MVA -BN 
live virus in 10 mM Tris (tromethamine), [ADDRESS_178325] -cell DNA (≤ 20 mcg), protein (≤ 500 mcg), benzonase 
(≤0.0025 mcg), gentamicin (≤0.163 mcg), and ciprofloxacin (≤0.005 mcg).  
 
5.1.2 Dosing and Administration 
In this platform trial, only JYNNEOS (MVA -BN vaccine) is being evaluated and there is no 
placebo group.  Vaccine will be administered by [CONTACT_154445] .  See the MOP for additional details.     
 In Stage 2, the second vaccination will be given in the contralateral arm unless the site deems that 
using the same arm is in the best interest of the participant in terms of safety or using the same arm (for the second injection) will enable the site to bette r evaluate reactogenicity (e.g., tattoo on 
opposite upper arm). If the second vaccination is given in the same arm as the first vaccination, 
the second injection should be given approximately [ADDRESS_178326] injection site if physically possible.  
Table 3 Study Arms Stage 2 (Adult and Adolescent)  
Arm  Dose of JYNNEOS (MVA -
BN) Route of 
Administration*  Vaccination Day 
Day 1  Day 29  
4 (Adult)   1 x 108 TCID 50 (0.5 mL)  Subcutaneous  X X 
Protocol [ADDRESS_178327]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 117 of 147 
  
5 (Adolescent)  1 x 108 TCID 50 (0.5 mL)  
 Subcutaneous  X X 
*Subcutaneous is administered in the fatty  subcutaneous tissue of the upper arm. 
5.1.[ADDRESS_178328] administration is unsuccessful, another administration will not be attempted.  
 
5.2 Preparation/Handling/Storage/Accountability  
5.2.[ADDRESS_178329], JYNNEOS (MVA- BN vaccine) . 
 
5.2.[ADDRESS_178330] Storage and Stability  
See main section of this document for information about storage and stability of JYNNEOS .  
 
5.2.4 Preparation  
Each dose (0.5 mL) is supplied in a single -dose vial. Sites should allow the vaccine to thaw and 
reach room temperature before use (about 15 to 30 minut es). After thawing, the total time stored 
at +2°C to +8°C (+36°F to +46°F) should not exceed 4 weeks. Once the vial is punctured and a 
dose is withdrawn, if it is not used in its entirety, it should be stored at +2°C to +8°C (+36°F to +46°F) and discarded within [ADDRESS_178331] puncture. If the unpunctured vial is initially shipped/stored at [ADDRESS_178332] 30 seconds.  
 
For the SC injection (Arms 4 and 5), 0.[ADDRESS_178333]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 118 of 147 
 See the protocol -specif ic MOP for detailed information on the preparation, labeling, storage, and 
administration for each study arm.  
 
5.3 Measures to Minimize Bias: Randomization and Blinding  
5.3.[ADDRESS_178334] 25% adolescents ages 12 to 14 years. 
 5.3.3 Blinding and Masking Procedures  
This study will not utilize blinding or masking procedures as it is an open- label, non- placebo -
controlled trial. Research laboratories will be blinded to participant study arm f or the purposes of 
immunogenicity/efficacy evaluations.  
5.[ADDRESS_178335]. Administration and date, 
time, and location of injection will be recorded on the appropriate eCRF. 
5.5 Concomitant Therapy  
At screening (i.e., the screening visit or Day 1 visit if the screening visit is not conducted), participants will be asked about receip t of immunosuppressive therapy, experimental therapeutic 
agents and vaccines, other medications, and vaccines. At each subsequent study visit through Day 57, new concomitant medication(s) and changes to existing medications will be recorded as well as receipt of a vaccine. For this study, concomitant medications to be reported in the Case Report Form (CRF) are prescription drugs, over -the- counter medications, and supplements. Concomitant 
medications taken and vaccines received in the 4 weeks prior to provid ing informed consent will 
be recorded in the CRF. Any drug taken or vaccine received by [CONTACT_154446] 57. In Stage 2, a fter Day 57, concomitant 
medication associated with a protocol specified AESI or related MAAE occurring through Day 210 and clinically relevant to report will be recorded in the CRF. After Day 57, concomitant medication associated with a related SAE occurring through the end of study and clinically relevant to report will be recorded in the CRF. Clinically relevant is defined as a medication that is prescribed or dose of an existing medication changed because of a SAE, AESI or MAAE. Medications taken that are unrelated to the adverse event do not need to be recorded (e.g., topi[INVESTIGATOR_154370]). An exception to this schedule for recording concomitant therapy is during sick visits for those who have laboratory -confirmed mpox (illness). During sick visits, concomitant 
medications and treatment will be collected.
 
 Medications that might interfere with the evaluation of the immune response to MVA -BN should 
not be used by [CONTACT_93308]- reporting period unless clinically indicated as part 
Protocol [ADDRESS_178336]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 119 of 147 
 of the participant’s health care for a condition diagnosed aft er enrollment.  This would include any 
systemic immunosuppressant medication that may impact the immunogenicity endpoints. In the 
event medical conditions dictate the use of these medications, participants are encouraged to obtain 
adequate care, comply with  the course of therapy as prescribed by [CONTACT_154447].   
6. STUDY  INTERVENTION  DISCONTINUATION  AND  
PARTICIPANT  DISCONTINUATION/WITHDRAWAL 
6.1 Halting Criteria and Discontinuation of Study Intervention  
6.1.1 Study  Halting Criteria  
Stage 2 will be paused if any of the following four events occur:  
1. One (1) participant experiences a SAE after the administration of the vaccine that is considered related to the vaccine.  
2. One (1) participant experiences a Grade 4 solicited AE after the administration of the vaccine that is considered related to the vaccine.  
3. Three (3) or more participants experience a Grade 3 or higher unsolicited AE coded to the same High -Level Term based on the medical dictionary for Regulatory Ac tivities 
(MedDRA) that are deemed related to the vaccine.  
4. Two or more participants experience a protocol specified AESI regardless of relatedness or severity. 
 In the event a halting rule is met, an unscheduled safety analysis by [CONTACT_154448]. Further administration of the vaccine, including a second dose, is suspended for all participants until an assessment by [CONTACT_154410].  
[IP_ADDRESS] Sentinel Participant Halting Rules  
Not Applicable.  
 
[IP_ADDRESS] Cohort Halting Rules 
Not Applicable.  
 6.1.2 Individual Halting Criteria
 
If a single participant meets an individual halting criterion, this will not halt the whole study but 
halts the participant’s involvement in terms of the administration of the second dose of the vaccine. However,  while the participant is discontinued from receipt of vaccine, they should be encouraged 
to remain in the study to monitor safety and evaluate immunogenicity until the end of the study.  For Stage 2, all five criteria listed below apply:  
  
Protocol [ADDRESS_178337]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 120 of 147 
 1. Any participant  experiences laryngospasm, bronchospasm, or anaphylaxis within 24 hours 
after the administration of the vaccine that is considered related to the vaccine within the 
24 hours after vaccination.  
2. Any participant experiences generalized urticaria (defined as urticarial lesions occurring at more than two body parts) within [ADDRESS_178338] of the participant. The participant could be withdrawn from the study at any time during the trial.  
6.1.3 Follow up for participants that discontinued study intervention
 
Discontinuation from vaccination administration does not mean discontinuation from the study, 
and remaining study procedures should be completed as indicated by [CONTACT_4690]. If a clinically significant finding is identified (including, but not limited to changes from baseline) after enrollment, the investigator or qualified designee will determine if any change in participant management is needed.  
 The second vaccinat ion will not be given, but other follow up visits will continue, if the participant:  
• Becomes pregnant.  
• Develops mpox (symptomatic, laboratory- confirmed disease) after the first vaccination  
• Meets an exclusion criterion for participation in the study (either newly developed or not previously recognized) that precludes further study participation. 
If a participant meets an exclusion criterion after enrollment and first dose, it does 
not necessarily mean the participant cannot receive the second dose of 
JYNNEOS.   The decision of what “precludes further study participation” depends 
on what exclusion criteria are met, with a focus on what is best for participant 
safety. The most likely exclusion criteria to be met are participants that receive a 
licensed vaccine after enrollment (i.e., exclusion criteria 7 and 8).  If a 
participant  receives an off -study vaccine during the study- defined restricted time 
periods (i.e., as defined in exclusion criteria and Section 5.4), receipt of the off -
study vaccine should be reported as a deviation. The participant can receive the 
second study vaccination if the investigator determines that the participant is 
otherwise eligible to receive the second MVA- BN in this trial.  
 T
here is no reactogenicity threshold for administration of the second dose of vaccine, that is the 
second dose may be administered even if there is residual erythema, induration or other reactogenicity  from the first vaccination. Participants and if applicable parent(s)/legal authorized 
representative (LAR) may decline the second vaccination for any reason at the Day 29 visit and will be discontinued from the study intervention. Parental/LAR permission is ongoing throughout the study and will be confirmed prior to the second vaccination.  See MOP for operational details.  
Protocol [ADDRESS_178339]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 121 of 147 
 However, if second vaccination is declined, the participant should remain in the study and followed 
for safety and immunogenicity through Day 394 visit unless they withdraw from the study.  The data to be collected at the time of study intervention discontinuation will include: 
• Reason for discontinuation study vaccination including, but not limited to, unacceptable (intolerable) reactogenicity, new medical condition identified that places participant at risk, participant or parent(s)/LAR(s) unwillingness to have second vaccination. 
• Confirmation of willingness to remain in the study and understanding of study schedule . 
6.2 Participant Withdrawal from the Study and Replacement   
Participants and if applicable parent(s)/LAR(s) are free to withdraw from participation in the study at any time upon request. An investigator may withdraw a participant from the study if the participant: 
• Has an AE or other medical condition that continued participation in the study would not be in the best interest of the participant. 
• Is lost to follow -up 
 The reason for participant discontinuation or withdrawal from the study, whether the decision was made by [CONTACT_1697], participant, or parent(s)/LAR(s), and the extent of the withdrawal (i.e., whether participant withdrew from all components of research study or just the study intervention) will be recorded on the CRF. If the participant agrees, every attempt will be made to follow all AEs through resolution (return to baseline) or until defined as stable. T he investigator will inform 
the participant and if applicable parent(s)/LAR(s) that already collected data will be retained and analyzed for this study even if the participant withdraws from this study. Biospecimens collected will still be used to analyze the study endpoints.  Participants who withdraw, or are withdrawn from this study, or are lost to follow -up after signing 
the ICF and administration of the study product will not be replaced.  
6.[ADDRESS_178340] to follow -up if he or she fails to return for two scheduled 
visits and is unable to be contact[CONTACT_154449]. Extensive effort (i.e., generally three documented contact [CONTACT_154413], e -mail, etc., made on separate 
occasions) will be made to locate or recall the p articipant, or at least to determine the participant’s 
health status. These efforts will be documented in the participant’s study file.  
7. STUDY  ASSESSMENTS  AND  PROCEDURES 
7.1 Screening Procedures  
In this study, screening assessments can occur in an optional screening visit on Day –7 to –1, or at 
Visit [ADDRESS_178341] vaccination. At the time of the screening assessment, the participant and if applicable parent(s)/LAR(s) will be provided with detailed study information and written informed consent or parental/LAR permission and informed assent, where appropriate, 
Protocol [ADDRESS_178342]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 122 of 147 
 will be obtained. The following assessments are performed to determine eligibility requirements 
as specified in the inclusion and exclusion criteria:  
• Obtain demographic data. 
• Obtain mpox exposure history in the 3 weeks prior to signing ICF.  
• Review vaccination history, including any experimental vaccines, and determine receipt of 
exclusionary vaccine(s): 
o Live vaccine or a COVID -19 vaccine  in the prior 4 weeks or an inactivated non-
COVID-19 vaccine in the prior 1 weeks.  
o Licensed or investigation smallpox or mpox vaccine.  
• Obtain medical history. Ask specifically about worsening of any chronic medical 
condition, hospi[INVESTIGATOR_602] , or history of COVID- 19 (with positive test for SARS -CoV-2, 
includi ng those performed at home ) in the prior [ADDRESS_178343] the 
following medical conditions: 
o HIV infection  
o History of mpox, cowpox or vaccinia infection 
o History of anaphylaxis or severe adverse reaction to a vaccine or vaccine product 
o History  of allergy to gentamicin, ciprofloxacin, chicken or egg protein 
o History of myocarditis or pericarditis, congenital heart defect or cardiac dysrhythmia (Stage 2 only, adolescents and adults)  
• Review medications and therapi[INVESTIGATOR_154371] [ADDRESS_178344] on the appropriate CRF and determine receipt of exclusionary medication(s): 
o Experimental therapeutic agent (or vaccine) in the 3 months prior to consent. 
o Use of immunosuppressing drugs prior to consent.  
• Perform targeted physical examination and inspect arms for smallpox vaccination scar 
• Measure vital signs (HR, BP, and temperature). 
• Review of birth control history wit h female of reproductive potential who are having sexual 
intercourse with male partners . 
o Counsel participants to use adequate birth control methods required during the trial to avoid pregnancy. 
o Do serum or urine pregnancy test (in female participants  of reproductive  potential). 
• Review incl usion and exclusion criteria. 
 The overall eligibility of the participant to participate in the study will be assessed once all screening values are available. The screening process can be suspended prior to complete assessment at any time if exclusions ar e identified by [CONTACT_3476]. 
Study participants who qualify for inclusion will be enrolled.  
7.1.[ADDRESS_178345]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 123 of 147 
 Participants will be provided the  results of pregnancy testing and abnormal clinical findings 
necessitating follow -up at the discretion of the participating site PI [INVESTIGATOR_29353]-investigator.  
 
 
7.2 Sick Visit  
Participants with signs and symptoms consistent with mpox (e.g., vesicular or  pustular lesions, 
fever, chills, lymphadenopathy, malaise, myalgias, headache, or respi[INVESTIGATOR_1856]) during the study are asked to call the study site.  Those who have laboratory -confirmed mpox will be 
evaluated at the clinical site; those who have not  been tested will be asked to have a diagnostic test 
done. During the visit, the participant will be asked about the current illness (e.g., onset date, treatment received) and for information about the diagnostic testing that was done. Participants will ha ve a targeted physical examination done. For more information about this visit, see the MOP 
and the CRF.  
7.[ADDRESS_178346] the visit conducted virtually via 
video teleconference (e.g., Zoom, FaceTime) if deemed necessary. If an in -person visit is thought 
to be necessary, the clinical site may do a physical examination on an as needed basis.   
 
In Stage 2, Visit 7 (Day 90) is conducted by [CONTACT_648] (teleconference call) by a delegated study staff member. However, the site may choose to conduct the visit by [CONTACT_154450] (e.g., Zoom, FaceTime) or in -person. 
 
7.3.[ADDRESS_178347] on their participation in the study.  Photographs will not be entered into the study database or used for determination of study objectives. 
7.3.3 Missed Study Visits  
Participants should complete all study visits as specified in the SOA. Phone or virtual video 
teleconferences may be considered for s ubjects who cannot return for protocol specified in- clinic 
visits but are willing to be contact[CONTACT_154451]. See MOP for additional details.  
7.4 Immunogenicity Assessments 
7.4.1 Immunogenicity/Efficacy Evaluations  
Protocol [ADDRESS_178348]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 124 of 147 
 Prior compara tor studies used the Bavarian Nordic (BN) Vaccina virus Western Reserve strain 
(VV-WR) plaque reduction neutralizing antibody ( PRNT ) assay and enzyme-linked 
immunosorbent assay (ELISA) to evaluate immunogenicity. For Stage 2, VV -WR PRNT will be 
used as the primary assay and plan to test timepoints of Days 1, 29, 43, 210, and 394. 
  This study will also measure a MPXV specific PRNT and will test a minimum of 2 timepoints 
(Days 1 and 43). The MPXV PRNT assay is not yet developed, and therefore this endpoint i s as 
an exploratory endpoint. Additional timepoints for each will be evaluated as able (given lab throughput and cost).   
7.4.2 Exploratory Assessments
 
Additional assessments of humoral immunity including ELISAs may be performed on samples 
from this trial.   
7.5 Safety and Other Assessments  
Study procedures are specified in the SOA and more detailed information as needed is provided in the MOP. A study clinician, licensed to make medical diagnoses and listed on the Form FDA 1572 as the participating site PI [INVESTIGATOR_29353]- investigator, will be responsible for all study- related 
medical decisions.  
• Medical history  
o A complete medical history will be obtained by [CONTACT_154452] (i.e., the screening visit or on Day 1 if no screening visit is conducted).  
o An interim medical history will be obtained by [CONTACT_154453]. Any changes since the previous clinic visit will be noted. The interim medical history should inclu de an assessment for adverse events and new medical conditions.  
• Physical examination  
o Stage 2: A targeted (symptom -driven) physical exam will be done at screening 
(i.e., screening visit or Day 1), on Days 8, 29, 36, and 43 (at least assessment of 
vaccinatio n site and presence of skin discoloration and nodules will be done), and 
as needed in all other visits if interim change in medical status reported by [CONTACT_3445].  
• Reactogenicity Assessments  
o Reactogenicity assessments of solicited systemic reactogenicity o ccurring from 
the time of each vaccination through [ADDRESS_178349] each vaccination (Days 8 and 36 respectively) in Stage 2 will include fever, chills, nausea, headache, fatigue, change in appetite, myalgia, and arthralgia.  
o Assessments of solicited local (injection site) reactogenicity occurring from the time of each vaccination [ADDRESS_178350] each vaccination in Stage 2 will include pain at injection site, erythema/redness, induration/swelling, and pruritis at site.  
o In Stage 2, any ongoing events at Day 8, Day 36, or Day 43 will be followed at 
subsequent visits in order to note a resolution date. See Memory Aid section below on measurement of ongoing erythema/redness and/or induration/swelling. 
• Memory Aid 
Protocol [ADDRESS_178351]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178352] vaccination (Days 1 through 8 
and Days 29 through 36).  
o Memory Aids will be reviewed with the participants for any solicited reactions, as well as unsolicited A Es and SAEs.  
o The vaccination injection site will be examined at all visits until symptoms resolve.  
o In Stage 2, for those with no residual systemic or local reactogenicity at the Day 8 or Day 36 visit, no more data is collected by [CONTACT_154416]. 
o For those with ongoing systemic and/or local reactogenicity at Day 8 and 36 in Stage 2, they will be asked to do the following:  
 Measure erythema/redness and/or induration/swelling and record in the Memory Aid until it has resolved, if applicable.  
 Record end date of all other signs and symptoms.  
o Nodules and hyperpi[INVESTIGATOR_154372] A Es, and not collected in the 
Memory Aid to avoid double counting these events which tend to develop at end of second week as a post -inflammatory reaction. Occurrence will be docum ented 
on the physical examination eCRF and the unsolicited AE eCRF, and severity assessed per Section [IP_ADDRESS]. 
 Nodules and hyperpi[INVESTIGATOR_154373]. 
o Site research teams will review and align the subject responses on the memory aid with clinical assessments.  
• Vital signs  
o Vital sign measurements will include systolic and diastolic BP, HR, and oral temperature. Vital signs will be measured at timepoints specified in the SOA.  
• Clinical laboratory evaluations  
o Serum or urine pregnancy test will be performed locally by [CONTACT_154454] [ADDRESS_178353] be confirmed as negative prior to enrollment on Day 1 and administration of each vaccination. 
 
7.5.1 Alternative Schedules
 
Given that peak humoral response after the second JYNNEOS vaccination is the primary endpoint 
and is likely to occur approximately two weeks (Day 43) to four weeks (Day 57) after the second 
dose is administered, it is important that subsequent visits occur within the protocol- specified 
window after the second dose is given.  If a participant is unable to receive the second dose within the pre -specified window, the site should contact [CONTACT_154455]. If a 
participant receives the second dose on any day other than Day 29, the target date of the remaining scheduled visits will be shifted, as appropriate so that immunogenicity timepoints post -second 
vaccination are consistent among participants.    Participants may not receive Dose 1 or Dose 2 of JYNNEOS within 4 weeks of COVID -19 illness 
(with positive test for SARS -CoV- 2 including those performed at home by [CONTACT_2299]) or 
Protocol [ADDRESS_178354]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178355] definitions of adverse events (AE), solicited AEs, unsolicited AEs, and serious adverse events (SAE). 
 
[IP_ADDRESS] Definition of Medically Attended Adverse Events (MAAE)  
A medically attended adverse event (MAAE) is defined as A Es with medically attended visits 
including hospi[INVESTIGATOR_307], emergency room, urgent care clinic, or other visits to or from medical personnel 
for any reason. Adverse events (e.g., abnormal vitals) identified at a routine study visit will not be considered MAAEs. In Stage 2, MAAEs that are deemed related to the vaccine or vaccination 
procedure will be collected from Day 1 through 210 and all SAEs will be collected from Day 1 
through the end of the study.     
[IP_ADDRESS] Definition of Suspected Unexpected  Serious  Adverse Reactions (S[LOCATION_003]R)  
A S[LOCATION_003]R  is a SAE that is considered related to study product  and unexpected. Unexpectedness 
to study product will be determined by [CONTACT_154456].   
[IP_ADDRESS] Definition of Adverse Event of Special Interest (AESI)  
In Stage 2, protocol specified Adverse Events of Special Interest ( AESIs ) will be collected . AESIs 
are any adverse events for which additional data (in addition to standard AE data) are desired. The 
Sponsor (DMID), regulatory agency, or industry partner may request AESI reporting; the decision 
to collect AESI may be driven by a regulatory requirement or a known/potential risk from the study product or class. Non- structured data similar to SAEs will be collected for AESIs. AESIs 
encompass the following terms:    Protocol Specified AESIs  
For Stage 2 of this trial, a protocol specified AESI is defined as a case of myocarditis or 
pericarditis.  All participants with signs and symptoms of myocarditis/pericarditis (e.g., chest pain, shortness of breath, palpi[INVESTIGATOR_814], etc.) in whom myocarditis/pericarditis is excluded, or for whom an alternative diagnosis is made, will not be considered a suspect case and as such, not reported as an AESI.  All other suspected cases of myocarditis or pericarditis should be reported as  an AESI 
and the case adjudicated using the Brighton Collaboration case definitions for myocarditis and pericarditis.  The Brighton Collaboration case definitions will be used to classify into possible, probable, or definite myocarditis or pericarditis cas es.
[ADDRESS_178356]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 127 of 147 
  
7.6.2 Classification of an Adverse Event 
See main section of the protocol for a description of the classification of an AE in terms of severity 
and causality.  
  
7.6.3 Time Period and Frequency for Event Assessment and Follow -Up 
For Stage 2, adverse events will be collected during the following time periods: 
• Systemic and local solicited adverse events will be collected from Day 1 through Day 8, 
and Day 29 through Day 36. However, participants with ongoing systemic and/or local 
reactogenicity at Day 8 or Day 36 visit, will be asked to measure erythema/redness and/ or 
induration/swelling until it has resolved, if applicable, and record end date of all other signs and symptoms. 
• Unsolicited adverse events will be collected from Day 1 through Day 57.  
• For Stage 2, all SAEs  will be collected from Day 1 through Day 394 (i.e., the end of study).  
Protocol specified AESIs, and related MAAEs will be collected from Day 1 through 210. 
 All A Es, related MAAEs, protocol specified AESIs, and SAEs will be followed through resolution 
or until the site investigator deems the event to be chronic or the participant is stable.  
 
7.6.4 Adverse Event Reporting
 
See the main section of the protocol for a description of AE reporting. 
 
7.7 Unanticipated Problems  
See the main section of the protocol for a def inition of Unanticipated Problems (UP) and 
information regarding UP reporting.  
8. STATISTICAL  CONSIDERATIONS 
8.[ADDRESS_178357] non -inferiority of the 1 x 10
8 TCID 50 MVA- BN SC regimen (standard dose 
regimen) in adolescents compared to adults.   Primary Hypothesis  
• At Day 43 the humoral immune response of the 1 x 10
8 TCID 50 MVA- BN SC (standard 
dose regimen) in adolescents will be non- inferior to the standard [ADDRESS_178358]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 128 of 147 
 • At Day [ADDRESS_178359] 1 x 108 TCID 50 MVA- BN SC regimen in 
adults, as assessed by [CONTACT_154421].  
• The humoral immune response of the 1 x 108 TCID 50 MVA- BN SC regimen in adolescents, 
as assessed by [CONTACT_154421], will be similar to the 1 x 108 TCID 50 MVA- BN SC regimen in 
adults at all study days.  
• The humoral immune response of the 1 x 108 TCID 50 MVA- BN SC regimen in adolescents 
as assessed by [CONTACT_154457] -life, will be similar to the 1 x 108 TCID 50 MVA-
BN SC regimen in adults.  
• The humoral immune response of the 1 x 108 TCID 50 MVA- BN SC regimen in adolescents, 
as assessed  by [CONTACT_154458], will be similar to the 1 x 108 TCID 50 
MVA-BN SC regimen in adults at Day 1 and 43.  
8.2 Sample Size Determination  
As a primary endpoint in Stage 2, 500 participants ( 130 adults in Arm 4; 70 adults in Arm 3 (Stage 
1); 300 adolescents in Arm 5) will provide approximately 92% power  for a test of non -inferiority 
of geometric mean titers using unequal variances and two- sided, type I error of 0.05 ( Table 4). 
This assumes that the adult arm will have a standard deviation of 0.[ADDRESS_178360] deviation on Day 42 in prior large studies using the SC route was 0.41 (Pi[INVESTIGATOR_2289], NEJM 2019) and 0.59 (Frey, Vaccine 2015), so the estimates used in 
calculations are justifiable ( Table 5 and 6). Stage 2 will enroll approximately 450 participants (135 
adults in Arm 4; 315 adolescents in Arm 5) assuming a 5% drop- out rate. Participant enrollment 
into the adolescent cohort will be stratified into two [ADDRESS_178361] 78, adolescents 
ages 12 to 14 years and a maximum of 237, adolescents ages 15 to 17 years, in order to ensure that adequate numbers of younger adolescents are enrolled (i.e., about 25% of all adolescents enrolled) . 
Arms 3 and 4 will be combined as a comparator group in the primary analysis. It is not anticipate d 
that there will be significant differences in immunogenicity outcomes between these two groups, however, a  sensitivity analysis  excluding Arm 3 participants  will be performed, and will be 
described in the statistical analysis plan (SAP) . 
 
 
Table 4: Power C alculation  
Power calculations  for a non -inferiority test of means using unequal variances and two- sided type 
one error rate of 0.05. Non-inferiority margin of 0.67. 
NI Margin  
 Sample Size 
Arm 5  
(Standard 
Deviation 
0.5) Sample Size 
Arm 3+4  
(Standard 
Deviation 0.6) 
   
Total sample size 
for NI test  Power  
0.67  
Log 10(0.67) = -0.174  300 200 500 0.92 
 Table 5: Standard Deviation Estimates  
Standard deviation estimates computed from Table S4 of Pi[INVESTIGATOR_154164], 2019
44 
  MVA -BN ACAM2000  Ratio of 
GMTs  95% CI  
Week  N GMT  95% CI  SD N GMT  95% CI  SD 
Protocol [ADDRESS_178362]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 129 of 147 
  (for 
log 10 
GMT)   (for 
log 10 
GMT)    
2 184 16.2 [13.0, 20.1]  0.65 184 16.2 [13.1, 20.0]  0.63 0.997  [0.738, 1.348]  
4 185 16.9 [13.7, 20.8]  0.63 186 79.3 [67.1, 93.8]  0.51 0.213  [0.163, 0.278]  
6 185 153.5  [134.3, 175.6]  0.41 181 64.7 [54.9, 76.2]  0.49 2.372  [1.922, 2.928]  
8 179 118.2  [102.9,135.8]  0.41 183 67.1 [56.9, 79.0]  0.49 1.763  [1.422, 2.185]  
Peak  185 153.5  [134.3, 175.6]  0.41 186 79.3 [67.1, 93.8]  0.51 1.935  [1.562, 2.397]  
 
Protocol [ADDRESS_178363]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 130 of 147 
  
Table 6: Standard Deviation Estimates  
Standard deviation estimates computed from Frey et al, 201521 
Study visit day  Liquid SC 1x108 
N=149  Liquid ID 2x107 
N=146   
 VV-WR GMT [95% CI]  SD VV-WR GMT [95% CI]  SD 
Day 14  10.0 [9.0, 11.1]  0.28 10.3 [9.3, 11.3]  0.27 
Day 28 9.6 [8.7, 10.6] 0.27 10.8 [9.9, 11.9] 0.23 
Day 42 45.2 [36.4, 56.2] 0.59 54.4 [43.7, 67.8] 0.[ADDRESS_178364] 2nd vaccination  49.5 [40.0, 61.3] 0.58 59.6 [48.1, 74.0] 0.59 
 
 
8.3 Statistical Analyses  
8.3.1 General Methodology  
For Stage 2, the non -inferiority of adolescent immune response relative to adult immune response 
will be determined using a non- inferiority (NI) margin of 0.67 (NI= -0.174 log10 scale).  No 
stepwise testing will be done in Stage 2.  The primary safety endpoint is descriptive with no hypothesis testing planned.  
8.3.2 Timing of Analyses
 
[IP_ADDRESS] Interim  Safety Analyses 
AEs and SAEs may be reviewed as necessary outside of DSMB reviews. The DSMB may not need 
to meet (unless halting rules are met) and materials will be provided electronically. Documentation of review and any concerns noted will be solicited electronically.  The DSMB will review separate cumulative AE data reports for all participants within each arm. Given the safety database known for authorized/approved vaccines, there is no routine mandatory review by [CONTACT_154424].   
[IP_ADDRESS] Interim Immunogenicity Analyses  
For Stage 2, interim immunogenicity analyses may be conducted and will include at least an 
analysis of Vaccinia virus specific PRNT GMT  at Day 1 and 43 and Monkeypox virus specific 
PRNT GMT at Day 1 and 43.  
 
 
[IP_ADDRESS] Final Analyses  
The final efficacy/immunological/safety outcome(s) may be analyzed after all data for the primary 
and secondary outcome(s) have been collected and locked. Data will be locked and analyzed by [CONTACT_64367]. Analysis of Stage [ADDRESS_178365]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 131 of 147 
  
 
8.3.3 Populations for Analyses  
There will be three analysis populations in this study. The safety analysis population includes all 
enrolled participants who received at leas t one dose of study vaccine. Analyses for the safety 
population will include safety reported through the end of the study. The modified intent -to-treat 
(mITT) population includes all participants who received at least one dose of vaccine and contributed both pre - and at least one post -vaccination venous blood sample for immunogenicity 
testing for which valid results were reported.  In the final analysis, protocol deviations will be reviewed to determine which protocol deviations may affect the analysis. The per protocol (PP) population will then be defined – and this includes 
all participants in the mITT subset with the following exclusions: 
• Data from all available visits for participants found to be ineligible at baseline.  
• Data from all visits after the pro tocol deviations that are considered to affect the science 
(as determined by [CONTACT_154425]). 
• Data from any visit that occurs substantially out of window. 
 For the PP and mITT  analyses, participants will be analyzed according to the study product that 
they received.  
 
8.3.[ADDRESS_178366] the analysis, a PP analysis may also be performed.  
 Geometric Mean Titers (GMT) and Geometric Mean Fold Ris e (GMFR) from baseline of VV -WR 
PRNT  will be calculated, along with 95% CIs, for all groups, at each timepoint. Summaries will 
also be displayed graphically. Geometric Mean Titer Ratio, defined as the ratio of each ID arm to the control SC arm, will also b e reported at each timepoint, along with 95% CIs.  
There are no imputations planned for missing data.  A SAP for Stage [ADDRESS_178367]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 132 of 147 
 specified AES Is, and related MAAEs will be evaluated from Day 1 through Day 210. A ll SAEs  
will be evaluated from Day 1 through Day 394 or the end of the study (see SOA). 
  
[IP_ADDRESS] Reactogenicity  
The number, percentage (observed rate) and exact two- sided 95% CI for participants  reporting 
each solicited local (injection site) reaction and solicited systemic reaction following vaccination 
will be summarized by [CONTACT_154426], and overall (i.e., after any vaccination). In addition, the most severe local and systemic reactions recorded during the follow -
up period (i.e., maximum severity) for each participant will be determined and summarized by [CONTACT_154427] (as well as overall) and the resulting number and percentage of participan ts will be summarized by [CONTACT_86953] (none, mild, moderate, severe, life -
threatening). Last, the daily severity of local and systemic reactions will be determined for each participant and the proportion of participants having a sign/symptom each day wil l summarized 
by [CONTACT_154428]. Rates for any severe (Grade 3 or 4) solicited local or systemic reaction following any vaccination will be compared between study arms.  
  
[IP_ADDRESS] Other Adverse Events  
The number of associated unsolicited AEs, protocol specified AESIs (Stage 2 only), MAAEs and 
SAEs following vaccine administration is expected to be small. A complete listing of all events will therefore be provided, including the nature of the event, timing relative to vaccination, 
severity, duration, and the investigator’s assessment of the likely relationship to vaccination. For each type of AE, the observed rate and exact two-sided confidence intervals will be computed for each study arm and listed by [CONTACT_154429]. AEs will be MedDRA
® coded for preferred term and 
system organ class. Event rates and exact 95% confidence intervals for each study arm and the entire study cohort will be presented, in aggregate and by [CONTACT_61132]
® categories. Related 
unsolicited AE, protocol specified AESI (Stage 2 only), MAAE and SAE rates will be compared 
between the study arms.   The number, percentage (observed rate) for participants that withdrew or discontinued their vaccination series due to safety or reactogenicity events will be tabul ated. Rates of 
withdrawal/discontinuation will be compared between study arms using Fisher’s exact test.    Refer to the SAP for additional information.  
9. SUPPORTING  DOCUMENTATION  AND  OPERATIONAL  
CONSIDERATIONS 
9.1 Regulatory, Ethical, and Study Oversight Considerations  
This study will be conducted in conformity with the principles set forth in The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Participants of Research (US National Commission for the Protection of Human Participant s of Biomedical and Behavioral 
Protocol [ADDRESS_178368]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 133 of 147 
 Research; April 18, 1979), and the federal policy for the Protection of Human Participants codified 
in 45 CFR Part 46, 21 CFR Part 50 (Protection of Human Participants), and the ICH E6(R2).  An OHRP -registered IRB will review and approve this protocol, associated informed consent, 
parental permission and assent documents, recruitment materials, and handouts or surveys intended for the participants, prior to the recruitment, screening and enrol lment of participants. 
The IRB review shall be in accordance with 45 CFR 46 and 21 CFR 50, 21 CFR 56 (IRBs), and other federal, state, and local regulations and policies, as applicable.  Each institution engaged in this research will hold a current Federal wide Assurance (FWA) issued 
by [CONTACT_19819] (OHRP) for federally funded research. and provide the FWA number to DMID. Each site principal investigator [INVESTIGATOR_154336] d at his/her research site(s).  
 Any amendments to the protocol or informed consent, parental permission and assent documents will be approved by [CONTACT_106526]. IRB review and approval will occur at least annually throughout enrollment and follow-up of participants, in accordance with applicable regulations and the requirements of the IRB/IEC. The participating site PI [INVESTIGATOR_154337], as applicable to the IRB policy.  DMID must r eceive the documentation that verifies IRB/IEC approval for this protocol, informed 
consent, parental permission and assent documents and associated documents, prior to the recruitment, screening and enrollment of participants, and any IRB approvals for continuing review or amendments as required by [CONTACT_122830].   
9.1.1 Informed Consent Process
 
Informed consent is a process that is initiated prior to an individual agreeing to participate in a trial 
and continuing throughout the individual’s trial participation. Before any study procedures are performed, informed consent or parental permission and assent, where appropriate, will be obtained and documented. This research can be categorized as greater than minimal risk but presenting the prospect of direct benefit to the participant (45 CFR 46.405) given that MPXV may continue to cause disease in the U.S. in 2023.  Given this, permission of one parent is sufficient for the adolescent participant.   Participants and the adolescent participant’s parent or LAR will receive a concise and focused presentation of key information about the clinical trial, that includes both a verbal discussion as well as written documentation. The key information about the purpose of the study, the procedures and experimental aspects of the study, study interventions/products, risks and discomforts, the expected duration of the participant’s participation in the trial, any expected benefits to the participant, and alternative treatments and procedures that may be available to the particip ant. The 
explanation will be organized and presented in lay terminology and language that facilitates understanding why one might or might not want to participate, why one might or might not want to allow one’s adolescent to participate or, in the case of assenting minors, why they themselves might or might not want to participate.  
 
Protocol [ADDRESS_178369]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 134 of 147 
 Participants and the adolescent participant’s parent or LAR will receive an explanation as to 
whether any compensation and any medical treatments are available if injury occurs,  and, if so, 
what they consist of, or where further information may be obtained. Participants and the adolescent participant’s parent or LAR will be informed of the anticipated financial expenses, if any, to the participant for participating in the trial, as well as any anticipated prorated payments, if any, to the participant for participating in the trial. They will be informed of whom to contact (e.g., the investigator) for answers to any questions relating to the research project. Information will also include the foreseeable circumstances and/or reasons under which the participant’s participation in the trial may be terminated. The participants and the adolescent participant’s parent or LAR will be informed that participation is voluntary and that they are free to withdraw from the study for any reason at any time without penalty or loss of benefits to which the participant is otherwise entitled.   Participants and the adolescent participant’s parent or LAR will be informed that records identifying the participant will be kept confidential, and, to the extent permitted by [CONTACT_29695]/or regulations, will not be made publicly available and, if the results of the trial are published, the participant’s identity will remain confidential. Participa nts and the adolescent 
participant’s parent or LAR will be informed whether private information collected from this 
research and/or specimens will be used for additional research, even if identifiers are removed. They will be informed that the monitor(s), auditors(s), IRB, NIAID, and regulatory authority(ies) will be granted direct access to the participant’s original medical records for verification of clinical trial procedures and/or data without violating the confidentiality of the participant, to the extent permitted by [CONTACT_4913], and that, by [CONTACT_2960] a written informed consent or assent form, the participant is authorizing such access. Participants and the adolescent participant’s parent or LAR will be allowed sufficient time to consider participation in this research trial and can discuss this trial with their family, friends or legally authorized representative, or think about it prior to agreeing to participate.  Informed consent, parental permission and assent forms will be IRB-approved, and participants 
will be asked to read and review the consent or assent form. Participants must sign the informed consent or assent form, where appropriate, prior to starting any study procedures being done specifically for this trial. Once s igned, a copy of the informed consent or assent form will be given 
to the participant and the adolescent participant’s parent or LAR for their records.  New information will be communicated by [CONTACT_16541] [INVESTIGATOR_154374]. The informed consent and parental permission and assent documents will be updated, and participants will be re -consented 
per IRB requirements, if necessary.   
[IP_ADDRESS] Requirements for Permission by [CONTACT_122781]/LARs and Assent by [CONTACT_63779] (in case 
of a minor)  
Stage [ADDRESS_178370]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 135 of 147 
   
The participant who reaches the age of majority or becomes emancipated during the study will be consented at the next visit prior to study procedures being performed. When no further visits are planned but the participant’s participation is ongoing, the consent will be obtained via IRB -
approved processes. 
[IP_ADDRESS] Other Informed Consent Procedures  
Participants and the adolescent participant’s parent or LAR will be asked for consent and assent, 
where appropriate, to collect blood for the use of residual specimens and samples for secondary research. This extra/resid ual blood and corresponding serum will be used as back -up specimens 
for PP defined assays or designated for secondary research use and stored indefinitely at a designated storage facility. Collection of extra/residual samples during the study will help fac ilitate 
rapid follow-on analyses, if warranted, to provide more comprehensive scientific insights into the impact (safety and immunological) of the vaccine on the host response to vaccination. To maintain statistical power in follow -on analyses it is important that extra blood collection and secondary 
research use be included in as many participants as possible, due to the limited sample size per treatment arm. For this reason, if participants choose not to provide permission for extra blood and secondary r esearch use, they will not be eligible for enrollment into the study.  
 The stored samples will be labeled with barcodes to maintain confidentiality. Research with identifiable samples and data may occur as needed, however, participant confidentiality will  be 
maintained as described for this protocol and with IRB approval. Samples designated for secondary research use may be used for additional immunological assessments that may include but are not limited to antibody epi[INVESTIGATOR_111050], B and T cell repertoire determination, non-traditional immune assay development, determination of innate immune factors and the ability of vaccine -induced antibodies to cross -react to different proteins and virus strains. These blood 
samples might be used in new or different immunological laboratory tests, to provide information for the development of new vaccines or therapeutics, or for the studies of monkeypox virus or other related viruses. Samples will not be sold for commercial profit. Although the results of any future res earch may be patentable or have commercial profit, participants will have no legal or 
financial interest in any commercial development resulting from any future research. There are no direct benefits to the participant for extra specimens collected or from the secondary research. No results from secondary research will be entered into the participant’s medical record. Incidental findings will not be shared with the participant, including medically actionable incidental findings, unless required by [CONTACT_2371].   Risks are associated with the additional volume of blood collected, such as anemia. Risks for loss 
of privacy and confidentiality are described below. Participants may withdraw permission to use samples for secondary use at any time. They will need to contac t the participating site and the 
samples will be removed from the study repository after this study is completed and documentation will be completed that outlines the reason for withdrawal of permission for secondary use of samples. Participants who withdraw consent before the last visit will not have the extra blood drawn for secondary use.   Participants will be asked to consent specifically on primary and secondary research samples. The consent process will include an explanation of the potential risks to the individual participants associated with data submitted to an NIH data repository and subsequent sharing. Data that may 
Protocol [ADDRESS_178371]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 136 of 147 
 potentially identify human participants will not be released in unrestricted databases. Participants 
will be informed that analytic al methods are associated with the risk of re- identification, even 
when specimens are de -identified. The consent will include whether individual participant data 
will be shared through a NIH controlled access data repository.  
9.1.2 Study Termination and Closure 
Section 7, Study Intervention Discontinuation and Participant Discontinuation/Withdrawal, 
describes the temporary halting of the study. This study may be premature ly terminated if there is 
sufficient reasonable cause, including but not limited to: 
• Determination of unexpected, significant, or unacceptable risk to participants 
• Results of interim efficacy or futility analysis  
• Insufficient compliance to protocol requirements 
• Data that are not sufficiently complete and/or evaluable 
• Regulatory authorities’ determination  
• Sponsor’s determination 
 
If the study is prematurely terminate d, the Principal Investigator (PI) will promptly inform study 
participants and the  IRB  and regulatory authorities as applicable. Study participants will be 
contact[INVESTIGATOR_530], as applicable, and be informed of changes to study visit schedule. The PI [INVESTIGATOR_154338] -up for the participants, as necessary. The sponsor will notify regulatory 
authorities as applicable.  
  
9.1.[ADDRESS_178372] by [CONTACT_3486], their staff, and 
the sponsor(s) and their agents. This confidentiality is extended to cover clinical information relating to participants, test results of biological samples and genetic tests, and all other information generated during participation in the study. No identifiable information concerning participants in the study will be released to any unauthorized third party. Participant confidentiality will be maintained when study results are published or discussed in conferences.    The study monitor, other authorized representatives of the sponsor, representatives of the Institutional Review Board (IRB), and/or regulatory agencies may inspect all documents and records required to be maintained by [CONTACT_093], including but not limited to, medical records (office, cl inic, or hospi[INVESTIGATOR_307]) and pharmacy records for the participants in this study. The clinical 
study site will permit access to such records.  
 All source records including electronic data will be stored in secured systems in accordance with institutional policie s and federal regulations. All study data and research specimens that leave the 
site (including any electronic transmission of data) will be identified only by a coded number that cannot be linked to a participant.  As this research is funded by [CONTACT_18121], it is covered by [CONTACT_154386] a Certificate of Confidentiality. By [CONTACT_122842], researchers cannot be forced to disclose or provide, in any Federal, State, or local civil, criminal, administrative, legislative, or other proceeding, the name [CONTACT_122867], document, or biospecimen that 
Protocol [ADDRESS_178373]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178374] be released in order to meet the requirements of the FDA.  A Certificate of Co nfidentiality does not prevent the participant from voluntarily releasing 
information about themselves or their involvement in this research. If any person or agency obtains 
a written consent to receive research information, then the researchers may not use the Certificate to withhold that information.   The Certificate of Confidentiality does not prevent the researchers from reporting without the participant’s consent, information that would identify the participant as a participant in the research project regarding matters that must be legally reported including child and elder abuse, sexual abuse, or wanting to harm themselves or others.   The release of individual private information or specimens for other research will only occur if consent was obtained from the individual or the parent(s) or LAR of the adolescent participants to whom the information, document, or biospecimen pertains, or  for the purposes of other research 
that the release is in compliance with applicable Federal regulations governing the protection of human participants in research.   
9.1.4 Secondary Use of Stored Specimens and Data 
 
 
[IP_ADDRESS] Samples for Secondary Research  
Repository Research Sample  
To participate in this study, participants and the parent or LAR of adolescent participants will be 
asked for consent for storage of samples for secondary use. Samples will be stored indefinitely at a DMID -designated storage facility. Each sample will be encoded (labeled) only with a barcode 
and a unique tracking number to protect participant confidentiality. Secondary research with coded samples and data may occur, however, participant confidentiality will be maintained as described for this protocol. An IRB review of the secondary research using coded specimens is required.  Repository Research Samples, upon written request and approval from DMID and any approvals required by [CONTACT_779], may be shared for secondary research with investigators at the participating site, with researchers at other sites or other institutions, or company- designated research 
laboratories. The samples will not be sold or used directly for production of any com mercial 
product. DMID will authorize shipment from the repository.  Reports from secondary research will not be kept in the participants’ health records or shared with participants, unless required by [CONTACT_2371]. Reports will not be sent to the specimen repository. The participant’s decision for secondary research can be changed at any time by [CONTACT_154459] [ADDRESS_178375]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 138 of 147 
 doctors or nurses in writing. If the participant changes his/her decision, the samples will be 
destroyed if the samples have not been used for research o r released for a specific research project.  
[IP_ADDRESS] Data Sharing for Secondary Research 
Data from this study may be used for secondary research. Individual participant data collected 
during the trial  that are sufficient to reanalyzed primary and secondary endpoint s will be made 
available after deidentification.  The SAP and Analytic  Code will also be made available. This data 
will be available  following publication, with no end date.  The data will be made available to 
researchers who provide a methodologically sound proposal. The data will be available for any 
purpose outlined in the approved proposal. Proposals should be directed to DMID. To gain access, data requestors will need to sign a data access agreement. The investigator may request removal of data on individual study participants from NIH data repositories in the event that a research participant withdraws or changes his or her consent. However, data that have been distributed for approved research use cannot be retrieved.  
9.1.5 Key Roles and Study Governance
 
This is a multi- site clinical trial and as such, all study team members and roles are listed in the 
Manual of Procedures (MOP). 9.1.[ADDRESS_178376] of members with appropriate expertise to contribute to the interpretation of the data from this trial. The DSMB will 
operate under the rules of a DMID -approved charter that will be written at the organizational 
meeting of the DSMB. Procedures for DSMB reviews/meetings will be  defined in the charter. 
Reports may include enrollment and demographic information and solicited and unsolicited AE/SAEs. The DSMB will review SAEs on a regular basis and ad hoc during this trial. The DMID Medical Monitor will be responsible for reviewing SAEs in real time.   For Stage [ADDRESS_178377] the following reviews: 
• Approximately 115 to 130 days after the study start. Given the planned 8 to 10- week 
enrollment period, and second dose of vaccine given on day 29, the window for r eview in 
Stage 2 was extended. As such, the review will focus on AEs utilizing real time reports where able.  
• Ad hoc meeting:  
o When trial -level halting criteria are met  
o At the request of DMID to review a potential safety concern identified in the trial.  
• Interim and final data will be shared with the DSMB, but the DSMB does not need to meet to review the final data.  
 Additional data may be requested by [CONTACT_4318]. The DSMB may receive data in aggregate and presented by [CONTACT_2939]. The DSMB may also be provided with expected and observed rates of the expected AEs in an unblinded fashion. As an outcome of each review/meeting, the DSMB 
Protocol [ADDRESS_178378]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 139 of 147 
 will make a recommendation as to the ad visability of proceeding with study interventions (as 
applicable), and to continue, modify, or terminate this trial. 
 The DSMB will operate under the rules of a DMID -approved charter that will be written at the 
organizational meeting of the DSMB. At this t ime, each data element that the DSMB needs to 
assess will be clearly defined. Procedures for DSMB reviews/meetings will be defined in the charter. The DSMB will review applicable data to include, but not limited to, study progress and participant, clinical, safety and safety related data. Reports may include enrollment and demographic information, medical history, concomitant medications, physical assessments, clinical laboratory values, dosing compliance, and solicited and unsolicited AE/SAEs.  DMID or the  DSMB chair may convene the DSMB on an ad hoc basis according to protocol 
criteria or if there are immediate concerns regarding observations during the course of this trial. The DMID Medical Monitor is empowered to stop enrollment and study product adminis tration if 
AEs that meet the halting criteria are reported. The DMID Medical Monitor will be responsible for reviewing SAEs in real time. The DSMB will review SAEs on a regular basis and ad hoc during this trial.  
9.1.[ADDRESS_178379] of the trial is in compliance with the currently approved protocol/amendment(s), International Council for Harmonisation (ICH), Good Clinical Practice, and with applicable regulatory requirement(s) and sponsor requirements.   Monitoring for this study will be overseen by [CONTACT_18127]/DMID and conducted by [CONTACT_18127] /DMID 
contractors. Details of clinical site monitoring are documented in a Clinical Monitoring Plan (CMP). The CMP describes in detail who will conduct the monitoring, at what frequency monitoring will be done, at what level of detail monitoring will be performed, and the distribution of monitoring reports. Monitoring visits will include, but are not limited to, review of regulatory files, investigational product administration and accountability records, eCRFs, informed consent, parental permission and ass ent forms, medical and laboratory reports, site study storage records, 
training records, and protocol and GCP compliance. Site monitors will have access to each participating site, study personnel, and all study documentation according to the NIAID or DMID -
approved site monitoring plan.  Study monitors will meet with site principal investigators (or 
designee) to discuss any problems and outstanding issues and will document site visit findings and discussions.   
9.1.8 Quality Assurance and Quality Control
 
Quality control (QC) and quality assurance (QA) activities are essential to the safety of 
participants, and the reliability of study data. Each site participating in the study is responsible for integrating quality control checks throughout the study and i mplementing a QA Checklist or 
Clinical Quality Management Plan (CQMP). The site will conduct the following:   
Protocol [ADDRESS_178380]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178381], protocol adherence, human participants’ protections, and reliability of the protocol- driven data collected.  
5. Processes for addressing data quality issues (i.e., collecting, recording), and reporting findings in a timely manner.  
6. Identify systemic issues (e.g., protocol or human participant protections non-compliance), and implementation and evaluation of Corrective and Preventative Action Plan (CAPA) procedures, if applicable. 
 
9.1.[ADDRESS_178382] Keepi[INVESTIGATOR_007]
 
[IP_ADDRESS] Data Collection and Management Responsibilities 
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the 
site investigator. The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the data reported. All source documents should be completed in a neat, 
legible manner to ensure accurate interpretation of data.  
 
[IP_ADDRESS] Data Coordinating Center / Biostatistician Responsibilities  
The data coordinating center for this study will be responsible for data management, quality 
review, analysis, and reporting of the study data. Adverse events and medical history will be coded according to the MedDRA dictionary. Concomitant medications will be coded according to the WHO Drug dictionary. At the end of the study, a copy of all datasets including annotated case report forms and data dictionary will be provided to DMID.   A separate Study Data Standardization Plan (SDSP) will be developed which  describes the 
technical recommendations for the submission of human study data and related information in a standardized electronic format throughout product development.  
[IP_ADDRESS] Data Capture Methods 
Clinical research data, including, but not limited to, AE/SAEs, concomitant medications, medical 
history, physical assessments will be abstracted from the source documentation and/or collected on source document worksheet by [CONTACT_154388] a [ADDRESS_178383]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 141 of 147 
 [IP_ADDRESS] Study Record Retention  
Study related records, including the regulatory file, study product accountability records, consent, 
parental permission and assent forms, participant source documents and electronic records should be maintained for a minimum period of [ADDRESS_178384] for the indication for which it is being investigated; or, if no application is to be filed or if the application is not approved for such indication, until 3 years after the investigation is disc ontinued and FDA is notified. These documents should be retained in 
compliance with all federal and local regulations and institutional policies; which may be longer. No records will be destroyed without the written consent of DMID. Consent and assent form s with 
specimen retention linked to identifiable specimens will be maintained for as long as the specimens remain in identifiable format, and a minimum of three years after use of the identifiable specimens in nonexempt human participant research.  
[IP_ADDRESS] Source Records  
Source data are all information, original records of clinical findings, observations, or other 
activities documented in a clinical trial necessary for the reconstruction and evaluation of the trial. Each participating site will maintain appropriate  medical and research records for this trial, in 
compliance with ICH GCP, regulatory, and institutional requirements. Data recorded in the electronic case report form (eCRF) derived from source documents should be consistent with the data recorded on the s ource documents. Data entered directly into the eCRFs will be considered 
the source document. All source documents should be completed in a neat, legible manner to ensure accurate interpretation of data.  
 Interview of participants is sufficient for obtaining medical history. Solicitation of medical records from the participant’s primary care provider is not required.  
9.1.10 Protocol Deviations 
A protocol deviation is any noncompliance with the clinical trial protocol, any process that is noted 
in the protocol and refers to details in the MOP, or GCP requirements.   The noncompliance may be either on the part of the participant, the investigator, or the study site staff. Following a deviation(s), corrective actions should be developed by [CONTACT_3483]. All individual protocol deviations will be addressed in participant study records.   It is the responsibility of the site principal investigator [INVESTIGATOR_154339], or within five working days of the scheduled protocol -required activity. All deviations 
must be promptly reported to DMID per the protocol deviation reporting procedures. Protocol deviations must be sent to the local IRB/IEC per their guidelines. The site principal investigator [INVESTIGATOR_154366].   
9.1.[ADDRESS_178385]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 142 of 147 
 [IP_ADDRESS] Human Data Sharing Plan 
All NIH protocols are required to have a Data Sharing Plan describe provisions for protecting the 
participants’ privacy and the confidentiality of the data. This study will be conducted in accordance with the following publication and data sharing policies and regulations: National Institutes of Health (NIH) Public Access Policy, which ensures that the public has access t
o the published results of NIH funded research. It requires scientists to submit final peer -reviewed 
journal manuscripts that arise from NIH funds to the digital archive PubMed Central  upon 
acceptance for publication.  
 A
s of January 2018, all clinical trials supported by [CONTACT_12242].gov, no later than [ADDRESS_178386] participant. Res ults of all 
clinical trials supported by [CONTACT_18121], generally, need to be submitted no later than 12 months following the primary completion date. As part of the result posting, a copy of this protocol and a copy of the Statistical Analysis Plan will be posted on ClinicalTrials.gov.   
[IP_ADDRESS] Genomic Data Sharing Plan 
Not Applicable. 
 
[IP_ADDRESS] Publication  
This study will comply with the NIH Public Access Policy, which ensures that the public has 
access to the published results of NIH funded research. As such, the final peer -reviewed journal 
manuscripts will be accessible to the public on PubMed Central no later than [ADDRESS_178387]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178388] (PREP Act). The PREP Act applies under the terms of the PREP 
Act declaration in place for smallpox/orthopoxvirus countermeasures for activities conducted pursuant to federal agreements or federal programs (ref: www.federalregister.gov/documents/2015/12/09/2015-[ZIP_CODE]/smallpox- medical -
countermeasures -amendment). JYNNEOS is used under an IND for mpox pursuant to a federal 
agreement/program and is therefore covered under the PREP Act. The PREP Act covers persons (such as manufacturers, distributers, program planners, and other qualified persons who prescribe, administer or dispense study product) are immune from liability from the administration, or use of a covered countermeasure, such as JYNNEOS. The PREP Act provides immunity for covered persons from liability, unless the injury was caused by [CONTACT_154389].   The PREP Act also established the Countermeasures Injury Compensation Program (CICP) to provide compensation for serious injuries or death that occur as the direct result of the administration or use of certain countermeasures. Any requests for compensation must be filed within one year of the administration or use of the covered countermeasure. Requests for Benefits must be made to the Health Resources an d Services Administration’s (HRSA) Countermeasures 
Injury Compensation Program (http://www.hrsa.gov/cicp/) by [CONTACT_154390] a Request for Benefits Form and all required medical records and supporting documentation. Additional information on filing a Request for B enefits is available on the CICP’s website at http://www.hrsa.gov/cicp/. 
Compensation may then be available for reasonable and necessary medical benefits, lost wages and/or death benefits to eligible individuals for certain injuries in accordance with regulations published by [CONTACT_154391] (found at 42 CFR part 110).  If an individual suffers a serious physical injury or death from the administration or use of a covered countermeasure in this study, the individual, the individual’s legal or personal representative, the administrator/executor of a deceased individual’s estate, or certain survivors may request benefits from the CICP. A serious physical injury means an injury that warranted hospi[INVESTIGATOR_059] (whether or not the person was actually hospi[INVESTIGATOR_9651]) or that led to a significant loss 
of function or disability. The CICP is the payer of last resort. This means that it only covers expenses or provides benefits that other third- party payers (such as health insurance, the 
Department of Veterans Affair s, or Workers’ Compensation programs) do not have an obligation 
to pay.  If the Secretary of HHS does not make a final determination on the individual’s request within [ADDRESS_178389] is reduced by [CONTACT_154460]’s compensation 
available to the injured individual. Awards for non- economic damages, such as pain, suffering, 
physical impairment, mental anguish, and loss of consortium are also limited. If the individual accepts compensation,  or if there is no willful misconduct, then the individual does not have a tort 
claim that can be filed in a US Federal or a State court.  
  
Protocol [ADDRESS_178390]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 144 of 147 
 10. REFERENCES  
1. Pan American Health Organization. Mpox (monkeypox) outbreak - 2022. 
(https://www.pah o.org/en/mpox-monkeypox-outbreak-
2022#:~:text=On%2023%20July%202022%2C%20the,of%20International%20Concern%20(PHEIC)).  
2. Centers for Disease Control and Prevention. 2022 Mpox Outbreak Global Map. (https://www.cdc.gov/poxvirus/monkeypox/response/2022/world-map.html ). 
3. Outbreak News Today. England: Monkeypox case confirmed, Patient had recent travel history from Nigeria. ( https://outbreaknewstoday.com/england-monkeypox- case-
confirmed -patient -had-recent -travel -history- from -nigeria-[ZIP_CODE]/ ). 
4. McCollum AM, Damon IK. Human monkeypox. Clin Infect Dis 2014;58(2):260- 7. DOI: 
10.1093/cid/cit703. 
5. Grant R, Nguyen LL, Breban R. Modelling human- to-human transmission of monkeypox. 
Bull World Health Organ 2020;98(9):638-640. DOI: 10.2471/BLT.19.242347. 
6. Gong Q, Wang C, Chuai X, Chiu S. Monkeypox virus: a re -emergent threat to humans. 
Virol Sin 2022. DOI: 10.1016/j.virs.2022.07.006. 
7. Rimoin AW, Mulembakani PM, Johnston SC, et al. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci U S A 2010;107(37):[ZIP_CODE]- 7. DOI: 
10.1073/pnas.[PHONE_3454]. 
8. World Health Organization. Emergence of monkeypox in West Africa and Central Africa, 1970- 2017. Wkly Epi[INVESTIGATOR_75313] 2018;93(11):125-32. 
(https://www.ncbi.nlm.nih.gov/pubmed/29546750).  
9. Centers for Disease Control and Prevention. Multistate outbreak of monkeypox-- Illinois, 
Indiana, and Wisconsin, 2003. MMWR Morb Mortal Wkly Rep 2003;52(23):537-40. (https://www.ncbi.nlm.nih.gov/pubmed/12803191).  
10. Erez N, Achdout H, Milrot E, et al. Diagnosis of Imported Monkeypox, Israel, 2018. Emerg Infect Dis 2019;25(5):980-983. DOI: 10.3201/eid2505.190076. 
11. Yong SEF, Ng OT, Ho ZJM, et al. Imported Monkeypox, Singapore. Emerg Infect Dis 2020;26(8):1826-1830. DOI: 10.3201/eid2608.191387. 
12. Rao AK, Schulte J, Chen TH, et al. Monkeypox in a Traveler Returning from Nigeria - 
Dallas, [LOCATION_007], July 2021. MMWR Morb Mortal Wkly Rep 2022;71(14):509- 516. DOI: 
10.[ZIP_CODE]/mmwr.mm7114a1. 
13. Vaughan A, Aarons E, Astbury J, et al. Human- to-Human Transmission of Monkeypox 
Virus, [LOCATION_008], October 2018. Emerg Infect Dis 2020;26(4):782- 785. DOI: 
10.3201/eid2604.191164. 
14. Hobson G, Adamson J, Adler H, et al. Family cluster of three cases of monkeypox imported from Nigeria to the [LOCATION_008], May 2021. Euro Surveill 2021;26(32). DOI: 10.2807/1560-7917.ES.2021.26.32.2100745. 
15. Mauldin MR, McCollum AM, Nakazawa YJ, et al. Exportation of Monkeypox Virus From the African Continent. J Infect Dis 2022;225(8):1367-1376. DOI: 10.1093/infdis/jiaa559. 
16. Yinka- Ogunleye A, Aruna O, Dalhat M, et al. Outbreak of human monkeypox in Nigeria 
in 2017- 18: a clinical and epi[INVESTIGATOR_154341]. Lancet Infect Dis 2019;19(8):872-879. 
DOI: 10.1016/S1473-3099(19)[ZIP_CODE]-4. 
Protocol [ADDRESS_178391]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_178392] and 
Central Africa, 1970 -2017. MMWR Morb Mortal Wkly Rep 2018;67(10):306- 310. DOI: 
10.[ZIP_CODE]/mmwr.mm6710a5. 
18. Constantino AK. Health officials confirm first U.S. case of monkeypox virus this year in 
[LOCATION_005].  CNBC Health & Science, 2022.  
19. Department of Health and Human Services. Determination that a public health emergency 
exists. (https://aspr.hhs.gov/legal/PHE/Pages/monkeypox-4Aug22.aspx ). 
20. Vollmar J, Arndtz N, Eckl KM, et al. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 2006;24(12):2065-70. DOI: 10.1016/j.vaccine.2005.11.022. 
21. Frey SE, Wald A, Edupuganti S, et al. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia -naive subjects. Vaccine 2015;33(39):5225- 34. DOI: 
10.1016/j.vaccine.2015.06.075. 
22. Wilck MB, Seaman MS, Baden LR, et al. Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration. J Infect Dis 2010;201(9):1361-70. DOI: 10.1086/651561. 
23. World Health Organization. Multi -country outbreak of mpox, External situation report 
#11. Emergency Situational Update. Geneva, Switzerland: December 1, 2022. (https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox --external -
situation -report--11---1- december -2022).  
24. Hennes see I SV, McArdle CE, et al.  . Epi[INVESTIGATOR_154342] <18 Years with Monkeypox — [LOCATION_002], May 17–September 
24, 2022. MMWR Morb Mortal Wkly Rep  2022(71):1407–1411. DOI: http://dx.doi.org/10.[ZIP_CODE]/mmwr.mm7144a4. 
25. Hutin W, R. J., Malfait, P., Pebody, R., Loparev, V. N., Ropp, S. L., Rodriguez, M., Knight, J. C., Tshioko, F. K., Khan, A. S., Szczeniowski, M. V., & Esposito, J. J.  . Outbreak of Human Monkeypox, Democratic Republic of Congo, 1996 to 1997. . Emerging Infectious Diseases 2001;7(3):434–438. DOI: https://doi.org/10.3201/eid0703.017311. 
26. Ježek Z, Szczeniowski M, Paluku KM, Mutombo M. Human Monkeypox: Clinical Features of 282 Patients. The Journal of Infectious Diseases 1987;156(2):293- 298. DO I: 
10.1093/infdis/156.2.293. 
27. US Food and Drug Administration. Summary Basis for Regulatory Action (https://www.fda.gov/media/131802/download).  
28. Overton ET, Lawrence SJ, Wagner E, et al. Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial. PLoS One 2018;13(4):e0195897. DOI: 10.1371/journal.pone.0195897. 
29. US Food and Drug Administration. Fact Sheet for Healthcare Providers Administe ring 
Vaccine: Emergency Use Authorization of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Non -replicating) for Prevention of Monkeypox Disease in Individuals 
Determined to Be at High Risk for Monkeypox Infection. 2022. 
30. Elizaga ML VS, Marovich MA, Sat o AH, Lawrence DN, Chaitman BR, Frey SE, Keefer 
MC; MVA Cardiac Safety Working Group. . Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia Ankara vaccines: a systematic review. . PLoS One 2013;8(1):e54407. DOI: 10.1371/journal.pone.0054407. 
Protocol [ADDRESS_178393]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 146 of 147 
 31. Scriba TJ, Tameris, M., Mansoor, N., Smit, E., van der Merwe, L., Isaacs, F., Keyser, A., 
Moyo, S., Brittain, N., Lawrie, A., Gelderbloem, S., Veldsman, A., Hatherill, M., Hawkridge, A., Hill, A.V.S., Hussey, G.D., Mahomed, H., McShane, H. and Hanekom, W.A., . Modified vaccinia Ankara -expressing Ag85A, a novel tuberculosis vaccine, is safe 
in adolescents and children, and induces polyfunctional CD4+ T cells. . Eur J Immunol 2010;40:279-290. (https://doi.org/10.1002/eji.200939754).  
32. Anywaine Z BH, Anzala O, Mutua G, Sirima SB, Eholie S, et al. . Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA- BN-Filo Ebola vaccination 
in children and adolescents in Africa: A randomised, placebo- controlled, multicentre Ph ase 
II clinical trial. PLoS Medicine   2022;19(1):e1003865. (https://doi.org/10.1371/journal.pmed.1003865).  
33. Afolabi MO ID, Manno D, et al. Safety and immunogenicity of the two- dose heterologous 
Ad26.ZEBOV and MVA -BN-Filo Ebola vaccine regimen in childr en in Sierra Leone: a 
randomised, double-blind, controlled trial. Lancet Infect Dis 2022;22:110-122. 
34. Suter M, Meisinger -Henschel C, Tzatzaris M, et al. Modified vaccinia Ankara strains with 
identical coding sequences actually represent complex mixtures  of viruses that determine 
the biological properties of each strain. Vaccine 2009;27(52):7442- 50. DOI: 
10.1016/j.vaccine.2009.05.095. 
35. Stittelaar KJ, Kuiken T, de Swart RL, et al. Safety of modified vaccinia virus Ankara (MVA) in immune -suppressed macaq ues. Vaccine 2001;19(27):3700- 9. DOI: 
10.1016/s0264-410x(01)[ZIP_CODE]-5. 
36. Overton ET, Stapleton J, Frank I, et al. Safety and Immunogenicity of Modified Vaccinia Ankara- Bavarian Nordic Smallpox Vaccine in Vaccinia- Naive and Experienced Human 
Immunodeficienc y Virus -Infected Individuals: An Open- Label, Controlled Clinical Phase 
II Trial. Open Forum Infect Dis 2015;2(2):ofv040. DOI: 10.1093/ofid/ofv040. 
37. Greenberg RN, Overton ET, Haas DW, et al. Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV -
infected subjects. J Infect Dis 2013;207(5):749-58. DOI: 10.1093/infdis/jis753. 
38. Overton ET, Lawrence SJ, Stapleton JT, et al. A randomized phase II trial to compare safety and immunogenicity of the MVA -BN smallpox vaccine at various doses in adults 
with a history of AIDS. Vaccine 2020;38(11):2600- 2607. DOI: 
10.1016/j.vaccine.2020.01.058. 
39. von Sonnenburg F, Perona P, Darsow U, et al. Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis. Vaccine 
2014;32(43):5696-702. DOI: 10.1016/j.vaccine.2014.08.022. 
40. Greenberg RN, Hurley MY, Dinh DV, et al. A Multicenter, Open- Label, Controlled Phase 
II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18 -40 Year Old Subjects with Diagnosed Atopic Dermatitis. PLoS One 
2015;10(10):e0138348. DOI: 10.1371/journal.pone.0138348. 
41. Cassimatis DC, Atwood JE, Engler RM, Linz PE, Grabenstein JD, Vernalis MN. Smallpox vaccination and myopericarditis: a clinical review. J Am Coll Cardiol 2004;43(9):1503-10. DOI: 10.1016/j.jacc.2003.11.053. 
42. Department of Health and Human Services. 46.[ADDRESS_178394]  2023 
 
DMID/NIAID/NIH  CONFIDENTIAL  Page 147 of 147 
 (https://www.hhs.gov/ohrp/sites/default/files/ohrp/sachrp/mtgings/2013%20March%20M
tg/approvedexpeditedreviewcategories.pdf ). 
43. Sexson Tejtel SK, Munoz FM, Al -Ammouri I, et al. Myocarditis and pericarditis: Case 
definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2022;40(10):1499-1511. DOI: 10.1016/j.vaccine.2021.11.074. 
44. Pi[INVESTIGATOR_154343], Hahn M, Lee HS, et al. Phase [ADDRESS_178395] Smallpox. N Engl J Med 2019;381(20):1897- 1908. DOI: 
10.1056/NEJMoa1817307. 
  